Title: Antimicrobial Topical and Other Preparations Containing Fluorescent or Illumination Dye and Tracer Agents or Compounds

Applicant/Assignee:

Application No.: 12/498217   Filing Date: 06/Jul/2009

Abstract:A formulation for topical application to human skin and other surface preparation compositions containing antimicrobial, antifungal and antiviral compounds which remain on human skin and other surface compositions to reduce or dominate bacteria, virus and fungi present, prevent future contamination by their presence and substantive character, contain agents or compounds that contain antibacterial, antiviral and antifungal properties and flourescent dyes and tracers that contain illumination properties exhibiting various colons including clear and no color pigment, that when exposed to certain light such as ultraviolet, will produce an illumination effect in various colors including dear and no color for a period of time within a preferred range of thirty minutes to six hours or longer from the time of initial application, and prior to for instance application of ultraviolet light, such flourescent dyes and tracers appear to be clear in color, invisible or have no color pigment showing on the skin or other surfaces, but when exposed to for instance ultraviolet fight, the surface illuminates allowing a person to determine if human skin or other surface has been adequately covered with the antibacterial, antifungal or antiviral composition agent or compound, and to significantly increase the activity to reduce and eliminate bacteria, virus and fungi on the surface, and support programs for antibacterial, antifungal and antiviral quality control, compliance, verification and education for industry and human handwash technique.

Priority: US20080133936P Applic. Date: 2008-07-07

Inventor: STOLMEIER PATRICK JOHN [US]; STOLMEIER JONATHAN P [US]

Title: Cosmetic Composition

Applicant/Assignee:

Application No.: 12/496352   Filing Date: 01/Jul/2009

Abstract:Cosmetic composition providing a high coverage of skin while retaining a natural skin appearance comprising iron oxide particles having an average primary particle size of less than or equal to 100 nm, iron-containing titanium dioxide particles having an average primary particle size of at least 105 nm and comprising from 1% to 15% iron by weight of the titanium dioxide, and a cosmetically acceptable carrier and its use as a foundation and/or as a composition to correct skin discoloration surrounding the eye.

Priority: EP20080159451 Applic. Date: 2008-07-01

Inventor: ELLIOTT RUSSELL PHILLIP [GB]; WATSON JOANNE [GB]

Title: Cosmetic Composition Containing A Protein And An Enzyme Inhibitor

Applicant/Assignee:

Application No.: 12/541439   Filing Date: 14/Aug/2009

Abstract:The present invention is a cosmetic composition comprising a water-soluble protein-based film-forming agent, the film-forming agent having a tertiary structure capable of undergoing a helix-coil transformation, a protease inhibitor in an amount sufficient to protect the protein on the stratum corneum and a cosmetically acceptable vehicle so that the protease inhibitor prolongs the pulling effect of the film-forming agent.

Priority: US2005-030664 Applic. Date: 2005-01-06; US20040535198P Applic. Date: 2004-01-07

Inventor: GIACOMONI PAOLO ULDERICO [US]; MANIRAZMAN ABUL M [US]; LENTINI PETER J [US]; HARVEY GEDEON [US]

Title: Photoprotective compositions comprising photosensitive 1,3,5-triazine compounds, dibenzoylmethane compounds and siliceous s-triazines substituted with two aminobenzoate or aminobenzamide groups

Applicant/Assignee: L'OREAL

Application No.: 11/987212   Filing Date: 28/Nov/2007

Abstract:UV-photoprotective, topically applicable cosmetic/dermatological compositions contain: (a) at least one dibenzoylmethane compound, (b) at least one 1,3,5-triazine compound that is photosensitive in the presence of a dibenzoylmethane compound, and (c) at least one siliceous s-triazine compound substituted with two aminobenzoate or aminobenzamide groups, or a tautomeric form thereof, the 1,3,5-triazine compounds being improvedly photostable in such compositions.

Priority: FR20060055164 Applic. Date: 2006-11-28; US20060873000P Applic. Date: 2006-12-06

Inventor: CANDAU DIDIER [FR]; RICHARD HERVE [FR]

Title: USE OF C-GLYCOSIDE DERIVATIVES AS PRO-DESQUAMATING ACTIVE AGENTS

Applicant/Assignee: L'OREAL

Application No.: 12/306565   Filing Date: 29/Jun/2007

Abstract:A cosmetic use of at least one C-glycoside derivative in a composition comprising a physiologically acceptable medium, as a cosmetic agent for promoting the desquamation of the skin and/or the scalp and/or for stimulating epidermal renewal.

Priority: FR20060006016 Applic. Date: 2006-07-03; US20060832943P Applic. Date: 2006-07-25; WO2007IB52527 Applic. Date: 2007-06-29

Inventor: DALKO MARIA [FR]; BOULLE CHRISTOPHE [FR]; BERNARD DOMINIQUE [FR]

Title: PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS

Applicant/Assignee:

Application No.: 12/305447   Filing Date: 19/Jun/2007

Abstract:The present invention relates to compounds of general formula (I): wherein: R1 and R2, identical or different, represent: an atom of hydrogen or halogen, CN or NO2, with R1 and R2 not representing hydrogen simultaneously, m represents: 1 or 2 n represents: 0, 1 or 2 R3 represents: phenyl substituted or not by one or more residues chosen among halogen, hydroxyl or C1-C6 alkyl

C2-C6 alkyl substituted or not by one or more residues chosen among halogen or hydroxyl

cycloalkyl

pyridine

thiophene

pyrrole substituted or not by C1-C6 alkyl

thiazole or furan

or the therapeutically-acceptable salts or solvates thereof.

Priority: FR20060005418 Applic. Date: 2006-06-19; WO2007EP56078 Applic. Date: 2007-06-19

Inventor: PEREZ MICHEL [FR]; LAMOTHE MARIE [FR]; LE GRAND BRUNO [FR]; LETIENNE ROBERT [FR]

Title: FINE-GRANULOMETRY FUNGAL EXTRACT CHITINE-GLUCANE

Applicant/Assignee:

Application No.: 12/312656   Filing Date: 20/Nov/2007

Abstract:The present invention relates to a chitin-glucan copolymer in the form of micrometric particles. The present invention in particular provides a composition containing a chitin-glucan copolymer in the form of micrometric particles for the preparation of cosmetic compositions, and in particular dermatological or dermocosmetic compositions. In particular, the present invention relates to a cosmetic composition for face or body care, such as hydrating, firming or smoothing the skin, and exercising an anti-aging effect, including an anti-wrinkle effect. The purpose of the invention is also to provide a porous material that can for example be used in tissue engineering or cell culture, or that can be used as a material in the cosmetics or pharmaceutical industry.

Priority: FR20060054998 Applic. Date: 2006-11-20; WO2007EP62601 Applic. Date: 2007-11-20

Inventor: GAUTIER SANDRINE [BE]; BRUYERE JEAN-MICHEL [BE]; MAQUET VERONIQUE [BE]

Title: Processes for Reducing the Appearance of Pastiness or Ashiness on Skin

Applicant/Assignee:

Application No.: 12/496376   Filing Date: 01/Jul/2009

Abstract:Processes for reducing the appearance of ashiness or pastiness on skin by applying thereto a cosmetic composition comprising transparent iron oxide particles, iron-containing titanium dioxide particles, and a cosmetically acceptable carrier. These processes are useful to provide coverage of skin imperfections and/or skin tonal variations and/or skin discoloration surrounding the eyes on different types of skin, while, at the same time, retaining a natural skin appearance.

Priority: EP20080159454 Applic. Date: 2008-07-01

Inventor: ELLIOTT RUSSELL PHILLIP [GB]; WATSON JOANNE [GB]

Title: METHODS OF DIFFERENTIATING STEM CELLS

Applicant/Assignee: OSSACUR AG

Application No.: 12/373757   Filing Date: 13/Sep/2007

Abstract:A method for at least partial differentiating stem cells and/or progenitor cells to at least one tissue type includes treating the stem cells and/or the progenitor cells with extracts which include active substances and/or components for differentiating stem cells and/or progenitor cells, and cultivating and differentiating the stem cells and/or the progenitor cells.

Priority: DE200610045848 Applic. Date: 2006-09-15; DE200610060247 Applic. Date: 2006-12-13; WO2007EP07971 Applic. Date: 2007-09-13

Inventor: BRIEST ARNE [DE]; SINDET-PEDERSEN STEEN [GB]

Title: SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES

Applicant/Assignee: GENFIT

Application No.: 12/309642   Filing Date: 24/Jul/2007

Abstract:The present invention relates to polysubstituted imidazolone derivatives, to the pharmaceutical compositions comprising them and to the therapeutic uses thereof in the human and animal health fields. The present invention also relates to a process for preparing these derivatives.

Priority: FR20060006752 Applic. Date: 2006-07-24; WO2007FR51716 Applic. Date: 2007-07-24

Inventor: BOUEY EDITH [FR]; MASSON CHRISTOPHE [FR]; BERTRAND KARINE [FR]

Title: Novel Protein Transduction Domains and Uses Therefor

Applicant/Assignee: THE ARIZONA BOARD OF REGENTS, A BODY CORPORATE ACTING ON BEHALF OF ARIZONA STATE UNIVERSITY

Application No.: 12/090474   Filing Date: 30/Oct/2006

Abstract:The present invention provides novel transduction domains, compositions comprising such transduction domains, and their use for in vivo molecular delivery.

Priority: US20050732365P Applic. Date: 2005-11-01; WO2006US42209 Applic. Date: 2006-10-30

Inventor: BROPHY COLLEEN [US]; PANITCH ALYSSA [US]; FURNISH ELIZABETH [US]; SEAL BRANDON [US]

Title: COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS

Applicant/Assignee:

Application No.: 12/109752   Filing Date: 25/Apr/2008

Abstract:Provided herein are pharmaceutical compositions comprising one or more phosphodiesterase inhibitors of type IV ("PDE-IV"), and at least one other active ingredient such as muscarinic receptor antagonists (MRA), beta2-agonists, p38 MAP Kinase inhibitors, or corticosteroids and optionally one or more pharmaceutically acceptable excipients. In addition, methods of treating autoimmune, inflammatory or allergic diseases or disorders are provided.

Priority: IN2005DE02793 Applic. Date: 2005-10-19

Inventor: RAY ABHIJIT [IN]; DASTIDAR SUNANDA G [IN]; SHIRUMALLA RAJKUMAR [IN]; GUPTA SUMAN [IN]

Title: WATERBORNE TOPICAL COMPOSITIONS FOR THE DELIVERY OF AZELAIC ACID

Applicant/Assignee:

Application No.: 12/486625   Filing Date: 17/Jun/2009

Abstract:A waterborne topical composition is designed specifically to address the treatment of acne vulgaris, rosacea, seborrheic dermatitis and other skin conditions. The composition contains effective amounts of essential components azelaic acid, niacinamide, and glycerin to create a rapidly penetrating and non-irritating compound.

Priority: US20080073102P Applic. Date: 2008-06-17

Inventor: DANNAKER CHRISTOPHER J [US]

Title: EXCITATORY AMINO ACID INHIBITORS FOR TREATING SENSITIVE SKINS

Applicant/Assignee: L'OREAL

Application No.: 12/556901   Filing Date: 10/Sep/2009

Abstract:Sensitive human skin/scalp/mucous membrane conditions, for example skin irritation and/or dry patches and/or erythemas and/or dysaesthesic sensations and/or sensations of heating and/or pruritus, are therapeutically treated by topically applying thereto an effective condition-alleviating amount of at least one inhibitor of at least one excitatory amino acid.

Priority: FR19970011959 Applic. Date: 1997-09-25; US2003-401685 Applic. Date: 2003-03-31; US1998-160151 Applic. Date: 1998-09-25

Inventor: BRETON LIONEL [FR]; NONOTTE ISABELLE [FR]

Title: Benefit agent containing delivery particle

Applicant/Assignee: APPLETON PAPERS INC

Application No.: 12/216941   Filing Date: 14/Jul/2008

Abstract:The present invention relates to benefit agent containing delivery particles, compositions comprising said particles, and processes for making and using the aforementioned particles and compositions. When employed in compositions, for example, cleaning or fabric care compositions, such particles increase the efficiency of benefit agent delivery, there by allowing reduced amounts of benefit agents to be employed. In addition to allowing the amount of benefit agent to be reduced, such particles allow a broad range of benefit agents to be employed.

Priority:

Inventor: DIHORA JITEN ODHAVJI [US]; SANDS PEGGY DOROTHY [US]; FOSSUM RENGE DIANNA [US]; YORK DAVID WILLIAM [GB]; LANG MATTHEW HENRY [US]; GUINEBRETIERE SANDRA JACQUELINE [US]

Title: New Biochemical Route to Astaxanthin

Applicant/Assignee:

Application No.: 12/226426   Filing Date: 20/Apr/2007

Abstract:Two sequences of a nucleic acid isolated from a cDNA library of the flowering plant Adonis aestivalis is disclosed (SEQ ID NO: 5). The first DNA sequence, referred to as AdKC28, encodes for a polypeptide (SEQ ID NO: 6) that acts in conjunction with polypeptides encoded by either one of two other closely-related Adonis aestivalis cDNAs, AdKeto1 (SEQ ID NO: 1) and AdKeto2 (SEQ ID NO: 2), to convert beta-carotene (beta,beta-carotene) into astaxanthin (3,3'-dihydroxy-4,4'-diketo-beta, beta-carotene). A second DNA sequence, referred to as AdKCl 7 is also disclosed (FIG. 9). Together, these Adonis aestivalis cDNAs, when operably linked to promoters appropriate to the transgenic host, enable the production of astaxanthin and other carotenoids with 3-hydroxy-4-keto-beta-rings in a variety of host cells and organisms.

Priority: US20060793645P Applic. Date: 2006-04-21; WO2007US09803 Applic. Date: 2007-04-20

Inventor: CUNNINGHAM JR FRANCIS X [US]

Title: COMPOSITION FOR IMPROVING SKIN CONDITION

Applicant/Assignee: KIRIN HOLDINGS KABUSHIKI KAISHA

Application No.: 12/438427   Filing Date: 23/Feb/2009

Abstract:This invention relates to a composition for improving skin conditions comprising, as an active ingredient, a yeast cell wall fraction obtained by removing soluble intracellular component from an enzymatically treated and/or non-enzymatically treated yeast. The composition of this invention is effective for improving skin conditions, such as, moistening, whitening, or active oxygen elimination.

Priority: WO2006JP316654 Applic. Date: 2006-08-24

Inventor: YOSHIDA MICHIKO [JP]; KONISHI YUTAKA [JP]

Title: PROPYLENE GLYCOL HYALURONATE, AND SKINCARE PREPARATION FOR EXTERNAL USE COMPRISING SAME

Applicant/Assignee: FOODCHEMIFA CO., LTD

Application No.: 12/444889   Filing Date: 01/Aug/2008

Abstract:A propylene glycol hyaluronate having an esterification degree of from 10 to 90% and a limiting viscosity of less than 3 dL/g has an excellent percutaneous absorption-promoting effect, and is widely usable as cosmetics and pharmaceutical products.

Priority: JP20070208503 Applic. Date: 2007-08-09; WO2008JP02079 Applic. Date: 2008-08-01

Inventor: HIRAI HIDEKI [JP]; WATANABE MAKOTO [JP]; NOZAWA TAKASHI [JP]; MURATA KATSUMI [JP]

Title: Cosmetic and Therapeutic Stick Products

Applicant/Assignee: AMCOL INTERNATIONAL CORPORATION

Application No.: 12/282535   Filing Date: 02/Apr/2007

Abstract:A composition wherein phase or chemically incompatible components are introduced into a stick composition through the use of a microparticle delivery system.

Priority: US20060788925P Applic. Date: 2006-04-04; WO2007US08164 Applic. Date: 2007-04-02

Inventor: SPINDLER RALPH [US]; URBANEC STEPHEN J [US]; LIU LIMIN [US]; VAKILI-TAHAMI GHOLAM-REZA [US]

Title: Transdermal estrogen device and delivery

Applicant/Assignee: NOVEN PHARMACEUTICALS, INC

Application No.: 12/216811   Filing Date: 10/Jul/2008

Abstract:Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.

Priority:

Inventor: MANTELLE JUAN [US]

Title: METHOD OF OBTAINING AN ACTIVE INGREDIENT INCREASING CUTANEOUS CELL AND TISSUE LONGEVITY, ACTIVE INGREDIENTS AND COMPOSITIONS

Applicant/Assignee: SOCIETE IND LIMO D'APPLICATION BIO, DITE SILAB

Application No.: 12/373215   Filing Date: 06/Jul/2007

Abstract:Method for obtaining of an active principle from Myrtus communis in order to increase the longevity of the cells and tissues of the skin.

Priority: FR20060052900 Applic. Date: 2006-07-11; WO2007FR51610 Applic. Date: 2007-07-06

Inventor: PAUFIQUE JEAN [FR]

Title: HYDROXYLATED AMIDE SKIN MOISTURIZER

Applicant/Assignee: L'OREAL

Application No.: 12/302398   Filing Date: 03/May/2007

Abstract:The invention relates to the cosmetic use, as a skin moisturizer, of a compound of formula (I): with (i) R1 and R2 represent a hydrogen atom or a C1-C6-alkyl group, or (ii) R1 and R2 can form, together with the nitrogen atom which bears them, a saturated heterocycle with 5 to 7 ring members

R5 representing a hydrogen atom or a (C1-C3) alkyl group

R6 representing a hydrogen atom or a (C1-C4) alkyl group

R3 represents a hydrogen atom or a (C1-C6) alkyl-group, or -OR3 represents a phosphate group

it being possible for the two groups R3 to form, together, an isopropylidene group

R4 represents a hydrogen atom or -OR4 represents a-phosphate group

and the salts, solvates and isomers thereof. The invention also relates to a cosmetic composition comprising a compound (I) and the corresponding new compounds.

Priority: FR20060051987 Applic. Date: 2006-05-31; US20060811094P Applic. Date: 2006-06-06; WO2007EP54278 Applic. Date: 2007-05-03

Inventor: MARAT XAVIER [FR]

Title: HIGH PENETRATION PRODRUG COMPOSITIONS OF RETINOIDS AND RETINOID-RELATED COMPOUNDS

Applicant/Assignee:

Application No.: 12/503739   Filing Date: 15/Jul/2009

Abstract:The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of retinoids and retinoid-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

Priority: WO2007IB50122 Applic. Date: 2007-01-15

Inventor: YU CHONGXI [US]

Title: Compositions and Methods for Treating Jellyfish Stings

Applicant/Assignee:

Application No.: 12/442144   Filing Date: 21/Sep/2007

Abstract:Methods and compositions for treating skin conditions, in particular jellyfish stings, are provided.

Priority: US20060846195P Applic. Date: 2006-09-21; WO2007US79180 Applic. Date: 2007-09-21

Inventor: GRAYSON JOHN C [US]

Title: LASER AND A METHOD FOR OPERATING THE LASER

Applicant/Assignee: LIGHTHOUSE TECHNOLOGIES PTY LTD

Application No.: 12/282804   Filing Date: 13/Mar/2007

Abstract:A laser comprising: a resonator cavity defined by at least two reflectors, wherein the at least two reflectors are highly reflective at a plurality of fundamental wavelengths

a laser medium disposed in the resonator cavity capable of generating plurality of fundamental wavelengths

an optical pump source for energizing the laser medium, thereby causing laser light at the plurality of fundamental wavelengths to resonate in the resonator cavity simultaneously

and a nonlinear material located in said resonator cavity capable of simultaneously converting each of the plurality of wavelengths of laser light to generate converted laser light having a plurality of converted wavelengths, said converted wavelengths being derived from but different to the fundamental wavelengths

wherein the non-linear material is at least partially phase matched to nonlinearly convert the frequencies of each of the fundamental wavelengths simultaneously such that a plurality of converted wavelengths are able to be simultaneously generated.

Priority: AU20060901269 Applic. Date: 2006-03-13; WO2007AU00309 Applic. Date: 2007-03-13

Inventor: OGILVY HAMISH [AU]; MILDREN RICHARD PAUL [AU]

Title: USE OF NATURAL, RECOMBINANT AND SYNTHETIC RESILINS IN COSMETICS

Applicant/Assignee: BASF SE

Application No.: 12/513709   Filing Date: 07/Nov/2007

Abstract:Use of resilin proteins in cosmetics, wherein the resilin proteins comprise between one and 100 repeat units with the consensus sequence SXXYGXP, where S is a serine, X is any desired amino acid, Y is a tyrosine, G is a glycine and P is a proline.

Priority: EP20060123659 Applic. Date: 2006-11-08; WO2007EP62005 Applic. Date: 2007-11-07

Inventor: BOLLSCHWEILER CLAUS [DE]; LIEBMANN BURGHARD [DE]; FEHR MARCUS [DE]; HUEMMERICH DANIEL [DE]; PTOCK ARNE [DE]; RAUNFT EVELYN [DE]

Title: Compositions for Improving Skin Conditions Comprising Alpha-Bisabolol as an Active Ingredient

Applicant/Assignee: BIOSPECTRUM INC

Application No.: 12/527756   Filing Date: 27/Feb/2008

Abstract:The present invention relates to a composition for improving skin condition comprising alpha-bisabolol as an active ingredient. alpha-Bisabolol used as an active ingredient has greater skin whitening effect inhibiting melanin synthesis by inhibiting intracellular tyrosinase activities compared to arbutin used as an existing skin whitening agent. In addition, alpha-bisabolol exhibits the inhibition effect on collagenase activity and promotion effect on collagen biosynthesis at a molecular level, contributing to excellent efficacy in improvement of skin wrinkles. Meanwhile, alpha-bisabolol indicates the improvement effects on UV-induced skin damage and the skin growth promotion or hair loss prevention. Therefore, alpha-bisabolol has the excellent improvement effects on skin condition. Furthermore, alpha-bisabolol has the excellent anti-obesity and anti-oxidation effects. The composition of this invention can be applied to cosmetic, pharmaceutical and food composition having no cytotoxicities and side effects with safety.

Priority: KR20070019899 Applic. Date: 2007-02-27; WO2008KR01141 Applic. Date: 2008-02-27

Inventor: PARK DEOK HOON [KR]; KIM SAE BOM [KR]; LEE JONG SUNG [KR]

Title: USE OF AT LEAST ONE (DIHYDRO)JASMONIC ACID DERIVATIVE FOR TREATING DRY SKIN

Applicant/Assignee: L'OREAL S.A

Application No.: 12/407359   Filing Date: 19/Mar/2009

Abstract:A cosmetic process for treating dry skin and/or a dry scalp of non-inflammatory origin, for example, in a menopausal woman, comprising topically applying to the skin and/or the scalp a composition comprising, in a physiologically acceptable medium, at least one (dihydro)jasmonic acid derivative

novel (dihydro)jasmonic acid derivatives and to the compositions, for example, suitable for topical application to the skin, comprising them.

Priority: FR20030001146 Applic. Date: 2003-01-31; US2004-768132 Applic. Date: 2004-02-02; US20030452108P Applic. Date: 2003-03-06

Inventor: DALKO MARIA [FR]

Title: PROGRAMMABLE BUOYANT DELIVERY TECHNOLOGY

Applicant/Assignee:

Application No.: 12/439775   Filing Date: 03/Sep/2007

Abstract:The present invention is concerned with a system for spatially and temporally programmable delivery of an active agent. When administered orally, the System can be retained in the gastric region for a prolonged period of time. It comprises of a core (I), one or more layers (II, IV, V) coated over the core and a preformed hollow space (III). The invention also concerns with a process for preparation of the System and a method for treating/preventing diseases, by administering to a subject in need thereof, the System of the invention.

Priority: IN2006MU01411 Applic. Date: 2006-09-04; WO2007IN00392 Applic. Date: 2007-09-03

Inventor: SINGH AMARJIT [IN]; SINGH SARABJIT [IN]; PUTHLI SHIVANAND [IN]; TANDALE RAJENDRA [IN]

Title: Method for producing grape extract with high ORAC value, and grape extract so produced

Applicant/Assignee:

Application No.: 12/287995   Filing Date: 14/Oct/2008

Abstract:Grape material is processed to yield a grape extract high in concentrated polyphenols, with ORAC values exceeding at least about 10,000 mumol TE/g. The grape material is dried, and soaked in ethanol to commence desired concentrate extraction. Following ethanol removal, inactive residue is at least partially separated from the desired concentrate solution, which passes through a macroporous absorption resin that absorbs desired active ingredients. Ethanol resin washing yields an intermediate extraction solution. After ethanol removal, the intermediate extract solution with the mixed active ingredients is refined. During refinement, high concentration of polyphenols and monomeric phenols are separated, and collected. These collected materials yield a desired high ORAC extract solution. Further drying yields the desired material, which is tested and packaged. This material exhibits good water solubility, mild flavor, and can be added to foodstuffs and nutritional supplements as a beneficial antioxidant.

Priority: CN20081135896 Applic. Date: 2008-07-21

Inventor: YING WEICHAO [CN]; XIONG XIAOYAN [US]; CHEN JIAOMEI [CN]; YANG JIANYING [CN]

Title: MICROPHASIC MICRO-COMPONENTS AND METHODS FOR CONTROLLING MORPHOLOGY VIA ELECTRIFIED JETTING

Applicant/Assignee:

Application No.: 12/506712   Filing Date: 21/Jul/2009

Abstract:The disclosure provides methods for preparation of multiphasic micro-components, such as core-shell or anisotropic (e.g., Janus) multiphasic particles with well-defined structures using electrohydrodynamic co-jetting of two polymer solutions containing polyelectrolytes. Suitable polyelectrolytes include polyacrylic acid (PAA), poly(acrylamide acrylic acid (PAAm), and/or poly(acryl amide-co-acrylic acid) (PAAm-AA), sodium polystyrene sulfonate (PSS), polyethylene imine (PEI), polypeptides, copolymers, and combinations of these. Control of certain variables, such as relative conductivities of the two jetting solutions, controls the particle morphologies formed, leading to a predetermined phase orientation for the same polymer system. In certain aspects, after cross-linking, core-shell particles are stable in aqueous solutions and exhibit reproducible swelling behavior, while maintaining the original core-shell geometry. In addition, micro-components formed in accordance with the present teachings are pH-responsive based on external environmental pH. Thus, such micro-components are useful for a variety of different applications, including micro- and nano-active ingredient delivery systems.

Priority: US2007-763842 Applic. Date: 2007-06-15; US2005-272194 Applic. Date: 2005-11-10; US20080082396P Applic. Date: 2008-07-21; US20040626792P Applic. Date: 2004-11-10; US20050651288P Applic. Date: 2005-02-09; US20060814706P Applic. Date: 2006-06-16

Inventor: LAHANN JOERG [US]; KAZEMI ABBASS [US]

Title: Compositions Comprising Sulfonated Estolides And Alkyl Ester Sulfonates, Methods Of Making Them, And Compositions And Processes Employing Them

Applicant/Assignee:

Application No.: 12/507011   Filing Date: 21/Jul/2009

Abstract:Compositions comprising sulfo-estolides and alkyl ester sulfonates are described. Detergent formulations, such as laundry detergents, softeners, and other materials, containing any of these materials are disclosed, as well as personal care formulations, hard surface cleaner formulations, and automatic dishwasher detergent formulations. Laundry methods employing these formulations are also disclosed. These formulations are useful as laundry detergents and can be biodegradable, heavy duty liquids, 2x or 3x and up to 6x concentrates, low foaming, and/or effective in a high efficiency washing machine. Methods for laundering fabrics with the compositions are also disclosed.

Priority: WO2009US31455 Applic. Date: 2009-01-20; US20080022662P Applic. Date: 2008-01-22

Inventor: BERNHARDT RANDAL J [US]; ALONSO LOURDES R [US]; DADO GREGORY P [US]; FILIPOVIC EDDIE I [US]; GARIEPY CHRISTOPHER A [US]; MASTERS RONALD A [US]; MURPHY DENNIS S [US]; PYTEL JACQUELINE MAAS [US]; SAJIC BRANKO [US]; SHAPIRO IRENE [US]; WEITGENANT JEREMY AARON [US]

Title: Mannich Base N-Oxide Drugs

Applicant/Assignee: STATE OF OREGON ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE U

Application No.: 12/563543   Filing Date: 21/Sep/2009

Abstract:Disclosed are Mannich base N-oxides of drugs containing acidic N-H groups. Pharmaceutical compositions comprising a therapeutically effective amount of Mannich base N-oxides, or a N-oxide rearrangement product, pharmaceutically acceptable salt or prodrug thereof, are also disclosed. Further, disclosed are methods of using the compounds, alone or in combination with one or more other active agents or treatments.

Priority: WO2008US03550 Applic. Date: 2008-03-19; US20070907048P Applic. Date: 2007-03-19

Inventor: KEANA JOHN F W [US]; WESTBERG PAUL [US]; CURD JOHN [US]; LALANI ALSHAD S [US]

Title: Anti-Inflammatory Agents

Applicant/Assignee: CAMBRIDGE ENTERPRISE LIMITED

Application No.: 11/922277   Filing Date: 14/Jun/2006

Abstract:The invention provides compounds, pharmaceutical compositions and uses of compounds and salts thereof of general formula (I), for the preparation of a medicament for treatment of an inflammatory disorder, but excluding (S)-3-(r-methylcyclohexyl-carbonylamino)-caprolactam: wherein z is 1, 2, 3 or 4

A is -CO- or -SO2-

Q is linear or branched alkyl, alkenyl, alkynyl, alkoxy, oxyalkyl, aminoalkyl, alkylamino, alkylaminoalkyl, haloalkyl, aryl or substituted aryl

T1 and T2 together constitute a cycloalkyl, cycloalkenyl or polycycloalkyl radical composed of n additional carbon atoms, where n is between 2 and 7

and each hydrogen atom bonded to the carbon atoms in the ring generated by T1 and T2 may be independently be substituted by a group R1, where R1 is independently selected from an alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl or alkylamino radical of 1 to 20 carbon atoms

or each R1 is independently selected from fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminoalkyl or aminodialkyl radical.

Priority: GB20050012241 Applic. Date: 2005-06-15; GB20050016468 Applic. Date: 2005-08-10; WO2006GB02217 Applic. Date: 2006-06-14

Inventor: GRAINGER DAVID J [GB]; FOX DAVID JOHN [GB]

Title: QUINOLINE COMPOUNDS

Applicant/Assignee: KOWA COMPANY, LTD

Application No.: 12/430397   Filing Date: 27/Apr/2009

Abstract:[Object] To provide a novel LXRbeta agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis

arteriosclerosis such as those resulting from diabetes

dyslipidemia

hypercholesterolemia

lipid-related diseases

inflammatory diseases that are caused by inflammatory cytokines

skin diseases such as allergic skin diseases

diabetes

or Alzheimer's disease. [Solving Means] A quinoline compound represented by the following general formula (1) or salt thereof, or their solvate.

Priority: US20080049090P Applic. Date: 2008-04-30

Inventor: KOURA MINORU [JP]; OKUDA AYUMU [JP]; MATSUDA TAKAYUKI [JP]; YAMAGUCHI YUKI [JP]; SUMIDA HISASHI [JP]; KUROBUCHI SAYAKA [JP]; WATANABE YUUICHIROU [JP]; ENOMOTO TAKASHI [JP]; SHIBUYA KIMIYUKI [JP]

Title: PATHOTROPIC TARGETED GENE DELIVERY SYSTEM FOR CANCER AND OTHER DISORDERS

Applicant/Assignee:

Application No.: 12/446976   Filing Date: 05/Nov/2007

Abstract:Systems for pathotropic (disease-seeking) targeted gene delivery are provided, including viral particles with extremely high titers. In particular, the viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastic sites. Personalized dosing regimens are also provided to treat diseases such as cancer efficaciously with reduced adverse side effects.

Priority: US2006-055666 Applic. Date: 2006-11-03; WO2007US23305 Applic. Date: 2007-11-05

Inventor: HALL FREDERICK L [US]; LEVY JOHN P [US]; REED REBECCA A [US]; GORDON ERLINDA M [US]

Title: METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING

Applicant/Assignee: SOL-GEL TECHNOLOGIES LTD

Application No.: 12/525331   Filing Date: 03/Feb/2008

Abstract:The invention relates to a process for coating a solid, water-insoluble particulate matter, with a metal oxide comprising: (a) contacting the solid, water-insoluble particulate matter with an ionic additive and an aqueous medium to obtain a dispersion of said particulate matter having positive charges on its surface

(b) subjecting the particulate matter to a coating procedure comprising precipitating a metal oxide salt onto the surface of the particulate matter to form a metal oxide layer thereon to thereby obtain particulate matter coated by a metal oxide coating layer

(c) repeating step (b) at least 4 more times

and (d) aging said coating layer. The invention further relates to particles comprising a particulate matter coated by a metal oxide layer, to a use of the particles for topical administration, and to a method for preventing, reducing, or eliminating pests at a locus, using the particles.

Priority: US20070898700P Applic. Date: 2007-02-01; WO2008IL00141 Applic. Date: 2008-02-03

Inventor: TOLEDANO OFER [IL]; BAR-SIMANTOV HAIM [IL]; BILMAN NISSIM [IL]; SHAPIRO LEORA [IL]; ABU-REZIQ RAED [IL]; SRIADIBHATLA SRIKANTH [US]; SOMMER WILLIAM T [US]

Title: HIGH PENETRATION PRODRUG COMPOSITIONS OF 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINES AND 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE-RELATED COMPOUNDS

Applicant/Assignee:

Application No.: 12/534096   Filing Date: 31/Jul/2009

Abstract:The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of 1H-imidazo[4,5-c]quinolin-4-amines and 1H-imidazo[4,5-c]quinolin-4-amine-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

Priority: WO2007IB50322 Applic. Date: 2007-01-31

Inventor: YU CHONGXI [US]

Title: Compounds, Formulations, and Methods for Ameliorating Telangiectasis

Applicant/Assignee: GALDERMA LABORATORIES INC

Application No.: 12/544663   Filing Date: 20/Aug/2009

Abstract:Methods, compounds, and topical formulations for treatment of telangiectasias are disclosed. The methods comprise topically applying a composition comprising an alpha-adrenergic receptor agonist to telangiectatic skin. Amelioration of telangiectasia symptoms begins within minutes after topical application of a disclosed composition. A single application can significantly lessen telangiectasia discoloration for at least about 2 hours.

Priority: US2006-449079 Applic. Date: 2006-06-08; US2004-853585 Applic. Date: 2004-05-25; US20030473611P Applic. Date: 2003-05-27

Inventor: DEJOVIN JACK A [US]; DEJOVIN ISABELLE JEAN [US]; POWALA CHRISTOPHER [US]

Title: DISPERSIONS OF INORGANIC PARTICULATES CONTAINING ALKOXYCRYLENE

Applicant/Assignee: HALLSTAR INNOVATIONS CORP

Application No.: 12/554329   Filing Date: 04/Sep/2009

Abstract:A composition comprising an inorganic particulate material in an amount of about 20 wt % to about 70 wt %, a carrier for the particulate material comprising a compound of formula (I) in an amount of about 1 wt % to about 70 wt %, a particulate material coating material in an amount of about 0 wt % to about 5 wt %, and a dispersing agent for the particulate material in an amount of about 0 wt % to about 5 wt %, based on the total weight of the composition, wherein one of R1 and R2 is a straight or branched chain C1-C30 alkoxy radical, and the non-alkoxy R1 or R2 is hydrogen

and R3 is a straight or branched chain C1-C30 alkyl radical.

Priority: US2009-432450 Applic. Date: 2009-04-29; US2008-022758 Applic. Date: 2008-01-30; US2007-891281 Applic. Date: 2007-08-09

Inventor: BONDA CRAIG A [US]; PAVLOVIC ANNA [US]; ZHANG JEAN [US]

Title: Cosmetic composition with skin tightening effect

Applicant/Assignee: LVMH RECHERCHE

Application No.: 12/585755   Filing Date: 24/Sep/2009

Abstract:The present invention relates to a mixture, having a skin-tightening effect, which is made up of: 10 to 80% by Weight of a polysaccharide, preferably of an alginate, having a molecular weight of less than 600,000 Daltons, preferably less than 400,000 Daltons and more preferably less than 200,000 Daltons, 15 to 75% by weight of a polyhydroxylated agent selected from sugars and their derivatives, particularly sugar esters and sugar, ethers, preferably sorbitol, 3 to 15% by Weight of polyvinyl alcohol) or polyvinylpyrrolidone, and 0 to 25% by weight of cellulose or of a derivative of cellulose, such as carboxymethylcellulose or hydroxymethylcellulose. The present invention also relates to cosmetic compositions which contain this mixture. These cosmetic compositions enable a mechanical smoothing of the surface of the skin to be obtained progressively with great comfort of use and enables a good fixing of make-up products.

Priority: FR20010011123 Applic. Date: 2001-08-27; US2004-487693 Applic. Date: 2004-02-26; WO2002FR02941 Applic. Date: 2002-08-27

Inventor: DELAGE-GROUILLER HERVE [FR]; NOE BRIGITTE [FR]; MAHE CHRISTIAN [FR]

Title: COSMETIC DEPILATORY COMPOSITION

Applicant/Assignee:

Application No.: 12/528016   Filing Date: 21/Feb/2008

Abstract:A cosmetic cold-wax depilatory composition is provided The depilatory composition comprises a hydrocarbon resin, from 50% to 99% by weight and a flexibilizer or plasticizer, from 0 5% to 10% by weight Methods of applying the composition to a strip of material for removal of hair without the need for heating are also provided.

Priority: ES20070000448 Applic. Date: 2007-02-21; WO2008US54565 Applic. Date: 2008-02-21

Inventor: BOSCH JOSE BENAVENT [ES]; FERNANDEZ MARTA TORRES [ES]

Title: COSMETIC USE OF ORGANIC RESINATES

Applicant/Assignee: CHANEL PARFUMS BEAUTE

Application No.: 12/531162   Filing Date: 14/Mar/2008

Abstract:A cosmetic method for releasing an active principle in a controlled fashion to uninjured skin, as a function of the ion content in or on skin, by exchange with the ions, in order to provide at least one cosmetic benefit to the skin, the method includes applying onto skin a composition containing, in a cosmetically acceptable medium, at least one resinate including one organic ion-exchange resin and at least one ionizable cosmetic active principle bonded in noncovalent fashion to the resin.

Priority: FR20070001840 Applic. Date: 2007-03-14; US20070941741P Applic. Date: 2007-06-04; WO2008EP53109 Applic. Date: 2008-03-14

Inventor: CASADO-CHAUDANSON AUDREY MARJORIE [FR]; PASTOR AUDREY CELINE MARCELLE [FR]

Title: Agent for Promoting the Production of Thioredoxin

Applicant/Assignee: KYOTO UNIVERSITY NIPPON ZOKI PHARMACEUTICAL CO., LTD

Application No.: 12/225415   Filing Date: 29/Mar/2007

Abstract:A novel pharmaceutical application of an extract from a vaccine virus-inoculated and inflamed tissue and relates to a thioredoxin production promoting agent containing the extract as an active ingredient. The extract has an excellent thioredoxin production promoting action against an oxidative stress caused by a stimulus by such as a tobacco smoke extract or hydrogen peroxide and showed a significant lung cell protective effect. Therefore, the pharmaceutical of the invention containing the extract as an active ingredient is highly useful as a preventive or therapeutic agent for a chronic obstructive lung disease considered to be mainly caused by a continuous oxidative stress such as chronic smoking and the pharmaceutical with less side effects and high safety.

Priority: JP20060093602 Applic. Date: 2006-03-30; WO2007JP56827 Applic. Date: 2007-03-29

Inventor: NAKAMURA HAJIME [JP]; YODOI JUNJI [JP]; HOSHINO YUMA [JP]

Title: NEURONAL EXOCYTOSIS INHIBITING PEPTIDES

Applicant/Assignee: LIPOTEC, S.A

Application No.: 12/447136   Filing Date: 24/Oct/2007

Abstract:The invention relates to peptides of general formula (I): R1-AA-R2 (I) which can regulate neuronal exocytosis, their stereoisomers and racemic or non-racemic mixtures thereof, and the cosmetically or pharmaceutically acceptable salts thereof, wherein AA is a sequence of 3 to 40 adjacent amino acids contained in the amino acid sequence of the SNAP-25 protein, R1 is selected from the group consisting of H or alkyl, aryl, aralkyl or acyl group

and R2 is selected from the group consisting of amino, hydroxyl or thiol, substituted or non-substituted with aliphatic or cyclic groups, with the condition that when R1 is H or acetyl, R2 is not non-substituted amino, hydroxyl or thiol. The invention also relates to a method of obtaining such peptides, cosmetic or pharmaceutical compositions containing them and their use to treat those conditions requiring neuronal exocytosis regulation, preferably for treating the skin.

Priority: ES20060002720 Applic. Date: 2006-10-25; WO2007ES00603 Applic. Date: 2007-10-24

Inventor: CARRENO SERRAIMA CRISTINA [ES]; PONSATI OBIOLS BERTA [ES]; VAN DEN NEST WIM [ES]; FERNANDEZ CARNEADO JIMENA [ES]; FERRER MONTIEL ANTONIO [ES]; CEBRIAN PUCHE JUAN [ES]; ALMINANA DOMENECH NURIA [ES]

Title: PH MODULATED FILMS FOR DELIVERY OF ACTIVES

Applicant/Assignee: MONOSOL RX, LLC

Application No.: 12/575261   Filing Date: 07/Oct/2009

Abstract:The invention relates to pH modulated films and methods of their preparation. The film compositions include at least one component having a non-neutral pH when combined with water

and a pH modulated polymer system selected to reduce or prevent synerisis when combined with the non-neutral component in combination with aqueous media. The films demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, extrusion process, or other process that maintains the required uniformity of the film.

Priority: US2006-639013 Applic. Date: 2006-12-14; US2002-074272 Applic. Date: 2002-02-14; US20050754092P Applic. Date: 2005-12-27; US20010328868P Applic. Date: 2001-10-12

Inventor: MYERS GARRY L [US]; SANGHVI PRADEEP [US]

Title: USE OF SUPEROXIDE DISMUTASES IN WASHING AND CLEANING AGENTS

Applicant/Assignee: HENKEL AG & CO. KGAA

Application No.: 12/548521   Filing Date: 27/Aug/2009

Abstract:The present invention relates to the use of superoxide dismutases to remove Amadori and Maillard products, and to washing and cleaning agents that contain superoxide dismutases.

Priority: DE200710010785 Applic. Date: 2007-03-02; WO2008EP52334 Applic. Date: 2008-02-27

Inventor: MAURER KARL-HEINZ [DE]; O'CONNELL TIMOTHY [DE]; MUSMANN NINA [DE]; PRUESER INKEN [DE]; HUCHEL URSULA [DE]; DEPPE VERONIKA [DE]

Title: Novel Derivatives of Cyclic Compound And The Use Thereof

Applicant/Assignee: WONKISOPHARM CO., LTD

Application No.: 12/307153   Filing Date: 02/Jul/2007

Abstract:Disclosed is tonovel cyclic derivatives having potent inhibiting effect on melanin formation and skin hyper-pigmentation activity with no adverse response to skin. They can be used as the therapeutics for treating and preventing the skin disease caused by over-reproduced melanin.

Priority: KR20060062703 Applic. Date: 2006-07-04; WO2007KR03199 Applic. Date: 2007-07-02

Inventor: CHO HYUN CHUL [KR]; CHOI YONGHYUN [KR]; YHEI JONGHAN [KR]

Title: COMPOUNDS

Applicant/Assignee:

Application No.: 12/519612   Filing Date: 19/Dec/2007

Abstract:The present invention relates to substituted 3-Aminopyrazole compounds of formula (I): and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for modulating SCD activity.

Priority: GB20060025604 Applic. Date: 2006-12-21; WO2007EP64218 Applic. Date: 2007-12-19

Inventor: BOUILLOT ANNE MARIE JEANNE [FR]; DAUGAN ALAIN CLAUDE-MARIE [FR]; DEAN ANTHONY WILLIAM [GB]; FILLMORE MARTIN CHRISTIAN [GB]

Title: Compounds Having CRTH2 Antagonist Activity

Applicant/Assignee: OXAGEN LIMITED

Application No.: 12/357792   Filing Date: 22/Jan/2009

Abstract:Compounds of general formula (I) W is chloro or fluoro

Z is a -SO2YR1 group wherein R1 is C3-C8 heterocyclyl, aryl or heteroaryl any of which may optionally be substituted with one or more substituents selected from halo, -CN, -C1-C6 alkyl, -SOR3, -SO2R3, -SO2N(R2)2, -N(R2)2, -NR2C(O)R3, -CO2R2, -CONR2R3, -NO2, -OR2, -SR2, -O(CH2)pOR2, and -O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, -C1-C6 alkyl, -C3-C8 cycloalkyl, aryl or heteroaryl

each R3 is independently, -C1-C6 alkyl, -C3-C8 cycloalkyl, aryl or heteroaryl

p and q are each independently an integer from 1 to 3

Y is a straight or branched C1-C4 alkylene chain

and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

Priority: GB20080001132 Applic. Date: 2008-01-22; GB20080001671 Applic. Date: 2008-01-30

Inventor: ARMER RICHARD EDWARD [GB]; WYNNE GRAHAM MICHAEL [GB]

Title: Treatment of faecal incontinence and other conditions with 1R, 2S-methoxamine

Applicant/Assignee: NORGINE EUROPE BV

Application No.: 12/586973   Filing Date: 30/Sep/2009

Abstract:1R,2S-Methoxamine may be used topically for effective treatment of faecal incontinence at low doses without local or systemic side effects, for example, without affecting blood pressure. 1R,2S-Methoxamine may be used to treat other disturbances and disorders of the gastrointestinal, as a pressor agent, as a nasal decongestant and in ophthalmology, at low does and without significant side effects.

Priority: GB20010030763 Applic. Date: 2001-12-21; WO2002GB05864 Applic. Date: 2002-12-20; US2004-499873 Applic. Date: 2004-12-27

Inventor: BARRAS NORMAN [GB]; THOMPSON JEFFREY MARTIN [GB]

Title: SYSTEM FOR EDITING AN AVATAR

Applicant/Assignee: MICROSOFT CORPORATION

Application No.: 12/178535   Filing Date: 23/Jul/2008

Abstract:Systems, methods and computer readable media are disclosed for updating the appearance of an avatar that exists across an online multi-player gaming system, including an executing video game. In addition to the general system, systems, methods and computer readable media for updating the avatar, techniques are disclosed for prompting networked video games to update an avatar that has been modified while the video game has been executing.

Priority:

Inventor: REVILLE BRENDAN K [US]; LAW STACEY [US]; SMITH DEREK [US]; KROYMANN DAN B [US]

Title: URETHANE COMPOUND COMPRISING AN INCORPORATED POLYETHER GROUP-CONTAINING SILICONE DERIVATIVE AND A NITROGEN HETEROCYCLE

Applicant/Assignee: BASF AKTIENGESELLSCHAFT

Application No.: 11/722189   Filing Date: 22/Dec/2005

Abstract:The present invention relates to a urethane compound which comprises, in incorporated form, at least one polyether group-containing silicone derivative, at least one nitrogen heterocycle and at least one polyisocyanate, to cosmetic and pharmaceutical compositions which comprise such a urethane compound, and to the use of such a urethane compound.

Priority: DE200410062201 Applic. Date: 2004-12-23; WO2005EP13927 Applic. Date: 2005-12-22

Inventor: NGUYEN-KIM SON [DE]

Title: SUNSCREEN COMPOSITIONS

Applicant/Assignee:

Application No.: 12/449932   Filing Date: 05/May/2007

Abstract:Sunscreen and sunblock formulations that provide cytoprotective and immuno-enhancing additives avoiding endocrine disrupting agents, (a) at least one inorganic sun-blocking or sunscreen agent that is a proven non-endocrine disrupter, (b) at least one emollient proven to be a non-endocrine disrupter

and (c) an oil component capable of protecting skin from harmful effects of radiation including sunlight and ultraviolet light wherein the oil is a carrier oil, an essential oil, or both are described. The formulations preferably include an essential oil of a naturally-occurring substance as well as suitable inorganic components including titanium dioxide, zinc oxide, silica or silicon dioxide, fluoropolymers, and mixtures thereof. Suitable organic components include butylmethoxy dibenzoylmethane. Cold-processed Aloe barbadensis Miller-Stockton, a single species of Aloe barbadensis containing glucose-rich mannose-containing oligosaccharide or oligosaccharides, can also be used. Test methodologies and results indicate specific differences from conventional formulations.

Priority: WO2007US05672 Applic. Date: 2007-03-05

Inventor: GRUNE GUERRY L [US]

Title: USE OF CHROMAN-4-ONE DERIVATIVES

Applicant/Assignee: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG

Application No.: 12/531369   Filing Date: 21/Feb/2008

Abstract:The invention relates to the use of compounds of the formula (I) or of a composition comprising at least one compound of the formula (I), containing radicals as described in the claims, for the care, preservation or improvement of the general state of the skin or hair.

Priority: DE200710013366 Applic. Date: 2007-03-16; WO2008EP01352 Applic. Date: 2008-02-21

Inventor: CAROLA CHRISTOPHE [DE]; ROSSKOPF RALF [DE]

Title: COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN DISORDERS

Applicant/Assignee: DERMAVRI PTY LTD

Application No.: 12/396649   Filing Date: 03/Mar/2009

Abstract:The present invention concerns methods and compositions for prophylactic or therapeutic treatment of skin disorders by administering therapeutically or prophylactically effective amounts of a probiotic. The present invention is also concerned with the treatment of symptoms of skin disorders.

Priority: AU2002PS00571 Applic. Date: 2002-02-15; US2004-504697 Applic. Date: 2004-08-12; WO2003AU00200 Applic. Date: 2003-02-17

Inventor: CONWAY PATRICIA LYNNE [AU]; COLLIER PAUL ANTHONY [AU]

Title: MEGALIN-BASED DELIVERY OF THERAPEUTIC COMPOUNDS TO THE BRAIN AND OTHER TISSUES

Applicant/Assignee: RAPTOR PHARMACEUTICAL INC RAPTOR PHARMACEUTICALS INC

Application No.: 12/508956   Filing Date: 24/Jul/2009

Abstract:The present invention is directed to a methods and compositions for receptor mediated drug delivery, particularly across the blood-brain barrier.

Priority: US2004-812849 Applic. Date: 2004-03-30; US2003-600862 Applic. Date: 2003-06-20

Inventor: ZANKEL TODD [US]; STARR CHRISTOPHER M [US]

Title: Personal Care Article

Applicant/Assignee:

Application No.: 12/226118   Filing Date: 05/Apr/2007

Abstract:A personal care article including a substrate having impregnated therein, applied thereon or arranged to substantially encase, a cosmetic composition which includes a hair modification active, wherein the pH of the composition is substantially less than 9.0, and at least a portion of the article has exfoliating properties.

Priority: GB20060006992 Applic. Date: 2006-04-07; GB20060012486 Applic. Date: 2006-06-23; WO2007GB01305 Applic. Date: 2007-04-05

Inventor: CAWTHORNE LEE [GB]; DODD KAREN [GB]; TINDAL ANNE [GB]

Title: Use of Polymers

Applicant/Assignee: CROMA-PHARMA GESELLSCHAFT M.B.H

Application No.: 12/520820   Filing Date: 21/Dec/2007

Abstract:The present invention relates to the use of a thiol-group-containing polymer for preparing an implant for tissue augmentation, wherein the basis polymer is a polysaccharide.

Priority: AT20060002136 Applic. Date: 2006-12-22; US20060871534P Applic. Date: 2006-12-22; WO2007AT00585 Applic. Date: 2007-12-21

Inventor: HORNOF MARGIT [AT]

Title: LAYERED BIO-ADHESIVE COMPOSITIONS AND USES THEREOF

Applicant/Assignee: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC

Application No.: 12/298698   Filing Date: 24/Apr/2007

Abstract:The invention generally provides compositions and methods for promoting and enhancing wound closure and healing. Specifically, the invention provides a biologic composition which comprises a support layer which serves as transport scaffold, for example made of gelatin, which is coated or impregnated with a bio-adhesive molecule such as rose bengal or glyceraldehyde. The composition can also comprise an artificial or biological matrix, optionally processed (i.e. cleaned and coated with extracellular matrix proteins) to enhance cell attachment and survival. The composition can further comprise a monolayer of epithelial, endothelial cells or mesenchymal cells. The invention provides methods for using the compositions for treating wounds due to disease, trauma or surgery. Specific methods for treating ocular wounds are provided.

Priority: US20060795437P Applic. Date: 2006-04-27; WO2007US09861 Applic. Date: 2007-04-24

Inventor: DEL PRIORE LUCIAN V [US]; KAPLAN HENRY J [US]; TEZEL TONGALP [US]

Title: COSMETIC USE OF ACTIVE AGENTS THAT STIMULATE MATRIPTASE EXPRESSION

Applicant/Assignee: CHANEL PARFUMS BEAUTE

Application No.: 12/442251   Filing Date: 18/Sep/2007

Abstract:The present invention relates to a cosmetic process for caring for human skin, intended to moisturize it and/or to protect it against drying out, comprising the topical application to the skin of a composition containing at least one active agent that stimulates the expression of the matriptase MT/SP1. It also relates to the cosmetic use of such an active agent for moisturizing human skin and/or protecting it against drying out. It further relates to the use of such an active agent to manufacture a pharmaceutical composition intended to prevent and/or alleviate skin tautness, stinging and/or itching and/or lip chapping. The active agents are extracts of Ceratonia siliqua, Cananga odorata hook, Cedrelopsis grevei and Cistus ladaniferus L.

Priority: FR20060008245 Applic. Date: 2006-09-20; FR20060008256 Applic. Date: 2006-09-20; US20060850276P Applic. Date: 2006-10-10; US20060850278P Applic. Date: 2006-10-10; WO2007EP59835 Applic. Date: 2007-09-18

Inventor: MAESTRO YANNICK GERARD [FR]; BERGIA DANIEL MICHEL PAUL [FR]; LASSERRE CHRISTELLE MARIE SUZANNE [US]

Title: PROCESS FOR OBTAINING AN ACTIVE INGREDIENT WITH AN IMMEDIATE TENSOR EFFECT ON THE SKIN, ACTIVE INGREDIENT AND COMPOSITIONS

Applicant/Assignee: SOCIETE INDUSTRIELLE LIMOUSINE D'APPLICATION BIOLOGIQUE, DITE SILAB

Application No.: 12/442441   Filing Date: 21/Sep/2007

Abstract:The invention relates to a method for obtaining an active ingredient having an immediate anti-wrinkle and skin-tensioning effect, characterised in that it comprises extracting and purifying high molecular weight polysaccharides from oat bran and/or fibres and/or grains, and solutioning and stabilising the polysaccharides in water. The invention also relates to the product thus obtained, to uses thereof, and to cosmetic compositions containing this active ingredient.

Priority: FR20060053903 Applic. Date: 2006-09-22; FR20070053714 Applic. Date: 2007-03-08; WO2007FR51992 Applic. Date: 2007-09-21

Inventor: PAUFIQUE JEAN [FR]

Title: DIHYDRO-TRITERPENES IN THE TREATMENT OF VIRAL INFECTIONS, CARDIOVASCULAR DISEASE, INFLAMMATION, HYPERSENSITIVITY OR PAIN

Applicant/Assignee: BSP PHARMA

Application No.: 12/572785   Filing Date: 02/Oct/2009

Abstract:The present invention relates to compositions comprising the triterpenes, dihydrobutyrospermol, dihydrolupeol and/or dihydroparkeol, the composition being applicable as a pharmaceutical, a dietary supplement or as a cosmetic. Further, the invention relates to the use of such compositions for the preparation of a medicament, a dietary supplement or a cosmetic for immunomodulating in a mammal such as suppression of viral infections, cardiovascular diseases, cancer, hypersensitivity and/or inflammatory reactions. The triterpenes may be in form of the free alcohol or derivatised, preferably with cinnamic acid, acetic acid or fatty acids. Furthermore, the triterpenes may be an extract obtainable from a natural source or synthetically made.

Priority: DK20010000049 Applic. Date: 2001-01-12; US2003-466093 Applic. Date: 2003-09-25; WO2002IB00081 Applic. Date: 2002-01-14; US20010261168P Applic. Date: 2001-01-16

Inventor: WEIDNER MORTEN SLOTH [DK]

Title: LOW-DOSE MOMETASONE FORMULATIONS

Applicant/Assignee: PERRIGO ISRAEL PHARMACEUTICALS LTD

Application No.: 12/535406   Filing Date: 04/Aug/2009

Abstract:Provided is a topical cream composition for the delivery of mometasone furoate comprising low dose mometasone furoate for the treatment of corticosteroid responsive dermatoses. The composition of the present invention can be safely applied over large surface areas of the skin (including areas with wrinkles and/or hair), and can be used therapeutically for extended periods of time (e.g., greater than 3 weeks). Treatment with the composition of the present invention carries reduced and/or fewer side effects compared with commercially available mometasone furoate cream products. The cream composition of the present invention is safe for the use of babies and infants under 2 years old. Additionally provided are methods of preparing and using the composition of the invention.

Priority: WO2008IL00485 Applic. Date: 2008-04-09; US20070911185P Applic. Date: 2007-04-11

Inventor: ARKIN MOSHE [IL]; ZEEVI AMIRA [IL]; CHERKEZ STEPHEN [IL]; ASCULAI EILON [IL]; UZAN RINA [IL]; BRAGHINSKI BELLA [IL]

Title: Chemokine Receptor Modulators

Applicant/Assignee:

Application No.: 12/414352   Filing Date: 30/Mar/2009

Abstract:The invention provides compounds of Formula (I) and pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, and/or esters thereof. These compounds, and pharmaceutical composition comprising such compounds are useful treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers

Priority: US20080040516P Applic. Date: 2008-03-28

Inventor: CLARK MICHAEL P [US]; WAGNER FLORENCE F [US]; DOROH BRANDON C [US]; JOHNSON TRICIA L [US]; TAHIROVIC YESIM ALTAS [US]; WILSON LAWRENCE [US]; WISEMAN JOHN M [US]; SKUDLAREK JASON W [US]; LOCKWOOD MARK A [US]; NATCHUS MICHAEL G [US]

Title: DERIVATIVES OF SUBSTITUTED 3-PHENYL-1-(PHENYLTHIENYL)PROPAN-1-ONES AND OF 3-PHENYL-1-(PHENYLFURANYL) PROPAN-1-ONES, PREPARATION AND USE

Applicant/Assignee:

Application No.: 12/448668   Filing Date: 28/Dec/2007

Abstract:The present invention relates to compounds derived from substituted 3-phenyl-1-(thien-2-yl)propan-1-ones, pharmaceutical compositions comprising them as well as their therapeutic applications, notably in the field of human and animal health.

Priority: FR20060056067 Applic. Date: 2006-12-29; WO2007FR52634 Applic. Date: 2007-12-28

Inventor: DELHOMEL JEAN-FRANCOIS [FR]

Title: Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris

Applicant/Assignee:

Application No.: 12/458982   Filing Date: 29/Jul/2009

Abstract:A regimen for the safe and effective long-term treatment of acne vulgaris entails topically applying onto the affected skin area of a subject afflicted therewith, for a period of time of at least four (4) months, e.g., for at least twelve (12) months and advantageously on a daily basis and preferably once a day, a thus effective amount of a topical medicament containing adapalene and benzoyl peroxide, formulated into a pharmaceutically acceptable medium therefor.

Priority: WO2008EP51155 Applic. Date: 2008-01-30; US20070898113P Applic. Date: 2007-01-30

Inventor: GRAEBER MICHAEL [US]; LIU YIN [US]; GORE BARBARA [US]

Title: Methods of Treating Wrinkles, Developing Wrinkle Treatments And Evaluating Treatment Efficacy, Based On Newly Discovered Similarities Between Wrinkles And Skin Wounds

Applicant/Assignee:

Application No.: 12/500374   Filing Date: 09/Jul/2009

Abstract:Disclosed are methods of measuring an endogenous wrinkle electric field and methods of characterizing topical applications, or other treatments, in terms of their effect on the endogenous electric field of wrinkles. Also included, are methods of developing topical applications, or other treatments that have a desired effect on the endogenous electric field of a wrinkle. The methods disclosed herein, are based on a new model of wrinkle physiology that exploits previously unknown similarities between skin wounds and wrinkles.

Priority: US20080085213P Applic. Date: 2008-07-31

Inventor: MAMMONE THOMAS [US]; IONITA-MANZATU VASILE [US]; HAWKINS GEOFFREY [US]; REIN GLEN [US]

Title: Novel gene disruptions, compositions and methods relating thereto

Applicant/Assignee:

Application No.: 12/221669   Filing Date: 04/Aug/2008

Abstract:The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO227, PRO233, PRO238, PRO1328, PRO4342, PRO7423, PRO10096, PRO21384, PRO353 or PRO1885 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders

cardiovascular, endothelial or angiogenic disorders

eye abnormalities

immunological disorders

oncological disorders

bone metabolic abnormalities or disorders

lipid metabolic disorders

or developmental abnormalities.

Priority:

Inventor: EDWARDS JOEL A [US]; HUANG WENHU [US]; MONTGOMERY CHARLES [US]; QIAN NI NANCY [US]; SHI ZHENG-ZHENG [US]; SPARKS MARY JEAN [US]; VOGEL PETER [US]; OOX MINDY [US]

Title: Method for Preparing a Lipophilic Vine Extract

Applicant/Assignee:

Application No.: 12/460742   Filing Date: 23/Jul/2009

Abstract:The present invention relates to a method for preparing a lipophilic extract from lignified portions of vine, such as shoots, stock and roots, characterized in that said method comprises a step for extraction from said lignified portions with an apolar solvent

to an extract obtained by such a method

to the use of such an extract as an excipient in a cosmetic composition

and to a cosmetic composition comprising such an extract.

Priority: FR20080055117 Applic. Date: 2008-07-25

Inventor: PECHER VIRGINIE [FR]; ANDRE PATRICE [FR]

Title: PYRIMIDINE DERIVATIVES FOR THE PREVENTION OF HIV INFECTION

Applicant/Assignee:

Application No.: 12/567051   Filing Date: 25/Sep/2009

Abstract:This invention concerns the use of a compound for the manufacture of a medicament for the prevention of HIV infection via sexual intercourse and related intimate contact between partners, wherein the compound is a compound of formula a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein the ring containing -a1=a2-a3=a4- and -b1=b2-b3=b4- represents phenyl, pyridyl, pyrimidinyl, pirazinyl, pyridazinyl

n is 0 to 5

m is 1 to 4

R1 is hydrogen

aryl

formyl

C1-6alkylcarbonyl

C1-6alkyl

C1-6alkyloxycarbonyl

substituted C1-6alkyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy

substituted C1-6alkyloxyC1-6alkylcarbonyl

R2 is hydroxy, halo, optionally substituted C1-6alkyl, C3-7cycloalkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(-O)pR6, -NH-S(-O)pR6, -C(-O)R6, -NHC(-O)H, -C(-O)NHNH2, -NHC(-O)R6, -C(-NH)R6 or a 5-membered heterocycle

X1 is -NR5-, -NH-NH-, -N-N-, -O-, -C(-O)-, C1-4alkanediyl, -CHOH-, -S-, -S(-O)p-, -X2-C1-4alkanediyl- or -C1-4alkanediyl-X2-

R3 is NHR13

NR13R14

-C(-O)-NHR13

-C(-O)-NR13R14

-C(-O)-R15

-CH-N-NH-C(-O)-R16

substituted C1-6alkyl

optionally substituted C1-6alkyloxyC1-6alkyl

substituted C2-6alkenyl

substituted C2-6alkynyl

C1-6alkyl substituted with hydroxy and a second substituent

-C(-N-O-R8)-C1-4alkyl

R7

or -X3-R7

R4 is halo, hydroxy, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, aminocarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyl, formyl, amino, mono- or di(C1-4alkyl)amino

and pharmaceutical compositions comprising them.

Priority: WO2003EP01291 Applic. Date: 2003-02-07; US2004-544735 Applic. Date: 2004-02-04; WO2004EP01011 Applic. Date: 2004-02-04

Inventor: HEERES JAN [BE]; LEWI PAULUS JOANNES [BE]; JANSSEN PAUL ADRIAAN JAN [BE]; ARTS FRANK XAVIER JOZEF HERWIG [BE]; DE JONGE MARC RENE [NL]; KOYMANS LUCIEN MARIA HENRICUS [BE]; DAEYAERT FREDERIK FRANS DESIRE [BE]; VINKERS HENDRIK MAARTEN [BE]; GULLEMONT JEROME EMILE GEORGES [FR]; PASQUIER ELISABETH THERESA JEANNE [FR]

Title: COMPOSITION COMPRISONG RUTIN AND POLYUNSATURATED FATTY ACID HAVING AN INHIBITORY ACTIVITY ON 5-ALPH REDUCTASE

Applicant/Assignee: GIULIANI S.P.A

Application No.: 12/450362   Filing Date: 18/Mar/2008

Abstract:The present invention relates to the use of selected active principles of a natural origin in substitution of extract from Boehmeria Nipononivea for regulating the trophism of hair follicles and the production of sebum on the skin and its use in alopecia, with considerable practical advantages and with respect to the safety profile. The composition of the invention is based on an association of omega 6 polyunsaturated acids and rutin in a pharmaceutically acceptable carrier.

Priority: IT2007MI00555 Applic. Date: 2007-03-21; WO2008IB00772 Applic. Date: 2008-03-18

Inventor: GIULIANI GIAMMARIA [IT]; BENEDUSI ANNA [IT]; BARONI SERGIO [IT]

Title: Use of rice-derived products in a universal cell culture medium

Applicant/Assignee:

Application No.: 12/228172   Filing Date: 11/Aug/2008

Abstract:The invention is used as an additive to a culture medium to maintain and grow various cells including stem cells and support their manufactured and secreted products including cytokines, chemokines and growth factors in an environment which provides: a) metabolic enabling or enhancement of measurable parameters within the cellular population b) availability and usage of nutrients to cells c) distinct and positive effect on cellular dynamics (i.e. cellular proliferation and secretion of manufactured products by the cells) d) stabilized environment for maintaining conditions for growth and other cellular and metabolic processes including secretion of manufactured products including signaling factors e) enhanced biological cellular function of inherent cellular processes f) non-interference with normal cellular metabolics (i.e. signaling) g) increased protection from toxic effects to the cell h) additional benefits to the cellular population which in absence of the additive would be lacking.

Priority:

Inventor: STEELE ANN MARIE [US]; SMITH MARK DARGAN [US]; BOONCHUEN SOMCHAI [TH]

Title: Nucleic Acid molecules and Collections Thereof, Their Application and Modification

Applicant/Assignee:

Application No.: 12/087649   Filing Date: 10/Jan/2007

Abstract:The invention provides a method for characterising a sample comprising nucleic acid derived from a cell. The method comprises determining whether a sample comprises at least a minimal sequence of at least one new microRNA (miRNA) according to the invention or a mammalian ortholog thereof and characterizing the sample on the basis of the presence or absence of the miRNA. The invention further provides nucleic acid molecules and collections thereof and their use in therapeutic and diagnostic applications. The invention furthermore provides a method for identifying a miRNA molecule or a precursor molecule thereof.

Priority: WO2006NL00010 Applic. Date: 2006-01-10; WO2006NL00491 Applic. Date: 2006-09-29; WO2007NL00012 Applic. Date: 2007-01-10

Inventor: PLASTERK RONALD H A [NL]; BEREZIKOV EUGENE [NL]; CUPPEN EDWIN P J G [NL]

Title: Branched Polyorganosiloxanes Modified With Aromatic Substances

Applicant/Assignee: MOMENTIVE PERFORMANCE MATERIALS GMBH

Application No.: 12/531936   Filing Date: 19/Mar/2008

Abstract:The invention relates to fragrance-modified branched polyorganosiloxanes, methods for producing them and their use.

Priority: DE200710012910 Applic. Date: 2007-03-19; WO2008EP53297 Applic. Date: 2008-03-19

Inventor: LANGE HORST [DE]; ROOS CHRISTOPHER [DE]; WAGNER ROLAND [DE]; KROPFGANS MARTIN [DE]

Title: METHOD OF PROMOTING SKIN COLLAGEN PRODUCTION

Applicant/Assignee: SNOW BRAND MILK PRODUCTS CO., LTD

Application No.: 12/579100   Filing Date: 14/Oct/2009

Abstract:It is intended to provide a skin collagen production promoter, foods and drinks for promoting skin collagen production and cosmetics for promoting skin collagen production which are useful in preventing skin chapping, wrinkles, worsening in skin fitness, etc. Namely, a skin collagen production promoter, foods and drinks for promoting skin collagen production and cosmetics for promoting skin collagen production which contain as the active ingredient(s) a milk-origin basic protein fraction and/or a basic peptide fraction obtained by digesting the above-described basic protein fraction with a protein digesting enzyme such as pepsin or pancreatin. The above basic protein fraction and basic peptide fraction have an effect of increasing skin collagen level.

Priority: US2003-553830 Applic. Date: 2003-05-07; WO2003JP05707 Applic. Date: 2003-05-07

Inventor: MORITA YOSHIKAZU [JP]; TAKADA YUKIHIRO [JP]; TOBA YASUHIRO [JP]; OOI WATARU [JP]; KAWAKAMI HIROSHI [JP]

Title: 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions

Applicant/Assignee: UCB PHARMA, S.A

Application No.: 12/440899   Filing Date: 11/Sep/2007

Abstract:The present invention concerns novel 2 amino pyrimidine derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as harmaceuticals.

Priority: GB20060017966 Applic. Date: 2006-09-12; EP20060019518 Applic. Date: 2006-09-19; WO2007EP07898 Applic. Date: 2007-09-11

Inventor: RAPHY GILLES [GB]; WATSON ROBERT JOHN [GB]; HANNAH DUNCAN [GB]; PEGURIER CECILE [BE]; ORTMANS ISABELLE [BE]; LOCK CHRISTOPHER JAMES [GE]; KNIGHT ROLAND LAURENCE [GB]; OWEN DAVID ALAN [GB]

Title: SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS

Applicant/Assignee: LEO PHARMA

Application No.: 12/520325   Filing Date: 21/Dec/2007

Abstract:The present invention relates to a compound according to formula: (I)

wherein X1, X2, X3, X4 and X5 independently of each other represent -CH- or N

or X3, X4 and X5 independently of each other represent -CH- or N, and Xi and X2 independently of each other represent C and form part of an additional 6-membered aromatic ring

R1 represents hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, or alkylcarbonyl, all of which are optionally substituted

R2 and R3 independently represent hydrogen, -CH2-C(O)NR-R', alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, haloalkyl, hydroxyalkyl, heterocycloalkenyl, alkylaryl, alkylalkoxycarbonyl, alkylcarbonyloxy, or alkoxyalkyl, all of which are optionally substituted

R11 represents hydrogen, halogen, cyano, amino, alkoxy or alkylamino, X1-X5 represent -CH- or N, including N-oxides, enantiomers and diastereomers

and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention relates further to processes for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

Priority: US20060871689P Applic. Date: 2006-12-22; US20070945470P Applic. Date: 2007-06-21; WO2007DK00564 Applic. Date: 2007-12-21

Inventor: FELDING JAKOB [DK]; NIELSEN SIMON FELDBAEK [DK]

Title: PENETRATING CARRIER, ANTI-FUNGAL COMPOSITION USING THE SAME AND METHOD FOR TREATMENT OF DERMATOPHYTES

Applicant/Assignee:

Application No.: 12/568833   Filing Date: 29/Sep/2009

Abstract:An antifungal liquid composition for topical administration is provided that contains turpentine and at least one of peppermint oil, mineral oil, and essential oil alcohols, and one or more antifungal medications selected from ciclopirox olamine, terbinafine, tolnaftate, microconazole, itraconazole, ketoconazole, econazole, and fluconazole, and optionally one or more antifungal essential oils, and its use in the topical treatment of fungal infection, particularly of the nail.

Priority: US2007-684869 Applic. Date: 2007-03-12; US2004-956073 Applic. Date: 2004-10-04; US20080194508P Applic. Date: 2008-09-29

Inventor: SELNER MARC [US]

Title: Compounds Having CRTH2 Antagonist Activity

Applicant/Assignee: OXAGEN LIMITED

Application No.: 12/374702   Filing Date: 20/Jul/2007

Abstract:Compounds of general formula (I) wherein R is phenyl optionally substituted with one or more halo substituents

and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

Priority: GB20060014608 Applic. Date: 2006-07-22; GB20060024176 Applic. Date: 2006-12-04; WO2007GB02761 Applic. Date: 2007-07-20

Inventor: ARMER RICHARD EDWARD [GB]; WYNNE GRAHAM MICHAEL [GB]; DORGAN COLIN RICHARD [GB]; JOHNSON PETER DAVID [GB]

Title: KIT FOR APPLYING A POLYMERIZABLE ADHESIVE COMPOSITION TO TISSUES

Applicant/Assignee:

Application No.: 12/579024   Filing Date: 14/Oct/2009

Abstract:The invention relates to a kit for the topical and/or internal application of a polymerisable adhesive composition to tissues, enabling improved control of the polymerisation speed on the surface of the tissue, in addition to the effective disinfection of the wound. The kit consists of at least one receptacle and contains a polymerisable adhesive composition based on cyanacrylate, in addition to a disinfectant composition.

Priority: DE200710019044 Applic. Date: 2007-04-20; WO2008EP54346 Applic. Date: 2008-04-10

Inventor: BROADLEY KENNETH N [IE]; GUTHRIE JOHN [IE]; SWORDS NOELEEN [IE]

Title: Prostaglandin E2 Binding Proteins and Uses Thereof

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 12/499646   Filing Date: 08/Jul/2009

Abstract:The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.

Priority: US20080134264P Applic. Date: 2008-07-08; US20080197258P Applic. Date: 2008-10-23

Inventor: GU JJIJIE [US]; HUTCHINS CHARLES W [US]; ZHU RONG-RONG [US]; SHEN JIANWEI [US]; HARRIS MARIA C [US]; BELANGER EILEEN [US]; MURTAZA ANWAR [US]; TARCSA EDIT [US]; STINE WILLIAM B [US]; HSIEH CHUNG-MING [US]

Title: HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS

Applicant/Assignee:

Application No.: 12/482373   Filing Date: 10/Jun/2009

Abstract:The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

Priority: WO2006IB54724 Applic. Date: 2006-12-10

Inventor: YU CHONGXI [US]

Title: Penetrating pharmaceutical foam

Applicant/Assignee: FOAMIX LTD FOAMIX, LTD

Application No.: 10/922358   Filing Date: 20/Aug/2004

Abstract:The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration.

Priority: IL20020152486 Applic. Date: 2002-10-25; WO2003IB05527 Applic. Date: 2003-10-24; US2004-911367 Applic. Date: 2004-08-04; US20030497648P Applic. Date: 2003-08-25; US20020429546P Applic. Date: 2002-11-29; US20030492385P Applic. Date: 2003-08-04

Inventor: TAMARKIN DOV [IL]; FRIEDMAN DORON [IL]; EINI MEIR [IL]

Title: ACTIVE DELIVERY SYSTEMS FORMULATIONS

Applicant/Assignee: CASTLE BEACH, LLC

Application No.: 12/540201   Filing Date: 12/Aug/2009

Abstract:The present invention relates to active delivery system formulations, and methods of making and using the same. Said formulations, when applied to a substrate surface, form a protective coating on the surface and permit constituent active agents to act on the surface and in the surrounding medium.

Priority: US20080104129P Applic. Date: 2008-10-09; US20080088155P Applic. Date: 2008-08-12

Inventor: HOMOLA ANDREW M [US]; PITTS R GARY [US]; DUNTON RONALD K [US]

Title: Steroidal compounds as melanogenesis modifiers and uses thereof

Applicant/Assignee: SKINMEDICA, INC

Application No.: 12/587882   Filing Date: 13/Oct/2009

Abstract:Provided are steroidal compounds of formula I, for example, conessine, and the use of such compounds and compositions thereof to modulate (e.g., inhibit) melanogenesis and pigmentation. Also provided are plant extracts containing a compound of formula I, for example, conessine, and the use of such a plant extract to modulate (e.g., inhibit) melanogenesis and pigmentation. The compound or plant extract may be prepared as pharmaceutical and cosmetic compositions, and may be used for the prevention and treatment of conditions that are related to aberrant melanogenesis activity.

Priority: US2009-433322 Applic. Date: 2009-04-30; US20080049114P Applic. Date: 2008-04-30

Inventor: ORLOW SETH J [US]; KOMATSU LI NI [US]

Title: Use of HMGB1 antagonists for the treatment of inflammatory skin conditions

Applicant/Assignee:

Application No.: 11/988896   Filing Date: 11/Jul/2006

Abstract:Methods are disclosed for treating an inflammatory skin condition in a subject. The methods comprise administering to a subject an HMGB antagonist, such as a high mobility group box (HMGB) A box or a biologically active fragment thereof, an antibody to HMGB or an antigen-binding fragment thereof, an HMGB small molecule antagonist, an antibody to TLR2 or an antigen-binding fragment thereof, a soluble TLR2 polypeptide, an antibody to RAGE or an antigen-binding fragment thereof, a soluble RAGE polypeptide and a RAGE small molecule antagonist.

Priority: US20050700704P Applic. Date: 2005-07-18; WO2006US27053 Applic. Date: 2006-07-11

Inventor: WAHREN-HERLENIUS MARIE [SE]; NYBERG FILIPPA [SE]; MARCHINI GIOVANNA [SE]

Title: METHOD OF ANTI-AGEING COSMETIC CARE BY STIMULATION OF SURVIVIN EXPRESSION

Applicant/Assignee: LVMH RECHERCHE

Application No.: 12/477409   Filing Date: 03/Jun/2009

Abstract:The invention relates to a cosmetic care method comprising the delivery of an effective amount of at least one cosmetically acceptable agent that activates or stimulates survivin expression in the stem cells of the basal layer of the epidermis. The invention makes it possible in particular to prevent or delay the appearance of the signs of skin aging or to treat them.

Priority: FR20080053794 Applic. Date: 2008-06-06

Inventor: DUMAS MARC [FR]; BONTE FREDERIC [FR]; RENIMEL ISABELLE [FR]

Title: HERBAL COMPOSITION FOR THE PREVENTION OF WRINKLES AND SKIN DISORDERS, METHODS OF PREPARING THE SAME AND USES THEREOF

Applicant/Assignee: HIMALAYA GLOBAL HOLDINGS, LTD

Application No.: 12/440917   Filing Date: 11/Mar/2009

Abstract:Disclosed is a natural herbal composition for preventing wrinkles and other skin disorders due to aging, stress and environmental factors without any side effect. The composition comprises extracts of Rhodomyrtus tomentosa, Cipadessa baccifera, Woodfordia fruticosa and Camellia sinensis.

Priority: WO2006IN00347 Applic. Date: 2006-09-12

Inventor: MITRA SHANKAR KUMAR [IN]; SAXENA EKTA [IN]

Title: FAT ABSORPTION INHIBITOR AND FOOD AND DRINK USING THE SAME

Applicant/Assignee: KRACIE FOODS, LTD

Application No.: 12/377233   Filing Date: 10/Aug/2007

Abstract:The present invention relates to a fat absorption inhibitor containing a chestnut skin extract, and a food and drink containing that fat absorption inhibitor. The present invention can therefore provide a fat absorption inhibitor, and a food and drink using the same, that can be obtained from waste products following primary use, inhibit increases in lipids such as blood neutral fats by inhibiting absorption of dietary lipids, and in turn are effective in preventing accumulation of lipids, have superior suitability for continuous ingestion without having an impact on flavor, and do not require a complex production process.

Priority: JP20060220710 Applic. Date: 2006-08-11; JP20070028811 Applic. Date: 2007-02-08; WO2007JP65985 Applic. Date: 2007-08-10

Inventor: KATAOKA HISASHI [JP]; SHIROMIZU TOMOKO [JP]; KAWASAKI KENJI [JP]

Title: Asthma/Allergy Therapy that Targets T-lymphoctyes and/or Eosinophils

Applicant/Assignee:

Application No.: 12/539731   Filing Date: 12/Aug/2009

Abstract:A pharmaceutical composition for the treatment and/or prophylaxis of diseases caused by type I hypersensitivity reactions consisting essentially of Glicophosphopeptical, or pure Nigella Sativa seeds, in a concentration which stimulate Th1 lymphocytes and selectively switch-off the eosinophilic airway inflammation A method of treatment of allergy using Th1 stimulating agents, to be administered to a mammal such as human in need of such treatment in a shot of 5 days only, resulted in significant decrease in symptom score started day 3, and in sputum eosinophils by day 14, followed by long-term clinical remission of a mean of 6 months. The BCG-like Th1 stimulation is also used in treating diseases in which the body defensive mechanism is a Cell Mediated Immunity, including viral infections, as but not limited to influenza and common cold, Chronic and recurrent urinary tract infection, pelvic inflammatory diseases as neuroimmune appendicitis, cancer, crohns disease and facial palsy.

Priority: GB19990004777 Applic. Date: 1999-03-02; US2001-944564 Applic. Date: 2001-09-04

Inventor: NASIF NEDAA ABDUL-GHANI [QA]

Title: Compounds

Applicant/Assignee:

Application No.: 12/519777   Filing Date: 19/Dec/2007

Abstract:The present invention relates to substituted 3-Aminopyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for modulating SCD activity.

Priority: GB20060025654 Applic. Date: 2006-12-21; WO2007EP64220 Applic. Date: 2007-12-19

Inventor: BOUILLOT ANNE MARIE JEANNE [FR]

Title: Method of Promoting Wound Healing

Applicant/Assignee: CORTHERA, INC

Application No.: 12/465613   Filing Date: 13/May/2009

Abstract:The present disclosure relates to methods of administering relaxin to promote wound healing and reduce scar formation. The disclosure further contemplates the use of relaxin in reconstructive and plastic surgery.

Priority: US20080127947P Applic. Date: 2008-05-16

Inventor: STEWART DENNIS R [US]

Title: Heterocyclic compounds as antiinflammatory agents

Applicant/Assignee:

Application No.: 12/311393   Filing Date: 29/Oct/2007

Abstract:A compound of Formula Ia or Ib in free or salt or solvate form, where R1, R2, R3, R4, R5 R20, R24, R25, X, Y and Z have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. These compounds are also useful for treating diseases mediated by the Pi3k receptor, the JAK-2 receptor and the TRK receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Priority: EP20060123156 Applic. Date: 2006-10-30; WO2007EP09382 Applic. Date: 2007-10-29

Inventor: FERRAND SANDRINE [FR]; GLICKMAN FRASER [CH]; LEBLANC CATHERINE [GB]; RITCHIE CATHY [GB]; SHAW DUNCAN [GB]; STIEFL NIKOLAUS JOHANNES [DE]; FURET PASCAL [FR]; IMBACH PATRICIA [CH]; STAUFFER FREDERIC [FR]; CAPRARO HANS-GEORG [CH]; GESSIER FRANCOIS [FR]; GAUL CHRISTOPH [CH]; ALBAUGH PAMEIA A [US]; CHOPIUK GREG [US]

Title: Compounds

Applicant/Assignee:

Application No.: 12/519877   Filing Date: 19/Dec/2007

Abstract:The present invention relates to substituted 4-Aminopyrazole compounds of the formula (I): and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for modulating SCD activity.

Priority: GB20060025594 Applic. Date: 2006-12-21; WO2007EP64192 Applic. Date: 2007-12-19

Inventor: DAUGAN ALAIN CLAUDE-MARIE [FR]; DEAN ANTHONY WILLIAM [GB]

Title: DERMAL COMPOSITIONS OF SUBSTITUTED AMIDES AND THE USE THEREOF AS MEDICATION FOR PAIN AND PRURITUS

Applicant/Assignee:

Application No.: 12/448760   Filing Date: 11/Jan/2008

Abstract:Dermal compositions comprising topical formulations of bupivacaine or ropivacaine, characterized by effective dermal absorption and long duration of dermal anesthetic activity, and intended for use in patients suffering from pruritus and dermal pain, including neuropathic pain, are provided. Compositions containing both bupivacaine and capsaicin are provided. Methods of alleviating pain by the topically administration of these compounds are also provided.

Priority: US20070880227P Applic. Date: 2007-01-12; WO2008US00425 Applic. Date: 2008-01-11

Inventor: ABERG A K GUNNAR [US]; JOHNSON KEITH A [US]

Title: Novel natural oil gels and their application

Applicant/Assignee: APPLECHEM, INC

Application No.: 12/589358   Filing Date: 21/Oct/2009

Abstract:The invention is an article of manufacture, comprising a blend of: (A) from 1 to 50 weight percent of at least one block copolymer, wherein the block copolymer has at least one polystyrene block and at least one unsaturated rubber segment

and (B) from 99 to 50 weight percent of a natural oil. The natural oil of this invention is of natural animal, plant or vegetable oils or mixtures thereof, and the block copolymers have a polystyrene block and a rubber block where the rubber blocks are unsaturated rubbers such as polyisoprene, polybutadiene, or mixtures thereof. The block copolymers useful for the present invention are triblock polymers, radial (star) polymers, multiblock polymers, diblock polymers, or mixtures thereof.

Priority: US2007-973826 Applic. Date: 2007-10-09; US20060850586P Applic. Date: 2006-10-10; US20070900512P Applic. Date: 2007-02-09; US20070900518P Applic. Date: 2007-02-09

Inventor: LIN SAMUEL [US]

Title: ACTVIE SUBSTANCE COMBINATION

Applicant/Assignee: ISDIN S.A

Application No.: 12/522890   Filing Date: 11/Jan/2008

Abstract:The present invention refers to a combination of at least 2 UV-absorbing active substances (A) and (B), wherein the UV-absorbing active substance (A) is at least one heptaazaphenalene compound of the general formula (I), which is defined in the description and the UV-ab-sorbing active substance (B) is at least one compound which has its ab-sorption maximum [lambda]maX(B) in the range of UV-A or UV-B radiation.

Priority: EP20070000631 Applic. Date: 2007-01-12; WO2008EP00172 Applic. Date: 2008-01-11

Inventor: GORCHS CAPA OLGA [ES]; JIMENEZ ALONSO OSCAR [ES]; TRULLAS CABANAS CARLOS RAMON [ES]; CORBERA ARJONA JORDI [ES]; PANYELLA COSTA DAVID [ES]

Title: Novel tyrosinase-specific anti-gene oligonucleotides as depigmenting agents

Applicant/Assignee: L.V.M.H. RECHERCHE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) MUSEUM NATIONAL D'HISTOIRE NATURELLE

Application No.: 11/991317   Filing Date: 01/Sep/2006

Abstract:The present invention relates to an anti-gene oligonucleotide which hybridizes specifically with the gene encoding human tyrosinase by Hoogsteen pairing between the complementary bases, said oligonucleotide forming a triple helix structure with the human tyrosinase gene. The invention also relates to the use of said oligonucleotide as a skin-depigmenting or skin-bleaching agent in a cosmetic composition or in a dermatological composition.

Priority: FR20050008981 Applic. Date: 2005-09-01; WO2006EP65902 Applic. Date: 2006-09-01

Inventor: KURFUERST ROBIN [FR]; BONNET-DUQUENNOY MATHILDE [FR]; LAZOU KRISTELL [FR]; GIOVANNANGELI CARINE [FR]

Title: NOVEL MICROSTRUCTURAL PROTEIN PREPARATIONS CONTAINING ADSORBED BIOLOGICALLY ACTIVE SUBSTANCES AND THEIR APPLICATION IN MEDICINE AND COSMETICS

Applicant/Assignee:

Application No.: 12/312576   Filing Date: 20/Nov/2007

Abstract:Protein preparations containing biologically active compounds and the application of the protein preparations obtained, particularly as a component of medicinal and cosmetic preparations as protective substances or in the regeneration of cells and tissues of the human organism, and which can comprise a component of culture media for dermal or hepatic tissues, or for stem cells destined for use in the regeneration of cells and tissues in the human organism.

Priority: PL20060381103 Applic. Date: 2006-11-21; WO2007PL00078 Applic. Date: 2007-11-20

Inventor: LIPKOWSKI ANDRZEJ [PL]; GRABOWSKA ANNA [PL]; KURZEPA KATARZYNA [PL]; SZCZUCINSKA ALEKSANDRA [PL]

Title: Dual variable domain immunoglobulin and uses thereof

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 12/459624   Filing Date: 02/Jul/2009

Abstract:The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.

Priority: US2006-507050 Applic. Date: 2006-08-18; US20050709911P Applic. Date: 2005-08-19; US20050732892P Applic. Date: 2005-11-02

Inventor: WU CHENGBIN [US]; GHAYUR TARIQ [US]; DIXON RICHARD W [US]; SALFELD JOCHEN G [US]

Title: IL-12/P40 BINDING PROTEINS

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 11/478096   Filing Date: 29/Jun/2006

Abstract:The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

Priority: US20050695679P Applic. Date: 2005-06-30

Inventor: LACY SUSAN E [US]; FUNG EMMA [US]; BELK JONATHAN P [US]; DIXON RICHARD W [US]; ROGUSKA MICHAEL [US]; HINTON PAUL R [US]; KUMAR SHANKAR [US]

Title: Strain Of Turkey Tail Mushroom, Extract From The Same, And Use Of The Same

Applicant/Assignee: NIKKEN SOHONSHA CORPORATION

Application No.: 11/996961   Filing Date: 28/Jul/2006

Abstract:The present invention provides a new strain of turkey tail mushroom (Trametes versicolor (L.: Fr.) Pilat) having excellent biological activities (Accession number: FERM BP-10633). The strain is excellent in platelet aggregation inhibitory effect, chemokine gene expression inhibitory effect, antimutagenic effect, antitumor effect, antihypertensive effect, and immunomodulatory effect. The effect of the strain is enhanced synergistically by combining with microalgae and other basidiomycetes. The turkey tail mushroom of the present invention has high safety, and a possibility that a side effect is caused because of long-term continuous use is very low. Thus, it is useful for food/drink, cosmetics, pharmaceuticals or the like, the objective of which is the prevention and improvement in inflammation, allergy, tumor, and other diseases. The turkey tail mushroom strain of the present invention has very high hyphal growth property and very high physiological functions compared with conventional strains

therefore, it can be used stably.

Priority: JP20050218554 Applic. Date: 2005-07-28; WO2006JP314978 Applic. Date: 2006-07-28

Inventor: EGUCHI FUMIO [JP]; SUMI RYO [JP]; MORI NOBUO [JP]

Title: COSMETIC FORMULATIONS WITH IR PROTECTION

Applicant/Assignee:

Application No.: 11/993607   Filing Date: 21/Jun/2006

Abstract:The present invention relates to cosmetic formulations with IR protection which are distinguished by the fact that they comprise functional pigments. The invention furthermore relates to cosmetic formulations which, besides the IR pigment, comprise colorants, fillers, cosmetic active compounds and cosmetic raw materials and auxiliaries, and to the use thereof in care and decorative cosmetics.

Priority: DE200510029647 Applic. Date: 2005-06-23; WO2006EP05949 Applic. Date: 2006-06-21

Inventor: HOCHSTEIN VERONIKA [DE]; SCHMIDT CHRISTOPH [DE]; SCHOEN SABINE [DE]

Title: SEMI-FINISHED PRODUCT IN THE MANUFACTURE OF A COMPOSITION FOR SKIN OR HAIR CARE

Applicant/Assignee: OY GRANULA AB LTD

Application No.: 12/377515   Filing Date: 14/Aug/2007

Abstract:A semi-finished product is manufactured from raw liquid, extract or powder obtained from wood material, an end product composition for skin or hair care being obtained from the semi-finished product by adding one or more components thereto. The semi-finished product optionally contains a UV protector, and is a liquid, emulsion, microemulsion or nanoemulsion or a dispersion, suspension, wax, lotion or gel or a solid substance. The semi-finished product further contains an active ingredient mixture which contains phenolic compounds having antioxidative and/or microbicidal properties and/or abilities to capture free radicals. The active ingredient mixture contains as phenolic compounds at least one oligolignan, and at least two lignans, tannins or flavonoids selected from a group consisting of hydroxymatairesinol, matairesinol, oxomatairesinol, lariciresinol, cyclolariciresinol, secoisolariciresinol nortrachelogenin, pinoresinol, pinosylvine, conidendrine, melacasidine, teracasidine, ellaga-tannin or a reaction product, stereoisomer or derivative of these compounds.

Priority: FI20060000729 Applic. Date: 2006-08-14; WO2007FI00201 Applic. Date: 2007-08-14

Inventor: AHLNAS THOMAS [FI]

Title: Low-Residue Cosmetic Or Dermatological Stick Based On An Oil-In-Water Dispersion/Emulsion III

Applicant/Assignee: HENKEL AG & CO. KGAA

Application No.: 12/465983   Filing Date: 14/May/2009

Abstract:Cosmetic or dermatological sticks, especially deodorant or antiperspirant sticks, based on an oil-in-water dispersion/emulsion to be applied to the skin.

Priority: DE200610053886 Applic. Date: 2006-11-14; WO2007EP62236 Applic. Date: 2007-11-13

Inventor: BANOWSKI BERNHARD [DE]; CLAAS MARCUS [DE]; BUSE NADINE [DE]

Title: NANOCRYSTALS FOR USE IN TOPICAL COSMETIC FORMULATIONS AND METHOD OF PRODUCTION THEREOF

Applicant/Assignee: ABBOTT GMBH & CO. KG

Application No.: 12/514621   Filing Date: 19/Nov/2007

Abstract:Provided are cosmetic preparations for topical application containing nanocrystals of cosmetic actives leading to an increased bioactivity of the molecules in the skin and methods of making the cosmetic preparations. The nanocrystals can be added to any cosmetic topical formulation, e. g. creams, lotions and liposomal dispersions. The drug nanocrystals are produced by a combination process of low energy pearl milling followed by a high energy high-pressure homogenization leading to nanocrystal suspensions (nanosuspensions) of improved physical stability.

Priority: US20060866233P Applic. Date: 2006-11-17; WO2007EP09943 Applic. Date: 2007-11-19

Inventor: PETERSEN ROLF [DE]

Title: PROCESS FOR TREATING THE SKIN BY APPLYING SILICONE COMPOUNDS

Applicant/Assignee: L'OREAL

Application No.: 12/519271   Filing Date: 19/Dec/2007

Abstract:The invention relates to a cosmetic treatment method for improving the superficial appearance of the skin, and especially for reducing the visible and/or tactile irregularities of the skin, such as cutaneous microrelief. According to said method, a filling product is applied to the irregularities, said product resulting from a hydrosilylation reaction, in the presence of a catalyst, between two compounds X and Y, at least one of said compounds being a silicone compound, and both compounds being brought into contact with each other in the presence of a catalyst such that the reaction occurs at least partially on the skin.

Priority: FR20060055727 Applic. Date: 2006-12-20; US20070883171P Applic. Date: 2007-01-03; WO2007FR52563 Applic. Date: 2007-12-19

Inventor: CASSIN GUILLAUME [FR]

Title: COMPOSITIONS FOR TOPICAL APPLICATION COMPRISING A PEROXIDE AND RETINOID

Applicant/Assignee: SOL-GEL TECHNOLOGIES LTD

Application No.: 12/525329   Filing Date: 03/Feb/2008

Abstract:The invention relates to a composition for topical application comprising as an active ingredient a peroxide and a retinoid wherein one of said peroxide and retinoid is in the form of first microparticles comprising a solid particulate matter of the active ingredient coated by a metal oxide layer and the other of said peroxide and retinoid is present in an uncoated free form or in a coated form of the active ingredient. The invention further relates to method for treating a surface condition in a subject using said composition, a method for preparing a composition exhibiting improved stability, and a kit comprising: (a) a first composition comprising a peroxide as a first active ingredient

and (b) a second composition comprising a retinoid as a second active ingredient

at least one of said first and said second active ingredient being coated by a metal oxide layer.

Priority: US20070898701P Applic. Date: 2007-02-01; WO2008IL00140 Applic. Date: 2008-02-03

Inventor: TOLEDANO OFER [IL]; SERTCHOOK HANAN [IL]; LOBODA NATALIA [IL]; BAR-SIMANTOV HAIM [IL]; SHAPIRO LEORA [IL]; ABU-REZIQ RAED [IL]

Title: Use Of Polyamines In The Treatment Of Psoriasis

Applicant/Assignee: BIOFORSKINING PHARMA AS

Application No.: 12/225060   Filing Date: 14/Mar/2007

Abstract:The present invention provides unbranched aliphatic polyamines for use in therapy, particularly for use in the treatment of psoriasis and compositions containing polyamines.

Priority: GB20060005107 Applic. Date: 2006-03-14; WO2007GB00894 Applic. Date: 2007-03-14

Inventor: KLAVENESS JO [NO]; KVALHEIM GEIR HAVARD [NO]

Title: Active Principle which is capable of inducing the conversion of inactive TGFb-Latent into active TGFb

Applicant/Assignee: BASF BEAUTY CARE SOLUTIONS FRANCE S.A.S LABORATOIRE DE DERMOCOSMETIQUE

Application No.: 12/613964   Filing Date: 06/Nov/2009

Abstract:The invention relates to active principles which are capable of inducing the conversion of inactive TGFb-Latent into active TGFb. The invention relates in particular to the use of such an extract for the manufacture of a composition for increasing the concentration of active TGFb1 in the skin, notably in the dermis. The present invention also relates to the uses which are derived from said use, as well as to cosmetic or pharmaceutical compositions which comprise said extract.

Priority: FR20040006047 Applic. Date: 2004-06-04; US2004-966168 Applic. Date: 2004-10-04

Inventor: PERRIER ERIC [FR]; ALTOBELLI CECILE [FR]; CLEMENT ANNE [FR]; REYMERMIER CORINNE [FR]; ABDUL MALAK NABIL [FR]

Title: OXAZOLE AND THIAZOLE PPAR MODULATOR

Applicant/Assignee: IRM LLC

Application No.: 12/092967   Filing Date: 07/Nov/2006

Abstract:The invention provides compounds (I) pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR[delta].

Priority: US20050734678P Applic. Date: 2005-11-07; WO2006US43586 Applic. Date: 2006-11-07

Inventor: EPPLE ROBERT [US]; COW CHRISTOPHER N [US]; AZIMIOARA MIHAI [US]; RUSSO ROSS [US]

Title: Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders

Applicant/Assignee: VASCULAR BIOGENICS LTD

Application No.: 12/588371   Filing Date: 14/Oct/2009

Abstract:Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.

Priority: US2006-528657 Applic. Date: 2006-09-28; US2008-567543 Applic. Date: 2008-04-25; WO2004IL00453 Applic. Date: 2004-05-27; US2003-445347 Applic. Date: 2003-05-27

Inventor: HARATS DROR [IL]; GEORGE JACOB [IL]; HALPERIN GIDEON [IL]; MENDEL ITZHAK [IL]

Title: PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS

Applicant/Assignee: GENKYOTEX SA

Application No.: 12/532336   Filing Date: 20/Mar/2008

Abstract:The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

Priority: EP20070109555 Applic. Date: 2007-06-04; US20070896284P Applic. Date: 2007-03-22; WO2008EP53390 Applic. Date: 2008-03-20

Inventor: PAGE PATRICK [FR]; ORCHARD MIKE [GB]; FIORASO LEITICIA [FR]; MOTTIROMI BIANCA [CH]

Title: TOPICAL COMPOSITIONS COMPRISING 5-ALPHA REDUCTASE INHIBITORS

Applicant/Assignee:

Application No.: 12/544737   Filing Date: 20/Aug/2009

Abstract:The present invention relates to topical compositions comprising 5[alpha]-reductase inhibitors. The present invention also includes processes for preparation of such topical compositions and methods of using them.

Priority: IN2008CH02033 Applic. Date: 2008-08-21; US20080106733P Applic. Date: 2008-10-20

Inventor: KANDAVILLI SATEESH [IN]; NALAMOTHU VIJENDRA [US]; PANDYA VISHVABHAVAN [IN]

Title: CARBINOL DERIVATIVES HAVING CYCLIC LINKER

Applicant/Assignee: KOWA COMPANY, LTD

Application No.: 12/474799   Filing Date: 29/May/2009

Abstract:[Object] To provide a novel LXR[beta] agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis

arteriosclerosis such as those resulting from diabetes

dyslipidemia

hypercholesterolemia

lipid-related diseases

inflammatory diseases that are caused by inflammatory cytokines

skin diseases such as allergic skin diseases

diabetes

or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.

Priority: US20080057070P Applic. Date: 2008-05-29

Inventor: YAMAGUCHI YUKI [JP]; KOURA MINORU [JP]; KUROBUCHI SAYAKA [JP]; MATSUDA TAKAYUKI [JP]; OKUDA AYUMU [JP]; SUMIDA HISASHI [JP]; WATANABE YUUICHIROU [JP]; ENOMOTO TAKASHI [JP]; SHIBUYA KIMIYUKI [JP]

Title: COMPOUNDS

Applicant/Assignee: SMITHKLINE BEECHAM CORP

Application No.: 12/519621   Filing Date: 19/Dec/2007

Abstract:The present invention relates to substituted 3-Aminopyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for modulating SCD activity.

Priority: GB20060025605 Applic. Date: 2006-12-21; WO2007EP64219 Applic. Date: 2007-12-19

Inventor: DAUGAN ALAIN CLAUDE-MARIE [FR]

Title: Composition based on xanthoxyline and its use in cosmetic

Applicant/Assignee: PIERRE FABRE DERMO-COSMETIQUE

Application No.: 12/310960   Filing Date: 11/Sep/2007

Abstract:The present invention relates to the use of xanthoxyline, and of plant extracts containing it, in cosmetic compositions.

Priority: FR20060008129 Applic. Date: 2006-09-15; WO2007FR01467 Applic. Date: 2007-09-11

Inventor: CHARVERON MARIE [FR]; BELAUBRE FRANCOISE [FR]; BELLE RENE [FR]; DUNOUAU CHRISTOPHE [FR]

Title: DEVICES, SYSTEMS, METHODS AND TOOLS FOR CONTINUOUS ANALYTE MONITORING

Applicant/Assignee:

Application No.: 12/545008   Filing Date: 20/Aug/2009

Abstract:One aspect of the invention provides an analyte monitor including a sensing volume, an analyte extraction area in contact with the sensing volume adapted to extract an analyte into the sensing volume, and an analyte sensor adapted to detect a concentration of analyte in the sensing volume. The sensing volume is defined by a first face, a second face opposite to the first face, and a thickness equal to the distance between the two faces. The surface area of the first face is about equal to the surface area of the second face and the extraction area is about equal to the surface area of the first and second face of the sensing volume. The analyte sensor includes a working electrode in contact with the sensing volume, the working electrode having a surface area at least as large as the analyte extraction area, and a second electrode in fluid communication with the sensing volume.

Priority: US2008-275145 Applic. Date: 2008-11-20; US2006-277731 Applic. Date: 2006-03-28; US2006-642196 Applic. Date: 2006-12-20

Inventor: JINA ARVIND N [US]; PARMAR ASHOK [US]; CHUA BEELEE [US]; TAMADA JANET [US]; LEE JONATHAN [US]; TIERNEY MICHAEL J [US]; KAUR NAVNEET [US]; MAGGINETTI PAUL [US]; DESAI SHASHI P [US]

Title: Internal Bleeding Detection Apparatus

Applicant/Assignee:

Application No.: 12/086976   Filing Date: 28/Dec/2006

Abstract:Abstract: An EIT system (1) adapted to detect internal bleeding in a body portion, the EIT system (1) comprising a plurality of electrodes (3) adapted in use to extend in a substantially linear orientation across one side only of the body portion and to be applied in electrical contact with the skin of the body portion, a current source adapted to cyclically apply an electric current between one pair of the electrodes (3), a voltage measuring means to measure the voltage across each of the other pairs of the electrodes resulting from the current, a data collection system (2) and a data analysis system (4) to analyse data resulting from the voltages that are measured by the voltage measuring means, wherein the analysis system (4) is configured to obtain quantitative information related to amounts and rates of conductive tissue changes occurring in the body, based on an EIT analysis equivalent to that obtained from data derived from electrodes spaced around the full perimeter of the body portion. Also disclosed is an electrode belt suitable for bioelectrical use and in particular for detection of change of volume of tissue in a body portion.

Priority: WO2006AU01990 Applic. Date: 2006-12-28; AU20050907263 Applic. Date: 2005-12-23

Inventor: SADLEIR ROSALIND [US]; DUNCAN ANDREW [AU]

Title: TOPICAL FORMULATIONS OF TELLURIUM-CONTAINING COMPOUNDS

Applicant/Assignee: BIOMAS LTD

Application No.: 12/440727   Filing Date: 10/Sep/2007

Abstract:Novel formulations of tellurium-containing compounds, which are suitable for topical application, are disclosed. The formulations are characterized by high chemical and physical stability and are easy to handle and use.

Priority: US20060843402P Applic. Date: 2006-09-11; WO2007IB04220 Applic. Date: 2007-09-10

Inventor: ALBECK MICHAEL [IL]; SREDNI BENJAMIN [IL]; FIREDMAN DORON [IL]

Title: CXCR4 Antagonists for Wound Healing and Re-Epithelialization

Applicant/Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENTLTD KYOTO UNIVERSITY

Application No.: 11/915428   Filing Date: 21/May/2006

Abstract:The present invention provides novel uses for CXCR4 antagonists, including specifically peptides of the T-140 family, in the treatment of skin burns and other injuries. The invention further provides methods for increasing epithelialisation in a subject in need thereof, and for preventing or inhibiting fibrosis and excessive scar formation, using peptide inhibitors of the T-140 family as well as other CXCR4 antagonists.

Priority: US20050684160P Applic. Date: 2005-05-25; WO2006IL00596 Applic. Date: 2006-05-21

Inventor: PELED AMNON [IL]; FUJII NOBUTAKA [JP]

Title: COMPOSITIONS OF PD-1 ANTAGONISTS AND METHODS OF USE

Applicant/Assignee:

Application No.: 12/547129   Filing Date: 25/Aug/2009

Abstract:Methods of treating cancer and infectious diseases utilizing a treatment regimen comprising administering a compound that reduces inhibitory signal transduction in T cells, in combination with a potentiating agent, such as cyclophosphamide, to produce potent T cell mediated responses, are described. Compositions comprising the PD-1 antagonists and potentiating agents useful in the methods of the invention are also disclosed.

Priority: US20090211697P Applic. Date: 2009-04-02; US20080091694P Applic. Date: 2008-08-25; US20080091709P Applic. Date: 2008-08-25; US20080091705P Applic. Date: 2008-08-25

Inventor: LANGERMANN SOLOMON [US]

Title: CROSS-REACTIVE AND BISPECIFIC ANTI-IL-17A/F ANTIBODIES

Applicant/Assignee:

Application No.: 12/547728   Filing Date: 26/Aug/2009

Abstract:The present invention relates generally to antibodies cross-reactive with IL-17A and IL-17F, and bispecific anti-IL-17A/F and their uses.

Priority: US20090164709P Applic. Date: 2009-03-30; US20080112644P Applic. Date: 2008-11-07; US20080093212P Applic. Date: 2008-08-29

Inventor: CHEN YONGMEI [US]; HU YAN HELEN [US]; OUYANG WENJUN [US]; STAWICKI SCOTT [US]; WU YAN [US]

Title: Microemulsion & sub-micron emulsion process & compositions

Applicant/Assignee: STIEFEL RESEARCH AUSTRALIA PTY LTD

Application No.: 12/457953   Filing Date: 25/Jun/2009

Abstract:An oil in water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, is provided. The composition includes an oil phase dispersed throughout a water phase, the oil phase including at least one member selected from the group consisting of an animal oil, a mineral oil, a vegetable oil, a silane member, a siloxane, an ester, a fatty acid, a fat, a halogen compound, and an alkoxylated alcohol

and at least one lipophilic surfactant, the water phase including at least one hydrophilic surfactant, water and optionally a non-surfactant amphiphilic compound, the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant being approximately 9.0:1.0 to 2.0:3.0.

Priority: US2005-216668 Applic. Date: 2005-08-31; US20050670722P Applic. Date: 2005-04-12; US20040606278P Applic. Date: 2004-08-31

Inventor: LARM MARIA GRAZIELLA [AU]; HARDING RONALD [AU]; JOHNSTON MICHAEL [AU]; ABRAM ALBERT ZORKO [AU]; VIJAYAKUMAR PREMA [US]; SUN PHOEBE [US]

Title: FUNCTIONAL CONSUMABLE COMPOSITIONS FOR PROMOTING SKIN HEALTH AND METHODS FOR USING THE SAME

Applicant/Assignee:

Application No.: 12/549589   Filing Date: 28/Aug/2009

Abstract:A functional consumable composition for promoting skin health may comprise, for each 100% by dry weight, no more than about 0.2% by dry weight catechin and no more than about 2% by dry weight amino acid. The amino acid may comprise at least one of 1-proline and 1-arginine, and the weight % 1-proline to weight % 1-arginine may be greater than about 2. Another functional consumable composition may comprise no more than about 0.2% by dry weight catechin and at least one of lipoic acid, selenium, vitamin E, vitamin B, and vitamin C. A source of the catechin may comprise at least one of white tea solids and epigallocatechin gallate extract. Methods for using such functional consumable compositions are also described.

Priority: US20080093150P Applic. Date: 2008-08-29

Inventor: MAINS KRISTINA [US]

Title: COSMETIC COMPOSITION FOR PROTECTING SKIN AGAINST UV LIGHT AND WRINKLE IMPROVEMENT CONTAINING THE EXTRACT OF MAGNOLIA SIEBOLDII FLOWER EXTRACTS

Applicant/Assignee:

Application No.: 12/448751   Filing Date: 13/Dec/2007

Abstract:Disclosed herein is a cosmetic composition for preventing photoaging, containing an extract of Magnolia sieboldii as an active ingredient. Also disclosed is a cosmetic composition for reducing skin wrinkles containing an extract of Magnolia sieboldii as an active ingredient. The extract of Magnolia sieboldii can protect the skin against UV lights and skin damage by suppressing skin cell death and cell DNA damage, and can reduce skin wrinkles by promoting the biosynthesis of collagen and suppressing the synthesis of collagenases. Also, the cosmetic composition containing the extract of Magnolia sieboldii has an excellent effect of inhibiting skin damage caused by UV lights, and an excellent effect of reducing skin wrinkles.

Priority: KR20070001833 Applic. Date: 2007-01-08; WO2007KR06509 Applic. Date: 2007-12-13

Inventor: LEE GHANG TAI [KR]; LEE JUNG NOH [KR]; YOU YOUNG KYOUNG [KR]; LEE SEUNG JI [KR]; LEE KUN KOOK [KR]

Title: COSMETIC COMPOSITION COMPRISING A COMBINATION OF LIPOCHROMAN-6 AND AN EXTRACT OF LONGOZA, AND ITS USE

Applicant/Assignee: LVMH RECHERCHE

Application No.: 12/533106   Filing Date: 31/Jul/2009

Abstract:The invention relates to a cosmetic composition formulated for topical application to the skin, comprising as active agent a combination of lipochroman-6 and an extract of Longoza (Aframomum angustifolium). It also relates to the use of this combination in a cosmetic composition compatible with topical application, or for preparing such a composition, as an active agent intended for preventing or retarding the appearance of signs of skin ageing, such as the appearance of wrinkles or a decrease in the firmness and the elasticity of the skin, or for attenuating the effects thereof and/or for enhancing the radiance of the complexion of the skin, especially of the skin of the face, or for giving it back its natural radiance. It also relates to a method of cosmetic care of the skin, intended to prevent or to retard the appearance of signs of skin ageing, such as the appearance of wrinkles or a decrease in the firmness and elasticity of the skin, or to attenuate the effects thereof, comprising applying to at least one part of the skin of the body or the face a cosmetic composition comprising said combination.

Priority: FR20080055370 Applic. Date: 2008-08-01

Inventor: NIZARD CARINE [FR]; NOBLESSE EMMANUELLE [FR]; SCHAEFFER PHILIPPE [FR]

Title: MEDICAL USES

Applicant/Assignee: LIPOPEPTIDE AB

Application No.: 12/305601   Filing Date: 20/Jun/2007

Abstract:The present invention provides the use of a polypeptide comprising an amino acid sequence according to SEQ ID NO: 1 (corresponding to the N-terminal 25 amino acid fragment of the human antimicrobial protein, LL-37) or a biologically active fragment, variant, fusion or derivative thereof, in the preparation of a medicament for the treatment of cancer. In particular, the inventions provides the use such polypeptides, or a fragment, variant, fusion or derivative thereof, to inhibit the proliferation and/or metastasis of cancer cells, such as breast cancer cells. The invention further comprises methods for the treatment of cancer in a patient.

Priority: US20060814877P Applic. Date: 2006-06-20; WO2007GB02289 Applic. Date: 2007-06-20

Inventor: STAHLE MONA [SE]; WEBER GUNTHER [SE]

Title: TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIBACTERIAL ACTIVITY

Applicant/Assignee: POLYPHOR LTD UNIVERSITAET ZUERICH

Application No.: 12/506794   Filing Date: 21/Jul/2009

Abstract:Template-fixed [beta]-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 12 [alpha]-amino acid residues which, depend on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to selectively inhibit the growth of or to kill microorganisms such as Pseudomonas aeruginosa and Acinetobacter. They can be used as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials, or as medicaments to treat or prevent infections. In a specific embodiment, the template is based on the D-Pro-L-Pro dipeptides. These [beta]-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid-and solution phase synthetic strategy.

Priority: US2005-062021 Applic. Date: 2005-02-18; WO2002EP09278 Applic. Date: 2002-08-20

Inventor: VRIJBLOED JAN WIM [CH]; OBRECHT DANIEL [CH]; ROBINSON JOHN ANTHONY [CH]; SELLIER ODILE [FR]; KESSLER MARC [FR]

Title: Depsipeptides and Their Therapeutic Use

Applicant/Assignee:

Application No.: 12/516110   Filing Date: 22/Nov/2007

Abstract:A compound of the general Structure (VII) or (VIII) including isoteres and pharmaceutically acceptable salts thereof, wherein R1, R2 (where X=-CONR6-), R3 and R7 are the same or different and each represents an amino-acid side chain moiety

R2 (where X=-CHZ-), R4 and R6 are the same or different and each represents hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl

K represents a linear or branched chain of carbon atoms and containing 1-10 atoms

L represents a moiety capable of chelating zinc in the active site of a histone deacetylase (HDAC) or of conversion to such a moiety in vivo (by hydrolysis or reduction, for example)

M is a linear or branched chain of carbon or other atoms and containing 1-10 atoms, and capable of undergoing in vivo cleavage to give Structure (VII)

and Z is a heteroatom bonded to the macrocycle by a single or double bond, and any other group bonded to Z is H or a protecting group.

Priority: GB20060023357 Applic. Date: 2006-11-22; GB20060023331 Applic. Date: 2006-11-23; WO2007GB04472 Applic. Date: 2007-11-22

Inventor: GANESAN ARASU [GB]; PACKHAM GRAHAM KEITH [GB]; CECIL ALEXANDER RICHARD LIAM [GB]

Title: HEPATITIS A VIRICIDE

Applicant/Assignee: ECOLAB INC

Application No.: 12/617468   Filing Date: 12/Nov/2009

Abstract:The invention relates to agents which combat the hepatitis A virus, containing only minimal amounts of chlorine-containing and/or chlorine cleaving active ingredients, or none of said substances. The inventions also relates to the use of these agents and to a method for their production.

Priority: DE19991062353 Applic. Date: 1999-12-23; US2002-168442 Applic. Date: 2002-09-18; WO2000EP12688 Applic. Date: 2000-12-14

Inventor: VON RHEINBABEN FRIEDRICH [DE]; BIERING HOLGER [DE]; BANSEMIR KLAUS-PETER [DE]; GLAESER SABINE [DE]

Title: Antiperspirant/Deodorant Compositions and Methods

Applicant/Assignee: REVLON CONSUMER PRODUCTS CORPORATION

Application No.: 12/593019   Filing Date: 25/Mar/2008

Abstract:An aqueous based antiperspirant/deodorant composition comprising (a) an antiperspirant active ingredient

(b) at least one water absorbing polymer pretreated with a non-aqueous polar solvent

and (c) water, wherein the pretreated water absorbing polymer inhibits the water absorbing properties of the polymer in the aqueous based composition prior to application to the skin.

Priority: US2007-691810 Applic. Date: 2007-03-27; WO2008US58139 Applic. Date: 2008-03-25

Inventor: JOSHI VIJAY K [US]; FRANCO PHILIP [US]

Title: Methods of Improving Stem Cell Homing and Engraftment

Applicant/Assignee:

Application No.: 12/085406   Filing Date: 29/Nov/2006

Abstract:A method of enhancing cell engraftment potential is provided. The method comprising ex-vivo or in-vitro subjecting a population of cells to an amount of nicotinamide for a period of time sufficient to effect the population of cells, thereby enhancing cell engraftment potential.

Priority: US2005-289004 Applic. Date: 2005-11-29; WO2006IL01381 Applic. Date: 2006-11-29

Inventor: PELED TONY [IL]

Title: Novel Stromal Cell-Derived Factor-1 Polypeptides, Polynucleotides, Modulators Thereof and Methods of Use

Applicant/Assignee: FIVE PRIME THERAPEUTICS, INC

Application No.: 11/587651   Filing Date: 29/Apr/2005

Abstract:Disclosed herein is a newly identified SDF-1 splice variant molecule, its polypeptide sequence, and the polynucleotides encoding the polypeptide sequence, and active fragments thereof. Also provided is a procedure for producing such polypeptides by recombinant techniques employing, for example, vectors and host cells. Also disclosed are methods for utilizing such polypeptides and modulators thereof for the treatment of diseases, including cancer, immune diseases, infectious diseases, and ischemic diseases.

Priority: US20040567311P Applic. Date: 2004-04-30; WO2005US14963 Applic. Date: 2005-04-29

Inventor: CHU KETING [US]; WILLIAMS LEWIS T [US]; WONG JUSTIN G P [US]; HESTIR KEVIN [US]; COLLINS AMY L TSUI [US]; LEE ERNESTINE [US]

Title: Product for the Targeted Release of Active Substances

Applicant/Assignee:

Application No.: 11/886353   Filing Date: 16/Feb/2006

Abstract:The invention relates to a product for the targeted release of active substances, especially detergents and/or cosmetic active substances. The inventive product has a layer structure, one layer being impermeable to the active substance and another layer being permeable to the active substance. The two layers define a compartment between them which contains the active substance and optionally a gas-releasing component. The product is preferably suitable for single use and can be used as a cosmetic agent and/or as a cleaning agent.

Priority: DE200510012248 Applic. Date: 2005-03-15; WO2006EP01392 Applic. Date: 2006-02-16

Inventor: ROREGER MICHAEL [DE]

Title: PEPTIDE-BASED COMPOUNDS AS NEW INHIBITORS OF METALLOECTOPEPTIDASES, COMPOSITIONS COMPRISING SAID COMPOUNDS AND THEIR PHARMACEUTICAL AND COSMETIC USES

Applicant/Assignee: GREENPHARMA

Application No.: 12/524955   Filing Date: 04/Feb/2008

Abstract:The invention relates to a compound that inhibits a metallo-ectopeptidase, selected in the group consisting of x-aa2-aa1-z, x-aa3-aa2-aa1-z, x-aa4-aa3-aa2-aa1-z and x-aa5-aa4-aa3-aa2-aa1-z, wherein: aa1 and aa4, independently from each other, represent an arginine amino acid, an histidine amino acid, an asparagine amino acid or a lysine amino acid, aa2 represents a serine amino acid, a glycine amino acid, a threonine amino acid or an alanine amino acid, aa3 represents a phenylalanine amino acid, a leucine amino acid, an isoleucine amino acid, a tyrosine amino acid or a tryptophan amino acid, aa5 represents a glutamine amino acid, a glutamic acid amino acid, an asparagines amino-acid or a lysine amino acid, x and z, independently from each other, represent: -H

-OH1 SH

-a halogen atom, -an amino group, -an alkyl, haloalkyl or heteroalkyl group containing from 1 to 30 carbon atoms, linear or branched, -an alkenyl or alkynyl group containing from 2 to 30 carbon atoms, linear or branched, -a cycloalkyl, cycloakenyl, cycloalkynyl or an heterocyclic group containing from 3 to 30 carbon atoms, linear or branched, -one or more aryl or heteroaryl groups containing from 3 to 10 carbon atoms per cycle, -a alkoxy, thioalkyl, sulfonylalkyl, aminoalkyl containing from 1 to 30 carbon atoms, linear or branched, -one or more heterocyclic group, containing from 5 to 10 carbon atoms per cycle, said groups being optionally substituted by one or more halogen atoms, alkyl groups, hydroxy groups, alkoxy groups, aryloxy groups, acyloxy groups, carbamoyloxy groups, carboxy groups, mercapto groups, alkylthio groups, acylthio groups, arylthio groups, aryl groups, heterocyclic groups, heteroaryl groups or amino groups.

Priority: US20070899033P Applic. Date: 2007-02-02; WO2008IB01328 Applic. Date: 2008-02-04

Inventor: BERNARD PHILIPPE [FR]

Title: DERMAL FILM-FORMING LIQUID FORMULATIONS FOR DRUG RELEASE TO SKIN

Applicant/Assignee: POLICHEM S.A

Application No.: 12/449571   Filing Date: 13/Dec/2007

Abstract:The present invention is directed to liquid compositions containing chitosan, a chitosan derivative or a physiologically acceptable salt thereof, forming a dermal film after application onto the skin, useful for delivery of actives onto the skin surface and in the stratum corneum.

Priority: EP20070102449 Applic. Date: 2007-02-15; US20070901405P Applic. Date: 2007-02-15; WO2007EP63869 Applic. Date: 2007-12-13

Inventor: MAILLAND FEDERICO [IT]; LEGORA MICHELA [IT]

Title: Compositions and Methods of Their Use for Improving the Condition and Appearance of Skin

Applicant/Assignee: AVON PRODUCTS, INC

Application No.: 12/621027   Filing Date: 18/Nov/2009

Abstract:The present invention relates to compositions and methods for treating, preventing and improving the condition and aesthetic appearance of skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, where the compositions include natural plant constituents, or synthetic equivalents thereof, which inhibit or decrease expression of C-reactive protein expression, production or secretion, thereby reducing, inhibiting, or ameliorating dermatological signs of aging. The compositions of the invention may be topically applied to the skin, or are delivered by directed means to a site in need thereof, in an amount effective in improving the condition and aesthetic appearance of skin.

Priority: US2006-647648 Applic. Date: 2006-12-29

Inventor: DRYER LAURENCE [US]; TAFURI SHERRIE R [US]; PTCHELINTSEV DMITRI S [US]

Title: Method For Preparing Icariside II, Cosmetic Composition Containing The Same and the Use Thereof For Skin Whitening

Applicant/Assignee: AMOREPACIFIC CORPORATION

Application No.: 12/440984   Filing Date: 19/Sep/2007

Abstract:Disclosed are a method for preparing icariside II represented by Formula 1, which inhibits the glycosylation of glycoprotein enzyme tyrosinase by inhibiting the enzymatic activity of alpha-glucosidase, which is an enzyme in the glycosylation of tyrosinase, as well as a skin whitening composition.

Priority: KR20060090795 Applic. Date: 2006-09-19; WO2007KR04557 Applic. Date: 2007-09-19

Inventor: PARK JUN SEONG [KR]; PARK HYE YOON [KR]; RHO HO SIK [KR]; AHN SOO MI [KR]; KIM DUCK HEE [KR]

Title: GELATINOUS ELASTOMER COMPOSITIONS

Applicant/Assignee: SILIPOS, INC

Application No.: 12/557496   Filing Date: 10/Sep/2009

Abstract:The present invention is directed to gelatinous elastomer compositions that are useful for topical application of biologically active agents. In certain embodiments, the invention is directed to a gelatinous elastomer composition comprising about 1.0% to 50.0% block copolymer, about 0% to 98% mineral and/or synthetic oil, and about 0.0% to 98% triglyceride oil, about 0-15.0% free fatty acids, about 0-30% of a tack modification agent, about 0-20.0% of a biologically active agent and, optionally a phytosterol, ceramide and/or bisabolol. The gelatinous elastomer compositions are useful for applying a biologically active agent to a mammal. In certain embodiments, the gelatinous elastomer composition is formed into a molded article.

Priority: US20080095941P Applic. Date: 2008-09-10; US20090171683P Applic. Date: 2009-04-22

Inventor: MATTELIANO CHARLES J [US]; SCHAFFER STEPHEN P [US]; SUTTON STEPHEN P [US]

Title: Organic compounds

Applicant/Assignee: GIVAUDAN SA

Application No.: 12/066518   Filing Date: 08/Sep/2006

Abstract:The invention relates to organic compounds having the ability to reduce or suppress the onset of skin irritation induced by extraneous cause selected from the group of 2-heptylcyclopentanone, 2-ethoxynaphthalene

2-methoxynaphthalene

1-methoxy-4-(prop-1-enyl)benzene

1-(cyclopropylmethyl)-4-methoxybenzene

wherein X, Y, and R1 to R11 have the same meaning as given in the description. Furthermore the invention refers to compositions for topical application to the skin comprising them. It further relates to a method of reducing or suppressing the formation of skin irritation.

Priority: GB20050018558 Applic. Date: 2005-09-12; WO2006CH00481 Applic. Date: 2006-09-08

Inventor: NATSCH ANDREAS [CH]; WASESCHA MICHAEL [CH]

Title: Composition for Repelling and Deterring Vermin

Applicant/Assignee: NOVARTIS AG

Application No.: 12/515663   Filing Date: 21/Nov/2007

Abstract:The invention describes essentially a non-therapeutical process for deterring vermin, which is based on the usage of the largely known beta amino-alcohol derivatives of formula (I), as defined herein before. Furthermore, it describes the corresponding vermin-deterring compositions which contain these substances as the active ingredient, compounds of the formula (I) for the preparation of vermin-deterring compositions, and the use of compounds of formula (I) in the defense against vermin. Thus, the invention describes how and in which form the compounds of the formula (I) or their acid addition salts are used to deter vermin from materials, places or warm-blooded animals.

Priority: EP20060124771 Applic. Date: 2006-11-24; WO2007EP62619 Applic. Date: 2007-11-21

Inventor: DUCRAY PIERRE [FR]; CAVALIERO TANIA [CH]; LOHRMANN MAIKE [CH]; BOUVIER JACQUES [CH]

Title: Compounds Having CRTH2 Antagonist Activity

Applicant/Assignee: OXAGEN LIMITED

Application No.: 12/625497   Filing Date: 24/Nov/2009

Abstract:Compounds of general formula (I) wherein W is chloro or fluoro

R1 is phenyl optionally substituted with one or more substituents, selected from halo, -CN, -C1-C6 alkyl, -SOR3, -SO2R3, -SO2N(R2)2, -N(R2)2, -NR2C(O)R3, -CO2R2, -CONR2R3, -NO2, -OR2, -SR2, -O(CH2)pOR2, or -O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, -C1-C6 alkyl, -C3-C8 cycloalkyl, aryl or heteroaryl

each R3 is independently, -C1-C6 alkyl, -C3-C8 cycloalkyl, aryl or heteroaryl

p and q are each independently an integer from 1 to 3

and R4 is hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with aryl, aryl, (CH2)mOC(-O)C1-C6alkyl, ((CH2)mO)nCH2CH2X, (CH2)mN(R5)2 or CH((CH2)mO(C-O)R6)2

m is 1 or 2

n is 1-4

X is OR5 or N(R5)2

R5 is hydrogen or methyl

and R6 is C1-C18 alkyl

and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

Priority: GB20080000874 Applic. Date: 2008-01-18; GB20080020526 Applic. Date: 2008-11-10; US2009-356822 Applic. Date: 2009-01-21

Inventor: ARMER RICHARD EDWARD [GB]; PETTIPHER ERIC ROY [GB]; WHITTAKER MARK [GB]; WYNNE GRAHAM MICHAEL [GB]; VILE JULIA [GB]; SCHROER FRANK [GB]

Title: Pyridin-4-yl derivatives as immunomodulating agents

Applicant/Assignee: ACTELION PHARMACEUTICALS LTD

Application No.: 12/310801   Filing Date: 06/Sep/2007

Abstract:The invention relates to pyridine derivatives of Formula (I) wherein A, R1, R2, R3, R4, R5, and R6 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

Priority: WO2006IB53147 Applic. Date: 2006-09-07; WO2007IB53594 Applic. Date: 2007-09-06

Inventor: BOLLI MARTIN [CH]; LEHMANN DAVID [CH]; MATHYS BORIS [CH]; MUELLER CLAUS [DE]; NAYLER OLIVER [CH]; STEINER BEAT [CH]; VELKER JORG [FR]

Title: SUBSTITUTED CARBINOL COMPOUND

Applicant/Assignee: KOWA COMPANY, LTD

Application No.: 12/516944   Filing Date: 29/Nov/2007

Abstract:There is provided a novel LXR[beta] agonist useful as a preventative and/or therapeutic agent for arteriosclerosis

arteriosclerosis such as those resulting from diabetes

hyperlipidemia

hypercholesterolemia

lipid-related diseases

inflammatory diseases caused by inflammatory cytokines, skin diseases such as allergic skin diseases, diabetes or Alzheimer's disease. The agonist is a carbinol derivative represented by the following general formula (1) or salt thereof, or their solvate.

Priority: JP20060322963 Applic. Date: 2006-11-30; WO2007JP01318 Applic. Date: 2007-11-29

Inventor: MATSUDA TAKAYUKI [JP]; OKUDA AYUMU [JP]; KOURA MINORU [JP]; YAMAGUCHI YUKI [JP]; KUROBUCHI SAYAKA [JP]; WATANABE YUUICHIROU [JP]; SHIBUYA KIMIYUKI [JP]

Title: AMPHOLYTIC COPOLYMER BASED ON QUATERNIZED NITROGEN-CONTAINING MONOMERS

Applicant/Assignee: BASF SE

Application No.: 12/441288   Filing Date: 14/Sep/2007

Abstract:The present invention relates to an ampholytic copolymer based on quaternized nitrogen-containing monomers which has a molar excess of cationogenic/cationic groups compared to anionogenic/anionic groups, to cosmetic or pharmaceutical compositions which comprise at least one such ampholytic copolymer, and to further uses of these copolymers.

Priority: EP20070111467 Applic. Date: 2007-06-29; EP20060120778 Applic. Date: 2006-09-15; WO2007EP59725 Applic. Date: 2007-09-14

Inventor: KIM SON NGUYEN [DE]

Title: TOPICAL COMPOSITION FOR THE PROTECTION AND/OR TREATMENT OF RADIATION RELATED SKIN DAMAGES

Applicant/Assignee:

Application No.: 12/559954   Filing Date: 15/Sep/2009

Abstract:There is provided a topical composition for the protection and/or treatment of radiation related skin damages comprising from 18.4% to 68% by volume of active principles comprising anti-oxidants, moisturizers, humectants, emollients, anti-inflammatory agents, healing promoting agents and dermal circulation enhancers in from 81.6% to 32% by volume of a pharmaceutically acceptable carrier.

Priority: CA20082639525 Applic. Date: 2008-09-16

Inventor: TODARY MICHAEL FAYEK [CA]

Title: PREPARATION AND STORAGE OF STABLE, BIOLOGICALLY ACTIVE MATERIALS

Applicant/Assignee:

Application No.: 12/293080   Filing Date: 15/Mar/2007

Abstract:A method for the preparation of biologically active materials is presented. The invention involves taking a base material such as allografts, xenografts, polymers, metals, and ceramics and combining it with a biologically active agent, such as proteins, cytokines, growth factors, and enzymes after which it is irradiated with ionizing radiation to sterilize and stabilize the material. The resulting biologically active material may then be stored at ambient temperature while maintaining its biological activity and the structural integrity of the base material. The invention is particularly useful for eliciting desired biological responses in human and animal medicine, and in certain industrial applications.

Priority: US20060782420P Applic. Date: 2006-03-15; WO2007US06592 Applic. Date: 2007-03-15

Inventor: MANDERS CHRISTIAN D [US]

Title: Abuse Potential Reduction in Abusable Substance Dosage Form

Applicant/Assignee: TRAVANTI PHARMA INC

Application No.: 12/621619   Filing Date: 19/Nov/2009

Abstract:The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure.

Priority: US2004-763628 Applic. Date: 2004-01-23

Inventor: ANDERSON CARTER R [US]; MORRIS RUSSELL L [US]

Title: COATED PELLETS

Applicant/Assignee: GRUENENTHAL GMBH

Application No.: 12/483646   Filing Date: 12/Jun/2009

Abstract:Coated pellets which comprise an active pharmaceutical ingredient that is poorly soluble in water, release at least 80% of the active ingredient under in vitro conditions in phosphate buffer at pH 5.0 after 30 minutes and are bioequivalent to a liquid formulation of the active ingredient under in vitro fed status test conditions and/or are coated with a composition, which includes a lipophilic component (A) and a hydrogel former (B), wherein the pure lipophilic component (A) has (i) an HLB value of !<=5, and/or (ii) a melting range of >=60 DEG C, and/or (iii) a solidification range [Delta] of less than 35 DEG C., and/or (iv) a density of >=0.80 g cm-3.

Priority: DE200610059510 Applic. Date: 2006-12-14; WO2007EP10862 Applic. Date: 2007-12-12

Inventor: ZIEGLER IRIS [DE]; JACOBS IRWIN [US]

Title: DERMATOLOGICAL EMULSION AND METHOD FOR THE PREPARATION THEREOF

Applicant/Assignee: PIERRE FABRE DERMO-COSMETIQUE

Application No.: 12/523263   Filing Date: 25/Jan/2008

Abstract:A foaming gelled composition in the form of a stable oil-in-water microemulsion comprising a fatty phase of microdroplets dispersed in an aqueous phase and a dermatological active ingredient, characterized in that it comprises a surfactant system comprising:-at least one ethoxylated nonionic surfactant

-at least one cosurfactant for stabilizing the ethoxylated nonionic surfactant

-at least one nonethoxylated hydrophilic nonionic surfactant

-at least one foaming agent chosen from the group of anionic surfactants.

Priority: FR20070052901 Applic. Date: 2007-01-26; WO2008EP50879 Applic. Date: 2008-01-25

Inventor: NIELLOUD FRANCOISE [FR]

Title: EXTERNAL COMPOSITION FOR SKIN CONTAINING SCROPHULARIA BUERGERIANA MIQ. EXTRACT AND THE USE THEREOF FOR THE SKIN MOISTURIZING COSMETICS

Applicant/Assignee: AMOREPACIFIC CORPORATION

Application No.: 12/528774   Filing Date: 19/Sep/2007

Abstract:Disclosed herein is a skin external composition for alleviating dry skin symptoms, which contains an extract of Scrophularia buergeriana Miq. as a main component and further contains an extract of Poria cocos Wolf, as well as the use thereof for skin-moisturizing cosmetics. The composition contains, as active ingredients, the Scrophularia buergeriana Miq. extract and the Poria cocos Wolf extract, which are prepared by extracting each of Scrophularia buergeriana Miq. and Poria cocos Wolf using water, ethanol, methanol, hexane, ethyl acetate or butanol.

Priority: KR20070020263 Applic. Date: 2007-02-28; WO2007KR04556 Applic. Date: 2007-09-19

Inventor: KIM HAN SUNG [KR]; LEE CHAN WOO [KR]; KIM YOUN JOON [KR]; KIM JEE EUN [KR]; KIM DUCK HEE [KR]; CHANG IH SEOP [KR]

Title: MEDICAMENT COMPRISING A REDUCING ALKYL-SUGAR MONOMER FOR THE TREATMENT OF INFLAMMATORY DISORDERS

Applicant/Assignee:

Application No.: 12/559107   Filing Date: 14/Sep/2009

Abstract:The invention relates to a medicament comprising at least one reducing alkyl-sugar monomer having a hydroxyl function which is substituted by an alkoxy radical at C2-C40, said medicament being preferably intended to regulate inflammatory mechanisms. The reducing sugar is preferably selected from the group containing rhamnose, fucose and glucose. The invention also relates to a cosmetic treatment method involving the topical application of a composition comprising at lest one reducing alkyl-sugar monomer having a hydroxyl function which is substituted by an alkoxy radical at C2-C40.

Priority: FR20030012798 Applic. Date: 2003-10-31; US2006-577444 Applic. Date: 2006-04-27; WO2004FR02794 Applic. Date: 2004-10-29

Inventor: HOULMONT JEAN-PHILIPPE [FR]; RICO-LATTES ISABELLE [FR]; PEREZ EMILE [FR]; BORDAT PASCAL [FR]

Title: COMPOSITION FOR APPLICATION TO SKIN OR MUCOSA

Applicant/Assignee: ROHTO PHARMACEUTICAL CO., LTD

Application No.: 12/513593   Filing Date: 09/Nov/2007

Abstract:Disclosed is a composition for application to skin or mucosa comprising alginic acid and/or salts thereof, which has reduced cytotoxicity against a skin cell or mucosa cell and higher safety, the composition for application to skin or mucosa comprises an alginic acid and/or salts thereof that contains substantially no low-molecular-weight fraction having a molecular weight of 3,500 or less.

Priority: JP20060305995 Applic. Date: 2006-11-10; WO2007JP71830 Applic. Date: 2007-11-09

Inventor: SETO TADASHI [JP]; MIYANO TAKAYUKI [JP]; HARUNA KENICHI [JP]; KUROSE TAKAHIRO [JP]

Title: HIGH PENETRATION PRODRUG COMPOSITIONS OF MUSTARDS AND MUSTARD-RELATED COMPOUNDS

Applicant/Assignee:

Application No.: 12/418564   Filing Date: 03/Apr/2009

Abstract:The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of mustards and mustard-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

Priority: WO2006IB53619 Applic. Date: 2006-10-03

Inventor: YU CHONGXI [US]; XU LINA [CN]

Title: METHODS FOR TREATING INFLAMMATION AND RELATED CONDITIONS

Applicant/Assignee: ORE PHARMACEUTICALS INC

Application No.: 12/500761   Filing Date: 10/Jul/2009

Abstract:A method for treating an inflammatory condition or immune disorder comprises administering to a subject having such a condition or disorder a therapeutically effective amount of at least one compound selected from irindalone, physiologically active enantiomers thereof, and pharmaceutically acceptable salts thereof. The invention further provides a method for elevating levels of anti-inflammatory cytokines such as IL-10 and IL-13 while inhibiting expression of pro-inflammatory cytokines. A pharmaceutical composition, useful for example in topical treatment of psoriasis, comprises a therapeutically effective amount of at least one compound selected from irindalone, physiologically active enantiomers thereof, and pharmaceutically acceptable salts thereof, in a vehicle comprising at least one pharmaceutically acceptable excipient, the vehicle being adapted for topical administration to skin of a subject.

Priority: US20080079808P Applic. Date: 2008-07-10

Inventor: MALSTROM SCOTT [US]; AMUGUNI HELLEN MULOMI [US]; CLISH CLARY [US]; DEIK AMY ANDERSON [US]; WHITE DAVID [US]

Title: Topical application of adapalene for the long-term treatment of acne vulgaris

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: 12/591343   Filing Date: 17/Nov/2009

Abstract:Administration of adapalene in a topical medicament to a patient so as to sustain its biological response in the treatment of acne vulgaris, wherein the administration pattern of the topical medicament comprises topically applying onto the afflicted skin area a therapeutically effective amount of adapalene at least once every two days for at least 6 months.

Priority: US2007-878736 Applic. Date: 2007-07-26; WO2006EP01140 Applic. Date: 2006-01-23; US20050647306P Applic. Date: 2005-01-26

Inventor: GRAEBER MICHAEL [US]

Title: ALCOHOLIC PUMP FOAM

Applicant/Assignee: STOCKHAUSEN GMBH

Application No.: 12/624073   Filing Date: 23/Nov/2009

Abstract:An alcoholic foam composition, which can be dispensed as a foam via a pump-foam system contains a) at least 52 to !<=99 wt % of an alcohol or mixture of alcohols, b) a surfactant or a surfactant mixture, c) at least one polyalkylene glycol, d) optionally, at least one foam stabilizer, e) optionally, at least one member selected from the group consisting of cosmetic auxiliaries, adjuvants, active ingredients, and mixtures thereof, and f) optionally water. The surface tension of component b) lies in the range of +-15 dyn/cm of the surface tension of component a) or corresponds to the surface tension of component a), and the sum of components a) to f) is 100 wt % relative to the total quantity of the foam composition.

Priority: DE200410062775 Applic. Date: 2004-12-21; US2005-312559 Applic. Date: 2005-12-21

Inventor: VEEGER MARCEL [DE]; HIMMING MARKUS [DE]

Title: STABLE MIXED EMULSIONS

Applicant/Assignee: COMBE

Application No.: 12/608391   Filing Date: 29/Oct/2009

Abstract:Stable mixed emulsion systems containing at least two discrete and distinctly different dispersed particle size ranges, i.e., both nanoemulsion and macroemulsion semisolid dispersions, as well as a method of making the same, are disclosed. The stable mixed emulsions may be used for cosmetic and dermatological applications and provide unique benefits.

Priority: US2006-369831 Applic. Date: 2006-03-08; US20050659410P Applic. Date: 2005-03-09

Inventor: SPENGLER ERIC [US]; PETRAIA TERESA [US]

Title: Passive Microwave Assessment of Human Body Core to Surface Temperature Gradients and Basal Metabolic Rate

Applicant/Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

Application No.: 12/483537   Filing Date: 12/Jun/2009

Abstract:A passive microwave thermography apparatus uses passive microwave antennas designed for operation, for example, at WARC protected frequencies of 1.400 to 1.427 GHz and 2.690 to 2.70 GHz (for core body gradient temperature measurement) and 10.68 to 10.700 GHz or higher microwave frequency (for surface body gradient temperature measurement) and a related directional antenna or antenna array to measure microwave radiation emanating from an animal, especially, a human body. The antennae may be radially directed toward a point within or on the surface of a human body for comparison with known temperature distribution data for that point and a given ambient temperature. Each frequency band may provide a plurality of adjacent noise measuring channels for measuring microwave noise naturally emitted by the human body. The apparatus measures short-term changes in, for example, core and body surface temperatures to establish a basal metabolic rate. Changes in core body temperature may be stimulated by the administration of food or certain organic and drug-related substances or stress to induce a change in basal metabolic rate over time. These changes correlate directly with a human subject's metabolism rate at rest and under certain dietary constraints and can be used to determine courses of treatment for obesity, metabolic disease, and other disorders. The apparatus can also be used to remotely monitor patients and subjects without physical contact.

Priority: US2007-931399 Applic. Date: 2007-10-31; US2008-336822 Applic. Date: 2008-12-17; US20080061513P Applic. Date: 2008-06-13

Inventor: ICOVE DAVID J [US]; ZEMEL MICHAEL B [US]; LYSTER CARL T [US]; FELD NEIL [US]

Title: EXTERNAL PREPARATION COMPOSITION

Applicant/Assignee: LION CORPORATION

Application No.: 12/605294   Filing Date: 23/Oct/2009

Abstract:An external preparation composition used for preventing or treating symptoms or diseases related to dermatopathy caused by dryness, UV rays and aging such as wrinkles and sags of the skin, pigmentation of the skin, skin roughness and coarse texture and skin diseases such as psoriasis, lichen, ichthyosis, keratosis, Darier's disease, pustulosis, acne, eczema and atopic dermatitis. The external preparation composition comprises at least one of acyl glucosamine derivatives represented by the following Formula (I): wherein R1, R2, R3, R4 and R5 are defined

and X is any one of groups represented by the following Formulas (A) to (C): wherein Y, n and R6 are also defined.

Priority: US2008-257853 Applic. Date: 2008-10-24; US2005-522032 Applic. Date: 2005-01-21; WO2002JP07549 Applic. Date: 2002-07-25

Inventor: KAMBAYASHI HIROAKI [JP]; KONTA HIROSHI [JP]

Title: COMPOSITIONS AND METHODS TO TREAT EPITHELIAL-RELATED CONDITIONS

Applicant/Assignee:

Application No.: 12/565335   Filing Date: 23/Sep/2009

Abstract:The described invention relates to the formulation and delivery of compositions to treat an epithelial-related condition selected from the group consisting of sparse hair growth, short hair growth, thin hair growth, alopecia and hair depigmentation and methods for their use. In some embodiments, the composition contains a first component and a second component wherein the first component is at least one prostaglandin analog and the second component is at least one imidazole analog, such that the at least one imidazole analog improves the efficacy of the at least one prostaglandin analog when delivered to a subject refractory to the effect of the prostaglandin analog alone.

Priority: US20080099226P Applic. Date: 2008-09-23

Inventor: LIPKIN PAMELA [US]; LUBIT BEVERLY [US]

Title: N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS

Applicant/Assignee:

Application No.: 12/628690   Filing Date: 01/Dec/2009

Abstract:Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.

Priority: EP20050102019 Applic. Date: 2005-03-15; EP20050108735 Applic. Date: 2005-09-21; US2007-885832 Applic. Date: 2007-09-07; WO2006EP60712 Applic. Date: 2006-03-14

Inventor: MAIER THOMAS [DE]; BAER THOMAS [DE]; BECKERS THOMAS [DE]; ZIMMERMANN ASTRID [DE]; SCHNEIDER SIEGFRIED [DE]; GEKELER VOLKER [DE]

Title: COMPOSITION FOR IMPROVING SKIN QUALITY AND A PROCESS FOR PREPARING THE SAME

Applicant/Assignee: COMPAGNIE GERVAIS DANONE

Application No.: 12/445205   Filing Date: 12/Oct/2007

Abstract:The present invention relates to a composition including, as active substance, a mixture of at least one polyunsaturated fatty acid, different from polyunsaturated fatty acid derived from milk, polyphenols, milk proteins and lactic bacteria, and the composition having a water content of at least 50% by weight

and wherein the polyunsaturated fatty acid presents an increased bioavailability compared with the one of the polyunsaturated fatty acid alone.

Priority: EP20060291607 Applic. Date: 2006-10-13; WO2007EP60922 Applic. Date: 2007-10-12

Inventor: GUYONNET DENIS [FR]; LASSEL TAOUS [FR]; SAMSON-VILLEGER SANDRINE [FR]; TRGO CHRISTIAN [FR]; RAWLINGS ANTHONY [GB]

Title: PROSTAGLANDIN E2 DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 12/499652   Filing Date: 08/Jul/2009

Abstract:The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

Priority: US20080134284P Applic. Date: 2008-07-08; US20080191711P Applic. Date: 2008-09-11

Inventor: GHAYUR TARIQ [US]; GU JIJE [US]; ISAAKSON PETER C [US]

Title: Cosmetic Composition

Applicant/Assignee:

Application No.: 12/496305   Filing Date: 01/Jul/2009

Abstract:Cosmetic composition providing a high coverage of skin while retaining a natural skin appearance comprising iron oxide particles having an average surface area from 30 m2/g to 150 m2/g, iron-containing titanium dioxide particles having an average surface area from 1 m2/g to 30 m2/g and comprising from 1% to 15% iron by weight of the titanium dioxide, and a cosmetically acceptable carrier and its use as a foundation and/or as a composition to correct skin discoloration surrounding the eye.

Priority: EP20080159449 Applic. Date: 2008-07-01

Inventor: ELLIOTT RUSSELL PHILIP [GB]; WATSON JOANNE [GB]

Title: MEDICINAL COMPOSITION FOR TRANSDERMAL ABSORPTION, MEDICINAL COMPOSITION STORING UNIT AND TRANSDERMAL ABSORPTION PREPARATION USING THE SAME

Applicant/Assignee: TEIKA PHARMACEUTICAL CO., LTD

Application No.: 12/529191   Filing Date: 29/Feb/2008

Abstract:An object of the invention is to provide a transdermal absorption preparation capable of sustaining the blood morphine concentration at an effective level over at least 48 hours, etc. This transdermal absorption preparation comprises a medicinal composition for transdermal absorption in which an active ingredient selected from morphine and salts thereof is blended in such an amount as corresponding to the saturation solubility or more in an active ingredient-holding vehicle having fluidity at a temperature around the human skin surface temperature and at least a portion of the active ingredient is held in a crystalline form, characterized in that, in the case where a preparation obtained from the above-described medicinal composition for transdermal absorption is applied to the uninjured skin of the back of a white rabbit having been shaven with electrical clippers for 72 hours, the available amount of the active ingredient per single dose of the preparation is from 10 mg to 400 mg in terms of morphine base, and the plasma concentrations of the active ingredient 24 hours and 48 hours after the application of the preparation under the above-described conditions are each at least 40 ng/mL in terms of morphine base, and so on.

Priority: JP20070053102 Applic. Date: 2007-03-02; WO2008JP53597 Applic. Date: 2008-02-29

Inventor: KIMURA TAKAHITO [JP]; ORIHASHI MASAHIRO [JP]; FUJISHITA SHIGETO [JP]; TAKABATAKE KOICHI [JP]; KATO TATSUHISA [JP]; SHIOTA SATOSHI [JP]; SHIMA YUICHIRO [JP]

Title: METHODS AND COMPOSITIONS FOR TARGETING FENESTRATED VASCULATURE

Applicant/Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION

Application No.: 12/443230   Filing Date: 27/Mar/2009

Abstract:Targeting of a fenestrated vasculature at a body site by micro or nanoparticles can be increased by using particles that have a radius substantially equal to a critical radius of a normal vasculature at the body site. The particles can be used for treating or monitoring a physiological condition responsible for the fenestrated vasculature. A method of improving an ability of micro or nanoparticles to target fenestrated blood vessels in a body site by selecting particles from a population of the micro or nanoparticles, where the selected particles have a radius that permits enhanced delivery into the fenestrated blood vessels.

Priority: WO2006US38196 Applic. Date: 2006-09-28

Inventor: DECUZZI PAOLO [IT]; FERRARI MAURO [US]

Title: Novel polynucleotides encoding polypeptides and methods using same

Applicant/Assignee:

Application No.: 11/043770   Filing Date: 27/Jan/2005

Abstract:Novel polypeptides and polynucleotides encoding same are provided. Also provided methods and pharmaceutical compositions which can be used to treat various disorders such as cancer, immunological-related, blood-related and skin-related disorders using the polypeptides and polynucleotides of the present invention. Also provided are methods and kits for diagnosing, determining predisposition and/or prognosis of various disorders using as diagnostic markers the novel polypeptides and polynucleotides of the present invention.

Priority: US20040607246P Applic. Date: 2004-09-07; US20040587851P Applic. Date: 2004-07-15; US20040539127P Applic. Date: 2004-01-27

Inventor: AYALON-SOFFER MICHAL [IL]; LEVINE ZURIT [IL]; SELLA-TAVOR OSNAT [IL]; DIBER ALEX [IL]; SHEMESH RONEN [IL]; TOPORIK AMIR [IL]; ROTMAN GALIT [IL]; NEMZER SERGEY [IL]; ROSENBERG AVI [IL]; DAHARY DVIR [IL]; WOOL ASSAF [IL]; COJOCARU GAD S [IL]; AKIVA PINCHAS [IL]; POLLOCK SARAH [IL]; SAVITSKY KINNERET [IL]; BERNSTEIN JEANNE [IL]

Title: METHODS FOR TREATING HERPES VIRUS INFECTIONS

Applicant/Assignee: NANOBIO CORPORATION

Application No.: 12/425984   Filing Date: 17/Apr/2009

Abstract:The present invention relates to methods for treating, killing, and/or inhibiting the growth of Herpes viruses in human subjects comprising topically administering to a human subject in need thereof a nanoemulsion composition having antiviral properties.

Priority: US20080046262P Applic. Date: 2008-04-18

Inventor: FLACK MARY R [US]; CIOTTI SUSAN MARIE [US]; HAMOUDA TAREK [US]; SUTCLIFFE JOYCE A [US]; BAKER JR JAMES R [US]

Title: USE OF EQUOL FOR TREATING SKIN DISEASES

Applicant/Assignee:

Application No.: 12/533169   Filing Date: 31/Jul/2009

Abstract:Equol (7-hydroxy-3(4'hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5[alpha]-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies of skin and hair. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes affecting skin and hair.

Priority: US2005-059951 Applic. Date: 2005-02-17; US2005-533045 Applic. Date: 2005-10-20; WO2003US34441 Applic. Date: 2003-10-29; US2003-625989 Applic. Date: 2003-07-24; US2008-167813 Applic. Date: 2008-07-03; US2003-625934 Applic. Date: 2003-07-24; US20040521457P Applic. Date: 2004-04-28; US20020422469P Applic. Date: 2002-10-29; US20020398270P Applic. Date: 2002-07-24

Inventor: LEPHART EDWIN DOUGLAS [US]; LUND TRENT D [US]; SETCHELL KENNETH DAVID REGINALD [US]; HANDA ROBERT J [US]

Title: FORMULATION CONTAINING PHOSPHATE DERIVATIVES OF ELECTRON TRANSFER AGENTS

Applicant/Assignee:

Application No.: 12/628443   Filing Date: 01/Dec/2009

Abstract:There is provided an emulsion composition for therapeutic administration comprising: (a) at least one mono-(electron transfer agent) phosphate derivative

(b) at least one di-electron transfer agent phosphate derivative

wherein the amount of transfer agent phosphate derivatives is no less than equimolar to the amount of di-electron transfer agent phosphate

and (c) a suitable carrier.

Priority: AU2001PR05499 Applic. Date: 2001-06-06; US2003-416775 Applic. Date: 2003-12-23; WO2001AU01475 Applic. Date: 2001-11-14; US20000247997P Applic. Date: 2000-11-14

Inventor: WEST SIMON MICHAEL [AU]

Title: SKIN CARE COMPOSITION

Applicant/Assignee:

Application No.: 12/440342   Filing Date: 05/Sep/2007

Abstract:The present invention relates to an oral composition containing an optimal combination of nutritional ingredients at high concentrations and at optimal ratios in order to maintain and/or achieve health and/or beautiful look of the skin.

Priority: EP20060018843 Applic. Date: 2006-09-08; EP20060026413 Applic. Date: 2006-12-20; WO2007EP07719 Applic. Date: 2007-09-05

Inventor: GORALCZYK REGINA [DE]

Title: Compositions and Methods for the Treatment of Inflammatory Dermatosis and Other Pathological Conditions of the Skin

Applicant/Assignee:

Application No.: 12/238481   Filing Date: 26/Sep/2008

Abstract:The present invention relates to a composition used as a vehicle for percutaneous absorption of Pharmaceutical and Cosmaceutical active agents that comprises Dimethiconol (hydroxyl-terminated polydimethydimethylsiloxane), dimethicone-350 (polydimethylsiloxane-350), cyclomethicone-5 nf (decamethylcyclopentasiloxane), alkymeth siloxane copolyol-lauryl peg/ppg 18/18 methicone (alkymethyl siloxane copolyol), cyclopentasiloxane and dimethicone Crosspolymer (silicone elastomer and decamethylcyclopentasiloxane), stearoxytrimethylsilane and stearyl alcohol (silicone wax), and deionized water. This composition serves several key applications: (1) it is a vehicle for percutaneous absorption of Pharmaceutical and Cosmaceutical active agents

(2) it acts as a method for utilizing other compositions in the treatment of inflammatory conditions of the skin including, but by no means limited to, atopic dermatitis (eczema), allergic contact dermatitis, seborrheic dermatitits, psoriasis, xerosis and atopia

(3) it is a treatment of inflammatory conditions of mucosae

(4) it relates to other compositions and methods for protecting and enhancing the barrier function of the skin.

Priority:

Inventor: MCGRAW THOMAS L [US]; MCGRAW DONALD M [US]; MCGRAW KELI C [US]; MCGRAW DONALD V [US]

Title: Composition Comprising Microcapsules

Applicant/Assignee:

Application No.: 12/569026   Filing Date: 29/Sep/2009

Abstract:A liquid composition having a microcapsule, the microcapsule having an aldehyde-containing resin, and one or more formaldehyde scavenger which reacts with formaldehyde to achieve more than about 60% reaction completeness in about 15 minutes time at pH 8 and at about 21 DEG C. A liquid composition having a microcapsule, the microcapsule having an aldehyde-containing resin, one or more sulfur-based formaldehyde scavenger and optionally a non-sulfur-based formaldehyde scavenger.

Priority: EP20080165469 Applic. Date: 2008-09-30

Inventor: BRAECKMAN KARL GHISLAIN [BE]; DEPOOT KAREL JOZEF MARIA [BE]; VAN PACHTENBEKE TIM ROGER MICHEL [BE]; SMETS JOHAN [BE]

Title: Film Material With Antimicrobial And/Or Odor-Absorbing Coating and Sanitary Article

Applicant/Assignee: NUOVA PANSAC S.P.A

Application No.: 12/515191   Filing Date: 26/Jun/2009

Abstract:A film material (1) is disclosed herein, particularly a polyolefin-based film material, coated on one side with a water resoluble resin-containing skin (2), and containing antimicrobial and/or odor-absorbing agents susceptible of being activated by organic liquids and blood liquids, such film material is particularly designed to form a disposable sanitary article (4) comprising a liquid-pervious topsheet (5), a liquid-impervious backsheet (6) and an absorbent layer (7) sandwiched between the topsheet (5) and the backsheet (6).

Priority: IT2006MI02253 Applic. Date: 2006-11-24; WO2007IB03588 Applic. Date: 2007-11-22

Inventor: LORI FABRIZIO [IT]; DELLA ZASSA SANTE AURELIO [IT]

Title: TRANSDERMAL EXTENDED-DELIVERY DONEPEZIL COMPOSITIONS AND METHODS FOR USING THE SAME

Applicant/Assignee:

Application No.: 12/551231   Filing Date: 31/Aug/2009

Abstract:A transdermal extended-delivery donepezil active agent composition is provided. Aspects of the compositions of the invention include a donepezil active agent layer that is formulated to provide for multi-day delivery of a therapeutically effective amount of a donepezil active agent to a subject when the composition is topically applied to the subject. Also provided are methods of using the formulations, e.g., for administering a donepezil active agent to a subject, and kits containing the formulations.

Priority: US20080101412P Applic. Date: 2008-09-30

Inventor: WEN JIANYE [US]; KATORI YOSHIKO [US]

Title: Cosmetic Methods And Compositions For Repairing Human Skin

Applicant/Assignee:

Application No.: 12/631585   Filing Date: 04/Dec/2009

Abstract:The present invention relates to methods and compositions for repairing adverse effects of the environment, daily stress, sun exposure, or pre-mature aging on human skin, comprising applying to the skin, prior to a period of bodily rest, a topical composition that contains resveratrol or a derivative thereof and at least one DNA repair enzyme.

Priority: US2007-837658 Applic. Date: 2007-08-13

Inventor: MAES DANIEL H [US]; MAMMONE THOMAS [US]; GOLDGRABEN KERRI [US]

Title: Eczema treatment with vitamin D and analogs thereof method, composition and cream

Applicant/Assignee: INNOVIA SKINCARE CORP

Application No.: 12/587070   Filing Date: 30/Sep/2009

Abstract:An eczema treatment method comprises application of a therapeutically effective composition in the form of an aqueous topical cream to an affected area of an exterior skin region of a patient, the aqueous topical cream comprising water, a water-soluble organic liquid, a surface active agent, and vitamin D3 compound or another claimed analog thereof, the vitamin D3 compound or the analog constituting at least approximately 10 international units per gram (IU/gram), and, most preferably at least approximately 400 IU/gram. An eczema treatment composition comprises a therapeutically effective formulation comprising at least approximately 50%-90% water, between approximately 1-5% PEG-40 stearate, between approximately 1-5% steareth-2, and cholecalciferal at a concentration of at least approximately 50 international units per gram (IU/g) of composition, and, most preferably at least approximately 400 IU/g. A topical vitamin D cream for therapeutic treatment of eczema includes vitamin D or an analog thereof chosen from the group consisting of cholecalciferol, alfacalcidol, calcifedol, and ergocalciferol

water

a water-soluble organic liquid

and a surface active agent, the vitamin D or analog being in a concentration of at least approximately 50 international units per gram (IU/g) of cream. Remarkably, relief from eczema conditions occurs immediately or in less than 3 days.

Priority: US20080194963P Applic. Date: 2008-10-01

Inventor: STRUBE MARILYN [US]

Title: Depilatory Composition

Applicant/Assignee: RECKITT & COLMAN (OVERSEAS) LIMITED

Application No.: 12/530426   Filing Date: 03/Mar/2008

Abstract:A depilatory cream composition comprising, a depilatory active, an emollient selected from at least one of mineral oil, silicone oil and emollient esters, and a silicone wax, a talc and/or polyamide resin.

Priority: GB20070004599 Applic. Date: 2007-03-09; WO2008GB00731 Applic. Date: 2008-03-03

Inventor: TINDAL ANNE [GB]; MANGASSI OUMOU [GB]

Title: Cosmetic/sunscreen compositions containing dibenzoylmethane compounds and dithiolane compound photostabilizers therefor

Applicant/Assignee: L'OREAL

Application No.: 12/588197   Filing Date: 07/Oct/2009

Abstract:Cosmetic/sunscreen compositions contain a combination of at least one dibenzoylmethane sunscreen compound and a photostabilizing amount of at least one dithiolane compound of formula (I) below:

Priority: FR20080056810 Applic. Date: 2008-10-08; US20080107075P Applic. Date: 2008-10-21

Inventor: LUCET-LEVANNIER KARINE [FR]; MULLER BENOIT [FR]

Title: BENEFIT AGENT CONTAINING DELIVERY PARTICLE

Applicant/Assignee:

Application No.: 12/632127   Filing Date: 07/Dec/2009

Abstract:The present invention relates to benefit agent containing delivery particles, compositions comprising said particles, and processes for making and using the aforementioned particles and compositions. When employed in compositions, for example, cleaning or fabric care compositions, such particles increase the efficiency of benefit agent delivery, there by allowing reduced amounts of benefit agents to be employed. In addition to allowing the amount of benefit agent to be reduced, such particles allow a broad range of benefit agents to be employed.

Priority: US2007-706675 Applic. Date: 2007-02-15; US20060834582P Applic. Date: 2006-08-01; US20060777629P Applic. Date: 2006-02-28

Inventor: DIHORA JITEN ODHAVJI [US]; SANDS PEGGY DOROTHY [US]; FOSSUM RENAE DIANNA [US]; YORK DAVID WILLIAM [GB]; LANG MATTHEW HENRY [US]; GUINEBRETIERE SANDRA JACQUELINE [US]

Title: MATERIAL, ITEM AND PRODUCTS COMPRISING A COMPOSITION HAVING ANTI-MICROBIAL PROPERTIES

Applicant/Assignee: NM TECH NANOMATERIALS MICRODEVICE TECHNOLOGY LTD

Application No.: 12/445307   Filing Date: 14/Oct/2009

Abstract:A coating product composition has the general formula AOx-(L-Men+)i, wherein AOx is a metal or metalloid oxide in which x indicates the number of the Oxygen atom(s) (O) bonded to the metal (A) atom, Men+ is a metal ion, L is a bifunctional molecule that could bind both metal oxide or metalloid oxide (AOx) and the metal ion (Men+), i is the number of the (L-Men+) groups bound to the metal oxide AOx. The value of the parameter i depends on various factors, such as the size of the nanoparticle of AOx, and the nature of the molecule L.

Priority: WO2006EP67361 Applic. Date: 2006-10-12

Inventor: BIGNOZZI CARLO ALBERTO [IT]; DISSETTE VALERIA [IT]

Title: Active Agent Loaded Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same

Applicant/Assignee:

Application No.: 12/565687   Filing Date: 23/Sep/2009

Abstract:Uniform, rigid, spherical nanoporous calcium phosphate particles that define an internal space and an amount of active agent present in the internal space are provided. Also provided are topical delivery compositions that include the active agent loaded particles, as well as methods of making the particles and topical compositions. The particles and compositions thereof find use in a variety of different applications, including active agent delivery applications.

Priority: US20080099500P Applic. Date: 2008-09-23

Inventor: OGAWA TETSURO [US]

Title: CAPSAICINOID DECONTAMINATION COMPOSITIONS AND METHODS OF USE

Applicant/Assignee: KAPSO, LLC

Application No.: 12/634418   Filing Date: 09/Dec/2009

Abstract:A therapeutic composition for inhibiting physiological responses elicited by exposure of skin to an irritant can be used to treat exposure to capsaicinoids or other chemical irritants. The therapeutic composition can include a carrier being present in an effective amount and form sufficient to be applied to skin and deliver active agents to the skin which has been previously exposed to a capsaicinoid. Also, the therapeutic composition can include a cooling agent in an effective amount within the carrier to provide a cooling sensation to the skin. Further, the therapeutic composition can include a capsaicin receptor antagonist in an effective amount within the carrier to inhibit calcium flux associated with activation of the capsaicin receptor by a capsaicinoid. The therapeutic composition can be part of a kit that also includes a cleansing composition, which is capable of cleaning and/or absorbing capsaicinoids from the skin.

Priority: US2006-366327 Applic. Date: 2006-03-02; US20050658822P Applic. Date: 2005-03-04

Inventor: REILLY CHRISTOPHER A [US]

Title: AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS

Applicant/Assignee:

Application No.: 12/531374   Filing Date: 29/Feb/2008

Abstract:The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

Priority: WO2007IB50921 Applic. Date: 2007-03-16; WO2008IB50742 Applic. Date: 2008-02-29

Inventor: BOLLI MARTIN [CH]; MATHYS BORIS [CH]; MUELLER CLAUS [DE]; NAYLER OLIVER [CH]; STEINER BEAT [CH]; VELKER JORG [FR]

Title: PHENYL DERIVATIVES AND THEIR USE AS IMMUNOMODULATORS

Applicant/Assignee: ACTELION PHARMACEUTICALS LTD

Application No.: 12/442203   Filing Date: 10/Jul/2007

Abstract:The invention relates to phenyl derivatives of formula (I), their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

Priority: WO2006IB53426 Applic. Date: 2006-09-21; WO2007IB52746 Applic. Date: 2007-07-10

Inventor: BOLLI MARTIN [CH]; LEHMANN DAVID [CH]; MATHYS BORIS [CH]; MUELLER CLAUS [DE]; NAYLER OLIVER [CH]; STEINER BEAT [CH]; VELKER JORG [FR]

Title: USE OF BIOTIN TO PREVENT PHOTOAGING

Applicant/Assignee:

Application No.: 12/597959   Filing Date: 07/May/2008

Abstract:Use of biotin, preferably in a combination of biotin and (-)-epigallocatechin gallate (EGCG) in a specific ratio, to prevent sunlight-induced aging (photoaging) of the skin.

Priority: EP20070009371 Applic. Date: 2007-05-10; WO2008EP03648 Applic. Date: 2008-05-07

Inventor: GORALCZYK REGINA [DE]; SCHWAGER JOSEPH [CH]

Title: Direct delivery applicator assembly and method of use

Applicant/Assignee:

Application No.: 12/286811   Filing Date: 02/Oct/2008

Abstract:An applicator directly delivers one or more active ingredients, such as flea, tick, or insect repellant to an animal's skin. The applicator comprises an applicator base connected to an applicator head having at least on prong member constructed with an internal channel therein in communication with a delivery aperture. A separately presented cartridge having a solution tube is appointed to be removably received within the applicator's base which, in turn is uniquely sized and shaped to receive a preselected one of those cartridges currently sold under recognized medicament brands. As the cartridge is squeezed, the solution traverses from the cartridge and applicator base into the applicator head and through the internal channels of the prong members, exiting through the delivery apertures onto the animal. Improved delivery owing to the prong members with channels therein terminating at fine delivery apertures is provided to yield direct delivery of the solution onto the animal's skin local to the fur shafts for a clean application and accurate dispersion of solution onto the animal.

Priority:

Inventor: HURWITZ MARNI MARKELL [US]

Title: HYDROGENATION OF CARYOPHELLENE

Applicant/Assignee: E.I. DU PONT DE NEMOURS AND COMAPNY

Application No.: 12/519614   Filing Date: 20/Dec/2007

Abstract:A process for the hydrogenation of a mixture of caryophyllenes by contact with hydrogen in the presence of a supported catalyst. The resulting products are useful for the application to skin.

Priority: US20060876555P Applic. Date: 2006-12-21; WO2007US25983 Applic. Date: 2007-12-20

Inventor: HUTCHENSON KEITH W [US]; JACKSON SCOTT CHRISTOPHER [US]; MANZER LEO ERNEST [US]; SCIALDONE MARK A [US]; SEAPAN MAYIS [US]

Title: RESILIENT PERSONAL CARE COMPOSITION COMPRISING POLYALKYL ETHER CONTAINING SILOXANE ELASTOMERS

Applicant/Assignee:

Application No.: 12/251154   Filing Date: 14/Oct/2008

Abstract:A stable personal care composition in the form of a water-in-oil emulsion may comprise a silicone elastomer comprising a polyalkyl ether pendant or a polyalkyl ether crosslink, wherein the alkyl group contains three or more carbon atoms

a non-emulsifying silicone elastomer

an emulsifier

a polar oil

and water. The personal care composition allows for previously unattainable levels of polar oils and/or aqueous phase within a water-in-oil emulsion.

Priority:

Inventor: BREYFOGLE LAURIE ELLEN [US]; TANNER PAUL ROBERT [US]; AISTRUP ELIZABETH REBECCA [US]

Title: NOVEL USE OF ANTIDEPRESSANT COMPOUNDS AND RELATED COMPOSITIONS

Applicant/Assignee:

Application No.: 12/520503   Filing Date: 20/Dec/2007

Abstract:What is described is a use of an antidepressant compound, preferably belonging to the class of selective serotonin reuptake inhibitors (SSRI), for regenerating the integumentary system and/or for stimulating the growth, the original trophism and/or original pigmentation of the corresponding cutaneous appendages, particularly body hair and/or head hair, in mammals. For this purpose, the antidepressant can be formulated in a cosmetic preparation, a pharmaceutical composition, a medical device, or in the form of a culture medium, alone or in combination with a further active ingredient such as a proteolytic enzyme and/or a vitamin.

Priority: IT2006TO00918 Applic. Date: 2006-12-22; IT2006TO00920 Applic. Date: 2006-12-22; IT2007TO00603 Applic. Date: 2007-08-20; WO2007IT00891 Applic. Date: 2007-12-20

Inventor: DE VIVO ENRICO [IT]; PONZETTO ANTONIO [IT]; CESANO CHIARA [IT]; GENNERO LUISA [IT]; MERIZZI GIANFRANCO [IT]; MORRA EMANUELLA [IT]

Title: Diagnosis and Treatment of Cancer Using Anti-Desmoglein-3 Antibodies

Applicant/Assignee: FORERUNNER PHARMA RESEARCH CO., LTD THE UNIVERSITY OF TOKYO

Application No.: 12/308695   Filing Date: 14/Aug/2007

Abstract:Methods that involve detection of a DSG3 protein for diagnosing cancer are disclosed. In lung cancer, the expression of DSG3 was found to be enhanced at very high frequency at the gene level and protein level. Methods of the present invention can be carried out using an antibody that recognizes a DSG3 protein. Pharmaceutical compositions, cell growth inhibitors, and anticancer agents containing a DSG3-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in DSG3-expressing cells and methods of suppressing proliferation of DSG3-expressing cells by contacting the DSG3-expressing cells with DSG3-binding antibodies are also disclosed.

Priority: JP20060221230 Applic. Date: 2006-08-14; JP20070019108 Applic. Date: 2007-01-30; WO2007JP65834 Applic. Date: 2007-08-14

Inventor: ABURATANI HIROYUKI [JP]; ISHIKAWA SHUNPEI [JP]; ITO HIROTAKA [JP]; NAKANO KIYOTAKA [JP]; KAWAI SHIGETO [JP]

Title: TREATMENT METHOD USING EGFR ANTIBODIES AND SRC INHIBITORS AND RELATED FORMULATIONS

Applicant/Assignee:

Application No.: 12/450196   Filing Date: 14/Mar/2008

Abstract:The present invention relates to the treatment of EGFR-mediated disease, particularly cancer by inhibiting or blocking EGFR and src in combination or simultaneously. The invention relates to treatment, prevention, or modulation of cancer, particularly EGFR-mediated disease, with one or more EGFR modulator and src inhibitor in combination. The invention further relates to the treatment of cancer with anti-EGFR antibodies and src inhibitors. Methods and compositions for treatment of cancer with the antibody anti-EGFR mAb806 in combination or series with a src inhibitor or src inhibitors are described.

Priority: US20070918084P Applic. Date: 2007-03-15; WO2008US03369 Applic. Date: 2008-03-14

Inventor: JOHNS TERRANCE GRANT [AU]; CAVENEE WEBSTER [US]; FURNARI FRANK [US]; SCOTT ANDREW [AU]

Title: TOPICAL COMPOSITIONS CONTAINING MAGALDRATE

Applicant/Assignee:

Application No.: 12/593299   Filing Date: 28/Mar/2008

Abstract:Disclosed are topical compositions containing the active ingredient magaldrate mixed with suitable vehicles and excipients.

Priority: IT2007MI00644 Applic. Date: 2007-03-29; WO2008IB02047 Applic. Date: 2008-03-28

Inventor: GUASTI PIER LUIGI [SM]

Title: METHOD FOR USING HYDROPHOBICALLY MODIFIED POLYMERS IN CONSUMER AND INDUSTRIAL APPLICATIONS

Applicant/Assignee:

Application No.: 12/575966   Filing Date: 08/Oct/2009

Abstract:This invention pertains to method of using a composition comprising one or more hydrophobically modified polyacrylamides, wherein the polyacrylamides contain acrylamide, one or more anionic monomers, and excludes a cationic monomer, and the method of combination with other compositions for use in combination for consumer and/or industrial applications.

Priority: US2007-853084 Applic. Date: 2007-09-11

Inventor: HESSEFORT YIN Z [US]; MAREK PATRICK J [US]; CRAMM JEFFREY R [US]; PATEL DAMYANTI J [US]; CARLSON WAYNE M [US]

Title: Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions

Applicant/Assignee: REVOTAR BIOPHARMACEUTICALS AG

Application No.: 12/440316   Filing Date: 07/Sep/2007

Abstract:A compound of formula (I) or a polymorphic form thereof can be used for the preparation of a cosmetic or dermato logical composition for the treatment of skin ageing.

Priority: EP20060120400 Applic. Date: 2006-09-08; WO2007EP59382 Applic. Date: 2007-09-07

Inventor: AYDT EWALD M [DE]; BOCK DANIEL [DE]; VOLLHARDT KARIN [DE]; WOLFF GERHARD [DE]

Title: DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY

Applicant/Assignee:

Application No.: 12/640578   Filing Date: 17/Dec/2009

Abstract:A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in sufficient amounts to treat disorders and symptoms associated with deficient endogenous levels of estrogen in women, and as a second active ingredient 6[beta],7[beta]

15[beta]

16[beta]-dimethylene-3-oxo-17[alpha]-preg-4-ene-21,17-carbolactone (drospirenone, DRSP) in sufficient amounts to protect the endometrium from the adverse effects of estrogen is useful for, amongst others, treating peri-menopausal, menopausal and post-menopausal women. This composition may be used for hormone replacement therapy and may be administered as a multi-phased pharmaceutical preparation. This combination therapy may comprise continuous, sequential or interrupted administration, or combinations thereof, of DRSP and estrogen, each optionally in micronized form.

Priority: US2001-757688 Applic. Date: 2001-01-11

Inventor: HEIL WOLFGANG [DE]; HILMANN JUERGEN [DE]; LIPP RALPH [DE]; SCHUERMANN ROLF [DE]

Title: STEROIDAL COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF

Applicant/Assignee:

Application No.: 12/433322   Filing Date: 30/Apr/2009

Abstract:A method for the identification of compounds) that control melanin synthesis (melanogenesis), and the preparation and use of such compounds, and compositions and formulations thereof to modify (e.g., inhibit) melanin production are disclosed. A representative compound of the invention is defined by formula I: The compounds may be prepared as pharmaceutical and cosmetic compositions, and in one embodiment, may be prepared in combination with each other, and with other melanogenesis inhibiting formulations. The compounds, compositions and formulations of the invention may be used for the prevention and treatment of conditions that are causally related to aberrant melanogenesis activity including, by way of non-limiting example, hyperpigmentation and others.

Priority: US20080049114P Applic. Date: 2008-04-30

Inventor: ORLOW SETH J [US]; KOMATSU LI NI [US]

Title: METHOD FOR TOPICAL TREATMENT OF TAR-RESPONSIVE DERMATOLOGICAL DISORDERS

Applicant/Assignee: TRISTRATA, INC

Application No.: 12/638505   Filing Date: 15/Dec/2009

Abstract:A method of treating a tar-responsive dermatological disorder includes topically applying an anhydrous tar composition to skin of a mammal, preferably a human, that is involved with the disorder, the composition including a wax and a therapeutically effective amount of tar for topical treatment of the tar-responsive dermatological disorder, the composition being in liquid form when at a temperature selected from room temperature and a temperature of skin of a mammal upon application of the composition to the skin of the mammal.

Priority: US2007-680227 Applic. Date: 2007-02-28; US20060778128P Applic. Date: 2006-03-01

Inventor: YU RUEY J [US]; VAN SCOTT EUGENE J [US]; LEE YALING [US]

Title: SOLUBILIZING SYSTEMS FOR FLAVORS AND FRAGRANCES

Applicant/Assignee: FIRMENICH SA

Application No.: 12/643269   Filing Date: 21/Dec/2009

Abstract:The present invention provides compositions and clear oil-in-water microemulsion containing up to 80% w/w of an oil, a surfactant system, a w/w oil/surfactant system ratio between 1 and 3, and a solubilizing-aid ingredient which is not a surfactant neither a VOC compound, the latter being present in an amount sufficient to ensure that the ratio oil/(surfactant+solubilizing aid) is comprised between 0.1 and 5. The present invention concerns also the articles and products associated the compositions and microemulsions, and the methods to manufacture them.

Priority: EP20040105185 Applic. Date: 2004-10-20; US2007-689635 Applic. Date: 2007-03-22; WO2005IB03329 Applic. Date: 2005-10-19; US2005-245704 Applic. Date: 2005-10-06; WO2004IB01473 Applic. Date: 2004-04-19; US2003-421216 Applic. Date: 2003-04-21; US20040620557P Applic. Date: 2004-10-20

Inventor: VLAD FLORIN JOSEPH [US]; MOUNIER REMY [FR]; WONG KENNETH [CH]; DAUGERON AUDE [FR]; HERD THOMAS [US]

Title: COMPOSITIONS CONTAINING AT LEAST ONE OIL STRUCTURED WITH AT LEAST ONE SILICONE-POLYAMIDE POLYMER, AND AT LEAST ONE CRYSTALLINE SILICONE COMPOUND AND METHODS OF USING THE SAME

Applicant/Assignee: L'OREAL

Application No.: 12/648020   Filing Date: 28/Dec/2009

Abstract:The invention relates to a physiologically acceptable composition, in particular a cosmetic composition, containing at least one liquid fatty phase structured with at least one structuring polymer of the silicone-polyamide type, the polymer being solid at room temperature and soluble in the liquid fatty phase at a temperature of from 25 to 250 DEG C., and at least one crystalline silicone compound, said oil having an affinity with said structuring polymer and/or with said crystalline silicone compound, and the liquid fatty phase, the polymer and the crystalline silicone compound forming a physiologically acceptable medium. This composition may be in the form of a stick of lipstick which is stable, which does not exude and whose application produces a glossy deposit with good staying power over time.

Priority: US2002-320601 Applic. Date: 2002-12-17

Inventor: YU WEI [US]

Title: PROMOTION OF PEROXISOMAL CATALASE FUNCTION IN CELLS

Applicant/Assignee: WAYNE STATE UNIVERSITY

Application No.: 12/568960   Filing Date: 29/Sep/2009

Abstract:The molecular mechanisms of peroxisome biogenesis have begun to emerge

in contrast, relatively little is known about how the organelle functions as cells age. The present inventors characterized age-related changes in peroxisomes of human cells and showed that aging compromises peroxisomal targeting signal 1 (PTS1) protein import, with the critical antioxidant enzyme, catalase, especially affected. The number and appearance of peroxisomes are altered in these cells, and the organelles accumulate the PTS1-import receptor, Pex5p, on their membranes. Concomitantly, cells produce increasing amounts of the toxic metabolite, H2O2, and this increased load of reactive oxygen species (ROS) may further reduce peroxisomal protein import and exacerbate the effects of aging. Disclosed are novel compositions and methods for restoring catalase in peroxisomes by use of targeted catalase modified at its C-terminus and/or N-terminus, optionally in combination with polypeptides which promote cellular uptake of proteins, to prevent or overcome the changes that follows aging or that are associated with a number of diseases or disorders.

Priority: US2005-533124 Applic. Date: 2005-12-27; WO2003US34512 Applic. Date: 2003-10-30; US20020422100P Applic. Date: 2002-10-30

Inventor: TERLECKY STANLEY R [US]; WALTON PAUL A [CA]

Title: METHODS, PROCESSES AND COMPOSITIONS COMPRISING THE PROTEIN CALMODULIN (CAM) FOR TREATMENT OF DAMAGED OR AGING SKIN, AND/OR HAIR LOSS

Applicant/Assignee:

Application No.: 12/449916   Filing Date: 21/Mar/2007

Abstract:The invention relates to compositions comprising the calcium binding protein, calmodulin (CaM), and the use of this protein additive in compositions suitable for topical application for the maintenance and development of healthy skin

for improving the aesthetic appearance of skin

for treating fine lines, and/or wrinkles, and/or age spots, and/or minor wounds and burns, and/or calloused skin-through its facilitation of natural healing processes initiated by disease, injury or aging

for enhancing hair growth

and as a cosmetic treatment process comprising application to the skin the compositions, preferably on a daily basis. The compositions may comprise, but not be limited to, UV blocking agents and/or penetration enhancers and/or one or more bio-active agents. CaM can be formulated into therapeutic compositions as lotions, creams, ointments, sprays, gels, skin coverings and wound dressings.

Priority: WO2007IB02725 Applic. Date: 2007-03-21

Inventor: TIPPENS DORR FELT [US]

Title: Novel Use Of An Extract Of Common Mallow As An Hydrating Agent, And Cosmetic Composition Containing It

Applicant/Assignee: LVMH RECHERCHE

Application No.: 12/500824   Filing Date: 10/Jul/2009

Abstract:The present invention relates to a novel use of an extract of common mallow for restoring, maintaining or reinforcing the state of moisturization of the skin

to a cosmetic composition containing it, and also to cosmetic care methods using said composition.

Priority: FR20080054780 Applic. Date: 2008-07-11

Inventor: DUMAS MARC [FR]; NOBLESSE EMMANUELLE [FR]; KRZYCH VALERIE [FR]; CAUCHARD JEAN HUBERT [FR]

Title: Powder Makeup Compositions And Methods

Applicant/Assignee:

Application No.: 12/255975   Filing Date: 22/Oct/2008

Abstract:An anhydrous powder composition wherein the ratio of platelet to non-platelet particulates is greater than about 5 to 1 respectively, which is preferably talc-free, oil-free, paraben-free, and fragrance-free

and a method for preparing the powder composition of the invention.

Priority:

Inventor: MERCADO CLARA G [US]; LOGALBO JOHN F [US]; DAO KHANH NGOC [US]

Title: GENE SEQUENCE VARIANCES IN GENES RELATED TO FOLATE METABOLISM HAVING UTILITY IN DETERMINING THE TREATMENT OF DISEASE

Applicant/Assignee:

Application No.: 12/390369   Filing Date: 20/Feb/2009

Abstract:The present disclosure describes the use of genetic variance information for folate transport or metabolism genes or pyrimidine transport or metabolism genes in the selection of effective methods of treatment of a disease or condition. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.

Priority: US2005-100921 Applic. Date: 2005-04-07; US2000-638267 Applic. Date: 2000-08-14; US2000-596033 Applic. Date: 2000-06-15; US1999-357743 Applic. Date: 1999-07-20; US1999-357024 Applic. Date: 1999-07-19; US19980093484P Applic. Date: 1998-07-20

Inventor: STANTON JR VINCENT P [US]

Title: Oligosaccharide Aldonic Acids and Their Topical Use

Applicant/Assignee:

Application No.: 12/643215   Filing Date: 21/Dec/2009

Abstract:Methods for using compositions comprising oligosaccharide aldonic acids for general care, as well as for treatment and prevention, of various cosmetic conditions and dermatological disorders, including those associated with intrinsic and/or extrinsic aging, as well as with changes or damage caused by extrinsic factors

general care, as well as treatment and prevention of diseases and conditions, of the oral, and vaginal mucosa

for general oral care, as well as treatment and prevention of oral and gum diseases

and for wound healing of the skin. Methods may comprise using compositions comprising oligosaccharide aldonic acids and additional cosmetic, pharmaceutical or other topical agents to enhance or create synergetic effects.

Priority: US2007-872459 Applic. Date: 2007-10-15; US2004-811998 Applic. Date: 2004-03-30; US2001-987023 Applic. Date: 2001-11-13; US2000-487228 Applic. Date: 2000-01-19; US19990141264P Applic. Date: 1999-06-30

Inventor: YU RUEY J [US]; VAN SCOTT EUGENE J [US]

Title: PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 12/446794   Filing Date: 23/Oct/2007

Abstract:The present invention relates to novel pharmaceutical compositions comprising at least one EGFR kinase inhibitor and at least one additional active compound selected from beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK1 antagonists, anticholinergics and endothelin antagonists, processes for preparing the compositions and the use thereof as medicament in the treatment of respiratory or gastrointestinal complaints, as well as inflammatory diseases of the joints, the skin or the eyes.

Priority: US20060862990P Applic. Date: 2006-10-26; WO2007EP61355 Applic. Date: 2007-10-23

Inventor: JUNG BIRGIT [DE]; HIMMELSBACH FRANK [DE]; POHL GERALD [DE]

Title: NOVEL PHOSPHODIESTERASE INHIBITORS

Applicant/Assignee: LEO PHARMA A/S

Application No.: 12/528649   Filing Date: 26/Feb/2008

Abstract:The present invention relates to a compound according to formula I, wherein X, A, G, E, R1, R2, R3 are as shown herein

and pharmaceutically acceptable salts, hydrates, N-oxides or solvates hereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

Priority: US20070903849P Applic. Date: 2007-02-28; US20070946849P Applic. Date: 2007-06-28; WO2008DK00080 Applic. Date: 2008-02-26

Inventor: FELDING JAKOB [DK]; NIELSEN SIMON FELDBAEK [DK]; LARSEN JENS CHRISTIAN HOEJLAND [DK]; BABU BOLLU RAVINDRA [IN]

Title: Compositions for Improving Skin Conditions Comprising Matrine or Its Oxidized Derivatives

Applicant/Assignee: BIOSPECTRUM INC

Application No.: 12/527237   Filing Date: 21/Feb/2008

Abstract:The present invention relates to a composition for improving skin conditions comprising matrine and oxymatrine as an active ingredient. Matrine and oxymatrine have lower cytotoxicity than retinol used as anti-wrinkle agents and exhibit the inhibition effect on collagenase activity and promotion effect on collagen biosynthesis at a molecular level, contributing to excellent efficacy in improvement of skin wrinkles. In addition, both matrine and oxymatrine exhibit the inhibition effect on melanin production by inhibiting intracellular tyrosinase activity, the improving effects of UV-induced skin damage and the skin growth promotion or hair loss prevention. Therefore, matrine and oxymatrine have the excellent improvement effects on skin conditions. Furthermore, matrine and oxymatrine have the excellent anti-obesity and anti-oxidation effects. The composition of this invention can be applied to cosmetic, pharmaceutical and food composition having no cytotoxicities and side effects.

Priority: KR20070017400 Applic. Date: 2007-02-21; WO2008KR01021 Applic. Date: 2008-02-21

Inventor: PARK DEOK HOON [KR]; JUNG EUN SUN [KR]; LEE JONG SUNG [KR]

Title: Microbe Reductions with Photosensitizers

Applicant/Assignee: CERAMOPTEC INDUSTRIES INC

Application No.: 12/643467   Filing Date: 21/Dec/2009

Abstract:Methods, devices and composition are disclosed for treating oral, skin and nail diseases, including inflammatory periodontal disease, onychomycosis and dermatophytosis. In a preferred embodiment a method for treating oral, skin and nail infections comprises administering a photosensitizing compound in long term effect or timed release formulations, including local highly concentrated formulations, and activating the photosensitizer with radiation to selectively destroy bacteria, fungi and other microbial bodies. In another preferred embodiment, photosensitizers are housed within nanoparticles, and can be gradually released through biodegradation or periodically released by such processes as brushing, irradiation and chemically induced release. The diffusion speed of the photosensitizers can be accelerated by brushing. In another embodiment, the photosensitizer molecule is also modified to more effectively target the molecule to the unwanted oral bacterial and fungal species. In another embodiment devices for treating oral, skin and nail infections includes a laser radiation source and delivery apparatuses such as brush or teethed comb for nail and scalp infections respectively.

Priority: US2006-523203 Applic. Date: 2006-09-19; US2002-241958 Applic. Date: 2002-09-12

Inventor: DRISCOLL TIM [US]; MEGA VERONICA INES [AR]; NEUBERGER WOLFGANG [AE]

Title: USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS

Applicant/Assignee:

Application No.: 12/159363   Filing Date: 29/Dec/2006

Abstract:There is provided the use as reducing agents of alpha-hydroxycarbonyl compounds capable of forming cyclic dimers. There is also provided corresponding methods of reducing reducible compounds, particularly reduction-activated prodrugs. Examples of the alpha-hydroxycarbonyl compounds used are dihydroxyacetone, glycolaldehyde, glyceraldehyde, erythrose, xylulose, erythrulose or 3-hydroxy-2-butanone.

Priority: GB20050026552 Applic. Date: 2005-12-29; WO2006GB04947 Applic. Date: 2006-12-29

Inventor: KNOX RICHARD J [GB]

Title: COSMETIC AND/OR PHARMACEUTICAL COMPOSITION COMPRISING AS AN ACTIVE PRINCIPLE AT LEAST ONE PEPTIDE AND USE OF THIS PEPTIDE

Applicant/Assignee: SOCIETE D'EXTRACTION DES PRINCIPES ACTIFS SA (VINCIENCE)

Application No.: 12/446958   Filing Date: 26/Oct/2007

Abstract:A cosmetic and/or pharmaceutical composition contains, as an active ingredient, at least one peptide from SEQ ID No1 to SEQ ID No8. The use of this peptide as an active ingredient for preparing compositions for inducing, increasing or restoring melanin synthesis in melanocytes of the skin or dermal papilla is also disclosed.

Priority: FR20060009416 Applic. Date: 2006-10-26; WO2007FR01777 Applic. Date: 2007-10-26

Inventor: DAL FARRA CLAUDE [FR]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]

Title: STABILIZATION OF UV-SENSITIVE ACTIVE INGREDIENTS

Applicant/Assignee: CIBA CORPORATION

Application No.: 12/520880   Filing Date: 16/Jan/2008

Abstract:Disclosed is the use of merocyanine derivatives of formula (1) for stabilizing UV-sensitive active ingredients like dibenzoylmethane derivatives.

Priority: EP20070101171 Applic. Date: 2007-01-25; WO2008EP50440 Applic. Date: 2008-01-16

Inventor: WAGNER BARBARA [DE]; HERZOG BERND [DE]; MULLER STEFAN [DE]; EHLIS THOMAS [DE]

Title: COSMETIC COMPOSITION FOR SKIN WHITENING COMPRISING ARCTIIN, ARCTIGENIN OR THE MIXTURE THEREOF AS ACTIVE

Applicant/Assignee:

Application No.: 12/449727   Filing Date: 25/Feb/2008

Abstract:Present Invention relates to a skin whitening cosmetic composition comprising arctiin, arctigenin or a mixture thereof as an active ingredient. The disclosed composition can control or inhibit the synthesis of melanin by acting on a melanin synthesis route of [alpha]-MSH secreted by UV, and thus show an excellent whitening effect compared to a conventional skin whitening cosmetic. Also, the composition has high formulation stability and low skin irritation.

Priority: KR20070020603 Applic. Date: 2007-02-28; WO2008KR01077 Applic. Date: 2008-02-25

Inventor: LEE JUNG NOH [KR]; CHOI JEONG EUN [KR]; KIM SANG WOO [KR]; LEE KANG TAE [KR]; LEE KUN KOOK [KR]

Title: METHODS OF MODULATING THE NEGATIVE CHEMOTAXIS OF IMMUNE CELLS

Applicant/Assignee:

Application No.: 12/572445   Filing Date: 02/Oct/2009

Abstract:The current invention is directed to methods of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell.

Priority: US20080102177P Applic. Date: 2008-10-02; US20090222217P Applic. Date: 2009-07-01

Inventor: CHAVAN SURENDRA [US]; MOON JONATHAN L [US]; BHATT LOPA [US]

Title: ANTIPERSPIRANT OR DEODORANT COMPOSITIONS

Applicant/Assignee: CONOPCO, INC., D/B/A UNILEVER

Application No.: 12/605598   Filing Date: 26/Oct/2009

Abstract:It is desirable for antiperspirant or deodorant roll-on compositions to be able to deliver fragrance over an extended period of time after application, but previously contemplated encapsulates were based on starch or similar water-soluble or dispersible shell materials, rendering them ineffective in aqueous emulsions. Capsules of fragrances in cross-linked coacervated gelatin shells satisfying defined particle size, shell thickness and hardness criteria enable roll-on compositions to be incorporated into aqueous antiperspirant or deodorant compositions encapsulated fragrance that can be released after the composition has been topically applied to skin.

Priority: EP20080167669 Applic. Date: 2008-10-27

Inventor: CHAN CATRIN SIAN [GB]; CROPPER MARTIN PETER [GB]; FRANKLIN KEVIN RONALD [GB]; JOHNSON SIMON ANTHONY [GB]; MCKEOWN ROBERT [GB]

Title: BENZOPYRANOPYRAZOLES

Applicant/Assignee:

Application No.: 12/373433   Filing Date: 12/Jul/2007

Abstract:Compounds of a certain formula I, in which Ra, Rb and Rc have the meanings indicated in the description, are effective compounds with anti-proliferative and/or apoptosis inducing activity.

Priority: EP20060117124 Applic. Date: 2006-07-13; WO2007EP57195 Applic. Date: 2007-07-12

Inventor: VENNEMANN MATTHIAS [DE]; BAER THOMAS [DE]; MAIER THOMAS [DE]; LINDENMAIER ANDREAS [DE]; BRAUNGER JUERGEN [AT]; BOEHM MARKUS [DE]; ZIMMERMANN ASTRID [DE]; GEKELER VOLKER [DE]

Title: COSMETIC AND/OR PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATIONS

Applicant/Assignee: LEGACY HEALTHCARE HOLDING LTD

Application No.: 12/526493   Filing Date: 08/Feb/2008

Abstract:Compositions are disclosed containing, as active ingredients, an extract of Allium species, an extract of Citrus species and either an extract of Paullinia species and an extract of Theobroma species, or an extract of Salix species and zinc sulphate, and the method of preparation of these compositions, and cosmetic and/or pharmaceutical application of these compositions.

Priority: FR20070001011 Applic. Date: 2007-02-13; WO2008FR00152 Applic. Date: 2008-02-08

Inventor: ULMANN ANDRE [FR]; STURER JEAN-FREDERIC [FR]

Title: 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS

Applicant/Assignee:

Application No.: 12/604959   Filing Date: 23/Oct/2009

Abstract:The present invention concerns 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

Priority: EP20020009746 Applic. Date: 2002-04-30; US2005-513347 Applic. Date: 2005-11-21; WO2003EP03909 Applic. Date: 2003-04-15

Inventor: LASSOIE MARIE-AGNES [BE]; KNERR LAURENT [SE]; DEMAUDE THIERRY [BE]; DE LAVELEYE-DEFAIS FRANCOISE [BE]; KOGEJ THIERRY [SE]; QUERE LUC [BE]; ROUTIER SYLVAIN [FR]; GUILLAUMET GERALD [FR]

Title: Therapeutic Methods and Compounds

Applicant/Assignee: DMI LIFE SCIENCES, INC

Application No.: 12/472738   Filing Date: 27/May/2009

Abstract:The invention provides diketopiperazines of formula I. The invention also provides pharmaceutical compositions comprising the diketopiperazines, or pharmaceutically-acceptable salts or prodrugs thereof, as the active ingredient. The invention further provides therapeutic treatments that utilize the diketopiperazines of formula I, including inhibition of a proliferative disease or condition, inhibition of angiogenesis, treatment of an angiogenic disease or condition, treatment of cancer and precancerous conditions, treatment of a fibrotic disorder, treatment of a viral infection, treatment of an Akt-mediated disease or condition, inhibition of the production, release or both of matrix metalloproteinase-9, and inhibition of Akt activation.

Priority: US20080056379P Applic. Date: 2008-05-27

Inventor: BAR-OR DAVID [US]

Title: ADMINISTRATION OF PYRIDINEDICARBOXYLIC ACID COMPOUNDS FOR STIMULATING OR INDUCING THE GROWTH OF HUMAN KERATINOUS FIBERS AND/OR ARRESTING THEIR LOSS

Applicant/Assignee: L'OREAL

Application No.: 12/650777   Filing Date: 31/Dec/2009

Abstract:The invention relates to the use in a composition for caring for human hair or eyelashes of an effective amount of a pyridinedicarboxylic acid derivative of general formula (I) or of one of its salts, in which R1 and R2 represent, independently of one another, OH, OR', -NH2, -NHR' or -NR'R'', and R' and R'' represent, independently of one another, a saturated or unsaturated and linear or branched C1-C18 alkyl radical or an aryl radical, this alkyl or aryl radical optionally being substituted by at least one OH, alkoxy, acyloxy, amino or alkylamino group, or R' and R'' together represent a heterocycle, the composition being intended to induce and/or stimulate the growth of human keratinous fibers, such as the hair and eyelashes, and/or slow down their loss

the invention also relates to a cosmetic treatment intended to stimulate the growth of human keratinous fibers, such as the hair and eyelashes, and/or slow down their loss.

Priority: FR20020004527 Applic. Date: 2002-04-11; US2009-463602 Applic. Date: 2009-05-11; US2003-410402 Applic. Date: 2003-04-10; US20020372414P Applic. Date: 2002-04-16

Inventor: DALKO MARIA [FR]; LOUSSOUARN GENEVIEVE [FR]; RAWADI CHARLES EL [FR]; BOULLE CHRISTOPHE [FR]; BERNARD BRUNO [FR]

Title: SACCHARIDE FOAMABLE COMPOSITIONS

Applicant/Assignee: FOAMIX LTD

Application No.: 12/646322   Filing Date: 23/Dec/2009

Abstract:A foamable composition, containing a saccharide for use in the treatment of various disorders including: water, a saccharide, about 0.2% to about 5% by weight of a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric agent selected from a bio-adhesive agent, a gelling agent, a film forming agent and a phase change agent, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

Priority: US2006-430437 Applic. Date: 2006-05-09; US20050679020P Applic. Date: 2005-05-09; US20060784793P Applic. Date: 2006-03-21

Inventor: TAMARKIN DOV [IL]; FRIEDMAN DORON [IL]; BESONOV ALEX [IL]

Title: Human sample matching system

Applicant/Assignee:

Application No.: 12/290877   Filing Date: 03/Nov/2008

Abstract:Methods and apparatus for a human sample (S), analyzing the sample (S) and then determining a match with a member of the opposite sex is disclosed. In one embodiment, a customer purchases an AromaMatch(TM) Test Kit (14), which comprises a bottle of cleaning solution (20), a cotton ball (22) a sample patch (24), a sample bag (28) and a mailing envelope (30). The user (10) opens the kit (14), cleans a patch of skin somewhere on his or her body, and then applies the patch (24). After wearing the patch (24) for an appropriate time period, the patch (24) is removed, and placed in the sample bag (28). The user (10) writes his or her password on the sample bag (28), and then mails it in the return envelope (30). A laboratory analyzes the sample patch (24), and determines a set of genetic attributes (G1) that are associated with the sample (S). The user (10) receives an analysis report by mail, or views the results of the analysis on a website (18). In another embodiment, a customized perfume is manufactured that is based on biological agents that are selected to match the set of genetic attributes identified by the analysis.

Priority:

Inventor: TUCK EDWARD F [US]; HASELTON MARTIE G [US]

Title: ANTI-BACTERIAL COMPOSITION AND METHOD OF USING SAME

Applicant/Assignee: ALLERA HEALTH PRODUCTS, INC

Application No.: 12/478157   Filing Date: 04/Jun/2009

Abstract:Disclosed is an alkaline extract of pine cones with anti-bacterial activity.

Priority: US20080058775P Applic. Date: 2008-06-04

Inventor: TUFARO FRANCIS [US]; TANAKA AKIKO [US]; BURROWS MICHAEL P [US]; BRADLEY WILLIAM G [US]; PETERKIN JOANNA [US]

Title: SUSTAINED-RELEASE COMPOSITION

Applicant/Assignee:

Application No.: 12/532218   Filing Date: 19/Mar/2008

Abstract:A composition which comprises (A) a plurality of cross-linked polymer particles, said polymer being the polymerization product of at least two monomer units selected from the group consisting of monoalkenyl aromatic compounds, alkyl esters derived from a saturated alcohol and acrylic or methacrylic acid, and vinyl esters of an aliphatic carboxylic acid

and said cross-line polymer particles being loaded with (B) an active ingredient, the weight ratio of the active ingredient (B) to the polymer particles (A) being from 0.05 to 50:1, is useful to release the active ingredient over an extended period of time while controlling sebum on skin and hair.

Priority: US20070919222P Applic. Date: 2007-03-21; WO2008US57444 Applic. Date: 2008-03-19

Inventor: ZHANG XIAODONG [US]; MEERBOTE MICHAEL [DE]; BATRA ASHISH [US]; KOSENSKY LINDA A [US]; SCHILLER KLAUS [DE]; NIETER ELKE [DE]

Title: OXYGEN-GENERATING COMPOSITIONS FOR ENHANCING CELL AND TISSUE SURVIVAL IN VIVO

Applicant/Assignee:

Application No.: 12/532520   Filing Date: 08/Apr/2008

Abstract:A method of treating hypoxic tissue such as wound tissue comprises contacting a composition to the hypoxic tissue in a hypoxia-treatment effective amount, the composition comprising a biodegradable polymer and an inorganic peroxide incorporated into the polymer.

Priority: US20070910686P Applic. Date: 2007-04-09; WO2008US04502 Applic. Date: 2008-04-08

Inventor: HARRISON BENJAMIN S [US]; YOO JAMES J [US]; ATALA ANTHONY [US]

Title: PEPTIDE COMPOUND AND USE THEREOF

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: 12/465536   Filing Date: 13/May/2009

Abstract:The present invention provides a method for the prophylaxis or treatment of cancer in a mammal, comprising administering a therapeutically effective amount of CBP501, a prodrug thereof or a pharmaceutically acceptable salt thereof to the mammal, wherein CBP501, a prodrug thereof or a pharmaceutically acceptable salt thereof is administered simultaneously with or before administration of a nucleic acid damaging agent.

Priority: US20080053190P Applic. Date: 2008-05-14; US20080116849P Applic. Date: 2008-11-21

Inventor: KAWABE TAKUMI [JP]; ISHIGAKI MACHIYO [JP]; SATO TAKUJI [JP]

Title: COMPLEX COMBINING AN ORGANIC SILICON DERIVATIVE WITH HYALURONIC ACID CALIBRATED FRAGMENTS, FOR PREVENTIVE AND REPAIRING ACTION OF CUTANEOUS DAMAGES

Applicant/Assignee: EXZYMOL S.A.M

Application No.: 12/572658   Filing Date: 02/Oct/2009

Abstract:The invention concerns a complex based on an organic silicon derivative. The invention is characterized in that said derivative is combined, by weak bonds, with one or several hyaluronic acid calibrated fragments of molecular weight comprised between 150 and 750 kDa, said derivative being of general formula (I): RXSi(OH)4-x (I) wherein: R is a (C1-C4)alkyl, x=1 and 2. The invention also concerns the use of such a complex in the prevention or the repair of cutaneous damages.

Priority: FR20080005479 Applic. Date: 2008-10-03

Inventor: SEGUIN MARIE-CHRISTINE [MC]

Title: TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES

Applicant/Assignee:

Application No.: 12/595922   Filing Date: 16/Apr/2008

Abstract:The present invention relates to a compound according to formula (I), wherein X and Y are either C and N or N and C

Z is CH2, CH2-CH2, CH2-NH, or NH

R1 is halogen, or R1 is alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, cycloalkyl, alkoxycarbonyl, aryl, all of which are optionally substituted

R2 is hydrogen, or R2 is alkyl, cycloalkyl, alkoxy, heterocycloalkyl, aryl, heteroaryl, alkoxycarbonyl, aminocarbonyl, amino, all of which are optionally substituted

A is aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl or heterocycloalkenyl, all of which are optionally substituted

and pharmaceutically acceptable salts, hydrates, or solvates hereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments, in particular for the treatment of dermal diseases.

Priority: US20070912020P Applic. Date: 2007-04-16; WO2008DK00135 Applic. Date: 2008-04-16

Inventor: FELDING JAKOB [DK]; SORNESEN MORTEN DAHL [DK]

Title: Controlled release transdermal drug delivery

Applicant/Assignee:

Application No.: 12/655938   Filing Date: 11/Jan/2010

Abstract:Provided herein is a device for controlling the release of a substance at a site of interest in a biological membrane comprising a means of monitoring a physiological state at the site of interest

and a means of releasing a variable amount of the substance to the site of interest where the amount varies in response to the status of the monitored physiological state. Also provided are methods of using the device.

Priority: US2003-422288 Applic. Date: 2003-04-24; US20020376112P Applic. Date: 2002-04-29

Inventor: MARCHITTO KEVIN S [US]; FLOCK STEPHEN T [US]

Title: PHARMACEUTICAL COMPOSITIONS STABILISED IN GLASSY PARTICLES

Applicant/Assignee: CAMBRIDGE BIOSTABILITY LIMITED

Application No.: 12/089386   Filing Date: 04/Oct/2006

Abstract:Present proposals for liquid-medium carriers for glass particles comprising pharmaceutical compositions have had problems associated with aggregation of the glass particles. This has been previously solved by matching the density of the particles and a liquid in which they are suspended. However, though this greatly constrains the choice of liquid carrier that can be used. An alternative solution to this problem has been found. By adding just a small amount of liquid (2) to the particles (1), a flowable mixture is formed of a creamy or paste-like consistency. Providing too much liquid (2) is not present, the particles (1) do not separate out and so the choice of liquid carriers available for use in compositions of this type is greatly increased.

Priority: GB20050020129 Applic. Date: 2005-10-04; WO2006GB50312 Applic. Date: 2006-10-04

Inventor: ROSER BRUCE [GB]

Title: ANTIMICROBIAL COMPOSITION

Applicant/Assignee: MERCK PATENT GMBH

Application No.: 12/523938   Filing Date: 10/Dec/2007

Abstract:The present invention relates to compositions comprising zinc oxide, barium sulphate and bound silver ions and their use in various applications, such as cosmetics, inks, lacquers or plastics.

Priority: EP20070001366 Applic. Date: 2007-01-23; WO2007EP10733 Applic. Date: 2007-12-10

Inventor: BICARD-BENHAMOU VALERIE [DE]; RUDOLPH THOMAS [DE]; BRUNNER MARCUS [DE]

Title: ANTIOXIDANT COMPOSITIONS FOR THE CLEANSING AND CONDITIONING OF SKIN

Applicant/Assignee:

Application No.: 12/615842   Filing Date: 10/Nov/2009

Abstract:Antioxidant cosmetic skin care compositions formulated to combat conditions associated with free radical damage and oxidative stress are provided. The compositions contain effective amounts of one of several active agents, including an agent derived from one or more of the plant species: Lycium barbarum, Punica granatum, Vitis vinifera, Aspalathus linearis, and Camellia Sinensis as well as cosmetically acceptable carriers. These cosmetic compositions find use in improving the appearance of aged or damaged skin.

Priority: US20080114019P Applic. Date: 2008-11-12

Inventor: JACOBS JUNE [US]

Title: Method and device for activating stem cells

Applicant/Assignee: SYNTHES USA, LLC

Application No.: 12/589956   Filing Date: 30/Oct/2009

Abstract:Invention embodiments described herein include methods and devices for stimulating mesenchymal stem cells in a stem cell source to differentiate into osteoblasts capable of forming bone. Devices and methods described include exposing a stem cell source, such as bone marrow aspirate, adipose tissue and/or purified allogenic stem cells, to an active agent, in a manner effective to form activated stem cells.

Priority: US20090152335P Applic. Date: 2009-02-13; US20080110096P Applic. Date: 2008-10-31

Inventor: HANS MEREDITH [US]; BUECHTER DOUG [US]; GRUSKIN ELLIOTT [US]; HORNSBY STEPHEN [US]; BROWN MELISSA [US]

Title: Compositions Having a Performance Indicator

Applicant/Assignee: AMCOL INTERNATIONAL CORPORATION

Application No.: 12/443998   Filing Date: 04/Oct/2007

Abstract:Compositions containing a delivery system including polymeric microparticles capable of undergoing a visual change, such as a color change, after application to a substrate are disclosed. The delivery system informs a consumer that the composition has been properly applied and/or has performed its intended function.

Priority: US20060849985P Applic. Date: 2006-10-05; WO2007US80403 Applic. Date: 2007-10-04

Inventor: SPINDLER RALPH [US]; LARIONOVA NATALIYA V [US]

Title: USE OF A SYNERGISTIC COMPOSITIONS AS A THERAPEUTIC AGENT OR DISINFECTANT

Applicant/Assignee: BODE CHEMIE GMBH MULTIBIND BIOTEC GMBH

Application No.: 12/452295   Filing Date: 27/Jun/2008

Abstract:The invention relates to the use of a composition comprising a vitamin, a metal ion, and a surfactant, as a therapeutic agent or disinfectant. The composition has been known as a decontaminant because the same efficiently decomposes DNA. It has now been possible to demonstrate that the agent has surprisingly good compatibility while having a wide-ranging disinfecting effect and is therefore also suitable for other purposes, e.g., for disinfecting or dressing wounds.

Priority: DE200710030103 Applic. Date: 2007-06-28; WO2008EP05292 Applic. Date: 2008-06-27

Inventor: KRUG BARBARA [DE]; EGGERSTEDT SVEN [DE]; OSTERMEYER CHRISTIANE [DE]; LISOWSKY THOMAS [DE]; ESSER KARLHEINZ [DE]; BUERGER FRANK [DE]; BLOSS RICHARD [DE]

Title: TRANSDERMAL THERAPEUTIC SYSTEM FOR ADMINISTERING THE ACTIVE SUBSTANCE BUPRENORPHINE

Applicant/Assignee: LTS LOHMANN THERAPIE-SYSTEME AG

Application No.: 12/515848   Filing Date: 07/Nov/2007

Abstract:The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and is characterized by a considerably increased utilization of the active substance.

Priority: DE200610054731 Applic. Date: 2006-11-21; WO2007EP09622 Applic. Date: 2007-11-07

Inventor: HILLE THOMAS [DE]; HORSTMANN MICHAEL [DE]; MUELLER WALTER [DE]

Title: Patch for Cutaneous Application

Applicant/Assignee: DBV TECHNOLOGIES

Application No.: 12/527407   Filing Date: 15/Feb/2008

Abstract:The invention relates to a patch for cutaneous application of a substance, the patch comprising a substance designed to penetrate the epidermis, means for placing the substance in contact with the skin and a peelable cutaneous exfoliation film enabling exfoliation of the skin, after placing the patch, at the level of the contact zone between said substance and the skin.

Priority: FR20070053265 Applic. Date: 2007-02-15; WO2008FR50252 Applic. Date: 2008-02-15

Inventor: DUPONT BERTRAND [FR]

Title: HIGHLY STABLE ELECTROLYTIC WATER WITH REDUCED NMR HALF LINE WIDTH

Applicant/Assignee: AKUATECH S.R.L

Application No.: 12/597587   Filing Date: 25/Apr/2008

Abstract:Electrolytic acid or alkaline water having a NMR half line width using 17O of from about 45 to less than 51 Hz, and an oxide reduction potential of from -1000 to +200 mV, or from +600 to +1300 mV, topical compositions that contain such water, uses for such water to hydrate skin, deliver drugs and treat various skin and mucosal conditions, and methods and apparatus for manufacturing the water.

Priority: US20070926182P Applic. Date: 2007-04-25; WO2008EP03383 Applic. Date: 2008-04-25

Inventor: CHEN YONGGE [CN]; DE NONI ROBERTO [IT]

Title: AQUEOUS GEL HAVING AN ALPHA-HYDROXY ACID AND SUSPENDED PARTICULATES

Applicant/Assignee:

Application No.: 12/607553   Filing Date: 28/Oct/2009

Abstract:A personal care composition in the form of an aqueous gel may comprise an alpha-hydroxy acid, wherein the pH of the composition is less than about 4.5. The personal care composition comprises a gelling agent and an aqueous solvent. The personal care composition further comprises particulates and an effective amount of suspension agent to suspend the particulates. The personal care composition exhibits a consumer desired viscosity and translucency.

Priority: US20080109354P Applic. Date: 2008-10-29

Inventor: GRIFFITHS-BROPHY SUSAN ADAIR [US]; KUHLMAN DENNIS EUGENE [US]

Title: Fatty acid-free, foaming cosmetic composition and method of use

Applicant/Assignee: L'OREAL

Application No.: 12/587891   Filing Date: 14/Oct/2009

Abstract:Disclosed are cosmetic compositions containing a disodium lauryl sulfosuccinate and a hydrophilically modified urethane. Also disclosed are methods for treating a keratinous substrate, such as skin or hair, by applying the cosmetic compositions to the keratinous substrate to, e.g., cleanse the keratinous substrate or deposit a cosmetically acceptable ingredient thereupon.

Priority: US20080196293P Applic. Date: 2008-10-15

Inventor: FARES HANI [US]; CORNELL MARC [US]; RUSSELL MICHAEL [US]

Title: Reactive Polyorganosiloxanes Modified With Aromatic Substances

Applicant/Assignee: MOMENTIVE PERFORMANCE MATERIALS GMBH

Application No.: 12/531894   Filing Date: 19/Mar/2008

Abstract:The invention relates to polyorganosiloxanes modified with fragrances and having reactive groups, to a method for coating a substrate using the polyorganosiloxanes according to the invention, use of the polyorganosiloxanes according to the invention for releasing the fragrance, to a method for producing the polyorganosiloxanes according to the invention as well as to their use, for example, in detergents or laundry detergents, in care products, in surface treatment agents and in cosmetics.

Priority: DE200710012909 Applic. Date: 2007-03-19; WO2008EP53287 Applic. Date: 2008-03-19

Inventor: LANGE HORST [DE]; ROOS CHRISTOPHER [DE]; WAGNER ROLAND [DE]; KROPFGANS MARTIN [DE]

Title: THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE

Applicant/Assignee:

Application No.: 12/528647   Filing Date: 26/Feb/2008

Abstract:The present invention relates to substituted thiadiazole compounds of the formula (I): and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for modulating SCD activity.

Priority: GB20070003906 Applic. Date: 2007-02-28; GB20070015654 Applic. Date: 2007-08-10; WO2008EP52276 Applic. Date: 2008-02-26

Inventor: BOUILLOT ANNE MARIE JEANNE [FR]; BOYER THIERRY [FR]; DAUGAN ALAIN CLAUDE-MARIE [FR]; DEAN ANTHONY WILLIAM [GB]; FILLMORE MARTIN CHRISTIAN [GB]; LAMOTTE YANN [FR]

Title: Peptides Having Activities of Epidermal Growth Factor and Its Uses

Applicant/Assignee: CAREGEN CO., LTD

Application No.: 12/444874   Filing Date: 08/Oct/2007

Abstract:The present invention relates to peptides comprising the amino acid sequence represented by the following formula 1 and having the activities of epidermal growth factor and their uses: Cys-Met-Tyr-Ile-Glu-Linker-Arg-Gly-Asp (1) The EGF-mimicking peptides of the present invention possess identical functions or activities to natural-occurring human EGF and are able to promote the generation of autocrine EGF in cells. In addition the peptides of the present invention are much higher stability and skin penetration potency than natural-occurring EGF. Therefore, the composition containing the peptide exhibits excellent treatment and prevention efficacies on diseases or conditions demanding EGF activities, and can be advantageously applied to pharmaceutical compositions, quasi-drugs and cosmetics.

Priority: KR20060098368 Applic. Date: 2006-10-10; WO2007KR04895 Applic. Date: 2007-10-08

Inventor: CHUNG YONG-JI [KR]; KIM YOUNG DEUG [KR]; KIM EUN MI [KR]; CHOI JUN YOUNG [KR]; SONG SANG SU [KR]

Title: COMPOSITIONS AND PRODUCTS CONTAINING S-EQUOL, AND METHODS FOR THEIR MAKING

Applicant/Assignee: AUSTRALIAN HEALTH & NUTRITION ASSOCIATION LIMITED CHILDREN'S HOSPITAL MEDICAL CENTER

Application No.: 12/558949   Filing Date: 14/Sep/2009

Abstract:A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism.

Priority: US2008-167813 Applic. Date: 2008-07-03; US2003-625934 Applic. Date: 2003-07-24; US20020398270P Applic. Date: 2002-07-24

Inventor: SETCHELL KENNETH DAVID REGINALD [US]; COLE SIDNEY JOHN [AU]

Title: KINASE INHIBITORS

Applicant/Assignee:

Application No.: 12/444957   Filing Date: 08/Oct/2007

Abstract:Compounds are provided for use with kinases that comprise a compound selected from the group consisting of formula (I) wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture in comprising such compounds

methods and intermediates useful for making the compounds

and methods of using said compounds.

Priority: US2006-539857 Applic. Date: 2006-10-09; US20070912629P Applic. Date: 2007-04-18; WO2007US80714 Applic. Date: 2007-10-08

Inventor: BROWN JASON W [US]; DONG QING [US]; PARASELLI BHEEMA R [US]; STAFFORD JEFFREY A [US]; WALLACE MICHAEL B [US]; WIJESEKERA HASANTHI [US]

Title: TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS

Applicant/Assignee: GENKYO TEX SA

Application No.: 12/532567   Filing Date: 28/Mar/2008

Abstract:The present invention is related to tetrahydroindole derivatives of Formula (I), pharmaceutical composition thereof, methods of preparation thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

Priority: EP20070109561 Applic. Date: 2007-06-04; US20070908414P Applic. Date: 2007-03-28; WO2008EP53704 Applic. Date: 2008-03-28

Inventor: PAGE PATRICK [FR]; ORCHARD MIKE [GB]; FIORASO-CARTIER LAETICIA [FR]; MOTTIRONI BIANCA [CH]

Title: METHODS, KITS, AND COMPOSITIONS FOR GENERATING NEW HAIR FOLLICLES AND GROWING HAIR

Applicant/Assignee:

Application No.: 12/443122   Filing Date: 27/Sep/2007

Abstract:The invention features methods, kits, and compositions for generating new hair follicles and growing hair on a subject.

Priority: US20060847854P Applic. Date: 2006-09-28; WO2007US20842 Applic. Date: 2007-09-27

Inventor: STEINBERG DAVID [US]; POJASEK KEVIN [US]; PROUTY STEPHEN [US]; COTSARELIS GEORGE [US]; ITO MAYUMI [US]

Title: Method and apparatus for skin treatment

Applicant/Assignee:

Application No.: 12/583578   Filing Date: 21/Aug/2009

Abstract:Disclosed is a system and method for treatment of skin disorders. More particularly, the disclosed invention is directed toward the use of multiple light sources for treating skin with or without the use of a topical compositions or photomodulation enhancing agents. Dual light emitting diodes may, for example, be used at relatively low power (less than about 10 J/cm2) to photomodulate skin or living tissue to reduce wrinkles, fine lines, acne, acne bacteria, and other skin disorders.

Priority: US2006-332517 Applic. Date: 2006-01-17; US2005-119378 Applic. Date: 2005-05-02; US2001-933870 Applic. Date: 2001-08-22; US2001-819082 Applic. Date: 2001-02-15; US1998-203178 Applic. Date: 1998-11-30

Inventor: MCDANIEL DAVID H [US]

Title: Implantable and Refillable Drug Delivery Reservoir

Applicant/Assignee: MED-EL ELEKTROMEDIZINISCHE GERAETE GMBH

Application No.: 12/614552   Filing Date: 09/Nov/2009

Abstract:Implantable drug delivery apparatuses and methods are described. An input port septum receives a therapeutic drug. An implantable delivery catheter holds a volume of the therapeutic drug and includes a proximal end in fluid communication with the input port septum, a distal end including an output septum for removing fluid from the catheter, and a drug permeable surface for diffusion of the therapeutic drug into nearby tissue.

Priority: US20080112818P Applic. Date: 2008-11-10

Inventor: JOLLY CLAUDE [AT]; HESSLER ROLAND [AT]

Title: Anti-Aging Product

Applicant/Assignee:

Application No.: 12/273258   Filing Date: 18/Nov/2008

Abstract:The present invention is directed to an anti-aging product, a single use multi-chamber packaging and a method of using the anti-aging product for reducing and/or preventing age-related skin symptoms. More particularly, the present invention is directed to a single use multi-chamber packet that has at least two chambers or compartments each containing at least one portion of an anti-aging composition, wherein said portions can be combined prior to application to the skin for reducing and/or preventing age-related skin symptoms. In another embodiment, the present invention is directed to an anti-aging kit comprising at least two or more single use multi-chamber packets, each having at a different composition for reducing and/or preventing age-related skin symptoms.

Priority:

Inventor: STUDIN JOEL R [US]

Title: Personal Care Compositions Containing Skin Conditioning Agents

Applicant/Assignee:

Application No.: 12/338327   Filing Date: 18/Dec/2008

Abstract:Personal care compositions are provided that include an aqueous base composition and a volatile post foaming agent mixed with the base composition. The base composition comprises a lipophilic skin conditioning agent, a structuring agent, and a water soluble or water dispersible surface active agent.

Priority: US20070009152P Applic. Date: 2007-12-26

Inventor: KYTE III KENNETH EUGENE [US]

Title: IN SITU RECOVERY FROM A HYDROCARBON CONTAINING FORMATION

Applicant/Assignee: SHELL OIL COMPANY

Application No.: 12/329942   Filing Date: 08/Dec/2008

Abstract:An in situ process for treating a hydrocarbon containing formation is provided. The process may include providing heat from one or more heaters to at least a portion of the formation. The heat may be allowed to transfer from the one or more heaters to a part of the formation such that heat from the one or more heat sources pyrolyzes at least some hydrocarbons within the part. Hydrocarbons may be produced from the formation.

Priority: US2007-657442 Applic. Date: 2007-01-23; US2002-279288 Applic. Date: 2002-10-24; US20010334568P Applic. Date: 2001-10-24; US20010337136P Applic. Date: 2001-10-24; US20020374970P Applic. Date: 2002-04-24; US20020374995P Applic. Date: 2002-04-24

Inventor: VINEGAR HAROLD J [US]; SUMNU-DINDORUK MELLIHA DENIZ [US]; WELLINGTON SCOTT LEE [US]; MAHER KEVIN ALBERT [US]; KARANIKAS JOHN MICHAEL [US]; DE ROUFFIGNAC ERIC PIERRE [NL]; MESSIER MARGARET ANN [CA]; ROBERTS BRUCE EDMUNDS [CA]; CRANE STEVEN DEXTER [US]

Title: COSMETIC COMPOSITIONS

Applicant/Assignee:

Application No.: 12/624236   Filing Date: 23/Nov/2009

Abstract:A cosmetic composition comprises a) from about 0.1% to about 15% of an emulsifying crosslinked siloxane elastomer

b) from about 0.1% to about 10% of a noncrosslinked silicone emulsifier having a polyglycerin unit

c) from about 1% to about 50% of a solvent for the emulsifying crosslinked siloxane elastomer

d) from about 0.05% to about 10% of an amphiphilic active

and e) water.

Priority: US20080117264P Applic. Date: 2008-11-24

Inventor: TANAKA SHUHEI [JP]; YOSHIMI NAOHISA [JP]

Title: ANTIMICROBIAL COMPOSITION WITH LOW CYTOTOXICITY

Applicant/Assignee: OY GRANULA AB LTD

Application No.: 12/626072   Filing Date: 25/Nov/2009

Abstract:A composition includes at least one antimicrobial agent

a possible solvent system with either hydrophobic or hydrophilic nature, selected according to the target of usage

as well as possible surface active agent. The compound mixture is obtained by pulverizing wood or plant material and/or by extracting the possibly pulverized wood or plant material, so that the compound mixture contains at least two different polyphenolic compounds selected from the following group: lignans, stilbenes, juvabiones and flavonoids

the compound mixture further containing oligomers of the polyphenolic compounds, so that the compound mixture preferably has the following properties: the compound mixture has an antimicrobial effect in the composition

the cytotoxicity of the polyphenols contained in the compound mixture is at least 10 times lower with respect to BHT

the compound mixture does not irritate the skin in a so-called single patch test with contents of 0.1 wt %.

Priority: US20080117684P Applic. Date: 2008-11-25

Inventor: AHLNAES THOMAS [FI]

Title: METHOD FOR PREPARING A COMPOSITION COMPRISING A COMPOUND MIXTURE AND A CARRIER AGENT

Applicant/Assignee: OY GRANULA AB LTD

Application No.: 12/626063   Filing Date: 25/Nov/2009

Abstract:In a method for preparing a composition including a compound mixture and a carrier agent, the compound mixture is obtained by pulverizing the wood material and/or by extracting the wood material so that the compound mixture contains at least two different compounds, selected from a first specified group, at least one compound selected from a second specified group, the compound mixture is mixed with the carrier agent, the amount of the compound mixture is kept in a range of 0.1-5 wt % from the total weight of the composition, providing that the range is also such that the total cytotoxicity of compound mixture dissolved in ethanol, measured for a HaCat cell culture after 24 h incubation period, is lower than the cytotoxicity of 0.02-0.1 wt % butylated hydroxy toluene (BHT) dissolved in ethanol for a HaCat cell culture after 24 h incubation period.

Priority: US20080117702P Applic. Date: 2008-11-25

Inventor: AHLNAS THOMAS [FI]

Title: METHODS AND PHARMACEUTICAL COMPOSITIONS FOR HEALING WOUNDS

Applicant/Assignee:

Application No.: 12/693968   Filing Date: 26/Jan/2010

Abstract:A pharmaceutical composition and method for inducing or accelerating a healing process of a skin wound are described. The pharmaceutical composition contains, as an active ingredient, a therapeutically effective amount of at least one agent for modulating PKC production and/or activation, and a pharmaceutically acceptable carrier. The method is effected by administering the composition to a wound.

Priority: US2009-404622 Applic. Date: 2009-03-16; US2003-644775 Applic. Date: 2003-08-21; US2002-169801 Applic. Date: 2002-07-09; WO2001IL00675 Applic. Date: 2001-07-23; US2002-214228 Applic. Date: 2002-08-08; US2000-629970 Applic. Date: 2000-07-31

Inventor: TENNENBAUM TAMAR [IL]; SAMPSON SANFORD [IL]; KUROKI TOSHIO [JP]; ALT ADDY [IL]; SHEN SHLOMZION [IL]

Title: Human Growth and Differentiation Factor GDF-5

Applicant/Assignee:

Application No.: 12/374080   Filing Date: 17/Jul/2007

Abstract:This invention relates to the production and use of pharmaceutical growth factor compositions with novel characteristics, e.g. improved solubility and controlled release characteristics under physiological conditions. Said compositions of one or more precursor proteins of growth factors of the GDF family provoke morphogenic effects such as for example growth, differentiation, protection and regeneration of a variety of tissues and organs, e.g. bone, cartilage, tendons, ligaments, nerves and skin. The invention can be advantageously used for the healing of tissue-destructive injuries and for the prevention or therapy of degenerative disorders.

Priority: EP20060014928 Applic. Date: 2006-07-18; WO2007EP06331 Applic. Date: 2007-07-17

Inventor: POHL JENS [DE]; PLOEGER FRANK [DE]

Title: ANTIBODIES TO IL-6 AND USE THEREOF

Applicant/Assignee:

Application No.: 12/502581   Filing Date: 14/Jul/2009

Abstract:The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other cogulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.

Priority: US20080117861P Applic. Date: 2008-11-25; US20080117839P Applic. Date: 2008-11-25; US20080117811P Applic. Date: 2008-11-25

Inventor: GARCIA-MARTINEZ LEON [US]; JENSEN ANN ELISABETH CARVALHO [US]; OLSON KATIE [US]; DUTZAR BEN [US]; OJALA ETHAN [US]; KOVACEVICH BRIAN [US]; LATHAM JOHN [US]; SMITH JEFFREY T L [US]

Title: LANOLIN COMPOSITIONS AND METHODS FOR MAKING AND USING SAME

Applicant/Assignee:

Application No.: 12/596334   Filing Date: 18/Apr/2008

Abstract:A composition suitable for application to the skin comprising lanolin, an oil, an anti-oxidant, and a combination thereof. The composition is suitable for particular application to a human breast.

Priority: US20070913238P Applic. Date: 2007-04-20; US20070913490P Applic. Date: 2007-04-23; WO2008US60890 Applic. Date: 2008-04-18

Inventor: THOMAS SHERRY L [US]; MARSEGLIA LAURA [US]; HANSON STEPHEN F [US]; AMIRAN MOHSEN [US]

Title: Use of Derivatives of Sinapinic Acid and Compositions Comprising Such Derivatives

Applicant/Assignee: COGNIS IP MANAGEMENT GMBH

Application No.: 12/530037   Filing Date: 26/Feb/2008

Abstract:The present invention relates to substances which can be used as cosmetic ingredients, especially for skin whitening and as cosmetic agents against signs of ageing skin. The present invention also relates to the use of such substances for the manufacture of a medicament for the treatment of disorders related to the pigmentation of the skin. The invention furthermore relates to specific substances.

Priority: EP20070004523 Applic. Date: 2007-03-06; WO2008EP01492 Applic. Date: 2008-02-26

Inventor: MARKERT THOMAS [DE]; MOUSSOU PHILIPPE [FR]; DANOUX LOUIS [FR]; RATHJENS ANDREAS [FR]

Title: TREATMENT OF HUMAN DISEASE CONDITIONS AND DISORDERS USING VITAMIN K ANALOGUES AND DERIVATIVES

Applicant/Assignee: VIRIDIS BIOPHARMA PVT. LTD

Application No.: 12/452803   Filing Date: 21/Jul/2008

Abstract:The present invention is related to the therapeutic uses of vitamin K, its analogues and derivatives in a diverse array of disease conditions. Vitamin K improves blood perfusion and ameliorates hypoxia in prevention and treatment of conditions such as chronic venous insufficiency manifestations, post thrombotic syndrome, skin conditions related to melanization, hyperpigmentation, Paresthesiae, oedema, varicose veins, VTE and cramps. The invention also provides pharmaceutical compositions comprising vitamin K, its analogues, derivatives or vitamin K-like compounds either alone or in combination with one or more therapeutically effective active agents for the diseases/conditions of venous, nerves and lymph, that are encompassed by this invention.

Priority: IN2007MU01419 Applic. Date: 2007-07-24; WO2008IN00465 Applic. Date: 2008-07-21

Inventor: VAIDYA ASHOK B [IN]; MEHTA DILIP S [IN]; DE SOUZA ANSELM [IN]; VAIDYA RAMA A [IN]

Title: Patches and method for the transdermal delivery of a therapeutically effective amount of iron

Applicant/Assignee:

Application No.: 12/459183   Filing Date: 25/Jun/2009

Abstract:Embodiments of the invention provide patches for the transdermal delivery of iron-containing compositions to an individual suffering from an iron deficiency. Many embodiments provide an iontophoretic patch for the transdermal delivery of a therapeutically effective amount of iron. The patch comprises an electrode and a reservoir containing a composition comprising ionic iron for the delivery of the therapeutically effective amount of iron. Various embodiments provide methods of using embodiments of the iontophoretic patch for delivering a therapeutically effective amount of iron to an individual suffering from one more forms of iron deficiency including iron deficiency anemia. Such methods can be used for treating and/or preventing the iron deficiency. The amount of delivered iron can be adjusted depending upon various treatment parameters such as patient weight and type and amount of iron deficiency.

Priority: US20080075720P Applic. Date: 2008-06-25

Inventor: BERENSON RONALD J [US]

Title: Depigmenting keratin materials utilizing dithiolane compounds

Applicant/Assignee: L'OREAL

Application No.: 12/591714   Filing Date: 30/Nov/2009

Abstract:A cosmetic regime or regimen for depigmenting, lightening and/or bleaching keratin materials, especially the skin, entails topically applying thereon a cosmetic composition containing a dithiolane compound of formula (I): in which: Y is O, NR1 or S R1 is a hydrogen atom

a C1-C20 alkyl radical or an optionally substituted phenyl radical

R is a hydrogen atom

or a C1-C20 alkyl radical, or an optionally substituted phenyl radical, or a C1-C8 alkyl radical containing an optionally substituted phenyl substituent

n=0 or 1 or 2

and also the salts, chelates, solvates and optical isomers thereof.

Priority: FR20080058075 Applic. Date: 2008-11-28; US20080193507P Applic. Date: 2008-12-04

Inventor: MARAT XAVIER [FR]

Title: METHODS FOR TREATING AND PREVENTING MULTIPLE SCLEROSIS

Applicant/Assignee:

Application No.: 12/598525   Filing Date: 01/May/2008

Abstract:We have discovered that LRG-47 (also called p47 GTPase), plays a central role in the pathogenesis of multiple sclerosis, and that inhibition of LRG-47 activity by anti-LRG-47 antibodies or of LRG-47 expression by siRNA dramatically reduce the pathology and symptoms of multiple sclerosis. Certain embodiments of the invention are directed to the therapeutic use of anti-LRG-47 antibodies (mouse or rabbit or other antibodies that are humanized or human antibodies to LRG-47, preferably antibodies made against human LRG-47) or siRNA or antisense nucleotides that specifically hybridize with the gene or mRNA or cDNA encoding human LRG-47 to treat or prevent multiple sclerosis and other autoimmune diseases that are T-cell-mediated. Other embodiments are directed to methods for the diagnosis of multiple sclerosis or to determining the aggressiveness of multiple sclerosis by determining the amount of human LRG-47 or LRG-47 mRNA in a biological sample from the patient.

Priority: US20070915127P Applic. Date: 2007-05-01; WO2008US62158 Applic. Date: 2008-05-01

Inventor: YAN SHI DU [US]

Title: COSMETIC ANTI-AGEING SKIN CARE COMPOSITIONS

Applicant/Assignee: TUPPERWARE PRODUCTS S.A

Application No.: 12/599419   Filing Date: 08/May/2008

Abstract:The invention is directed to an anti ageing skin care composition, more in particular a cosmetic anti aging skin care composition. The anti ageing skin care composition of the invention comprise, in a physiologically acceptable medium, (i) at least one peptide from Laminin-1 that is able to promote synthesis of Laminin-5

(ii) at least one peptide capable of at least partially inhibiting neuronal exocytosis

and (iii) at least one tripeptide producing a rapid and strong stimulation of collagen synthesis. The compositions of the present invention are effective in reducing existing wrinkles and/or preventing the formation of new wrinkles.

Priority: EP20070107712 Applic. Date: 2007-05-08; WO2008NL50278 Applic. Date: 2008-05-08

Inventor: OTTE STEPHANUS CORNELIS MARIA [NL]; ESTRADA HEMANDEZ CLAUDIA AMALIA [MX]; WON ANNIS [AU]

Title: MEDICAMENTS

Applicant/Assignee: INNOVATA BIOMED LIMITED

Application No.: 12/683959   Filing Date: 07/Jan/2010

Abstract:There is described a bimodal pharmaceutical composition comprising effective amounts of a first active ingredient which substantially comprises a coarse fraction and a second active ingredient which substantially comprise a fine fraction characterized in that the coarse fraction possesses a greater mass median aerodynamic diameter than the fine fraction. There is also described a method of delivering a therapeutically effective amount of a substantially fine active ingredient to the lung of a patient by co-administration with a substantially coarse active ingredient.

Priority: GB20010002902 Applic. Date: 2001-02-06; GB20010009215 Applic. Date: 2001-04-12; US2006-511730 Applic. Date: 2006-08-29; US2003-467153 Applic. Date: 2003-12-08; WO2002GB00480 Applic. Date: 2002-02-05

Inventor: SANDERS MARK [GB]

Title: NANOPARTICLE-COATED CAPSULE FORMULATION FOR DERMAL DRUG DELIVERY

Applicant/Assignee: UNIVERSITY OF SOUTH AUSTRALIA

Application No.: 12/596679   Filing Date: 21/Apr/2008

Abstract:A method and formulation for the delivery of an active substance to the skin (epidermis, including the stratum corneum and viable epidermis, and dermis) of a subject. The formulation comprises oil-based or aqueous droplets comprising the active substance within a coating of nanoparticles, particularly silica nanoparticles. The active substance may be suitable for the treatment of a disease or condition which is localised, or at least partially localised, to the skin (eg skin cancer, psoriasis, eczema, infections including bacterial and fungal infections, acne, dermatitis, inflammation, and rheumatoid arthritis).

Priority: AU20070902112 Applic. Date: 2007-04-20; WO2008AU00555 Applic. Date: 2008-04-21

Inventor: PRESTIDGE CLIVE ALLAN [AU]; SIMOVIC SPOMENKA [AU]; ESKANDAR NASRIN GHOUCHI [AU]

Title: Mineral oil free polymerically stabilized make-up remover

Applicant/Assignee: L'OREAL

Application No.: 12/587892   Filing Date: 14/Oct/2009

Abstract:Disclosed are make-up removal compositions, comprising a mineral oil-free oil phase

a sodium salt of an acrylate copolymer

a stabilizing polymer

and a hydrophobic wetting agent, and methods of using the compositions to remove make-up from facial tissue or skin. The disclosed compositions exhibit a rheological profile that features a variable ("up and down" or "increasing and then decreasing") shear stress response to increasing shear rates, and which is believed to contribute to better performance than known make-up removal compositions tested.

Priority: US20080196309P Applic. Date: 2008-10-15

Inventor: RUSSELL MICHAEL [US]; CORNELL MARC [US]

Title: USE OF AN ACTIVE PRINCIPLE ORIGINATING FROM AMARANTH (AMARANTHUS) FOR PREPARING A COMPOSITION INTENDED TO ACTIVATE CELLULAR ENERGY AND TO PROTECT THE SKIN FROM OXIDATIVE DAMAGE

Applicant/Assignee: SOCIETE D'EXTRACTION DES PRINCIPES ACTIFS S.A. (ISP VINCIENCE)

Application No.: 12/597867   Filing Date: 27/Oct/2009

Abstract:Methods of administering in a cosmetic composition or a pharmaceutical composition, an effective amount of a peptide active principle originating from amaranth of the species Amaranthus hypochondriacus. The active principle is intended to activate cellular energy and to protect the skin from oxidativ damage, and the active principle may be used alone or in association with at least one other active principles. The active principle may also be used in a cosmetic treatment for protecting the skin and the appendages from external aggressions and to combat cutaneous aging.

Priority: FR20070003062 Applic. Date: 2007-04-27; WO2008FR00576 Applic. Date: 2008-04-23

Inventor: DAL FARRA CLAUDE [FR]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]

Title: LIQUID COMPOSITION FOR EXTERNAL APPLICATION AND PREPARATION FOR EXTERNAL APPLICATION FOR TREATMENT OF SKIN ULCER

Applicant/Assignee: CELLGENTECH, INC

Application No.: 12/293622   Filing Date: 22/Mar/2007

Abstract:An object of the present invention is to provide a liquid composition for external application and a preparation for external application which are excellent in healing effect on skin ulcers including intractable skin ulcers such as bedsore (decubitus), diabetic skin ulcer and ischemic skin ulcer. The liquid composition for external application of the present invention as means for the resolution is characterized by comprising at least G-CSF (a granulocyte colony stimulating factor) as an active ingredient and 0.001% to 5% of alginic acid. The preparation for external application for treatment of a skin ulcer of the present invention is characterized by comprising the liquid composition for external application of the present invention as a medicinal ingredient.

Priority: JP20060079614 Applic. Date: 2006-03-22; WO2007JP55883 Applic. Date: 2007-03-22

Inventor: JIMI SHIRO [JP]; SUZUMIYA JUNJI [JP]

Title: PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION

Applicant/Assignee: FOAMIX LTD

Application No.: 12/705219   Filing Date: 12/Feb/2010

Abstract:A pharmaceutical or cosmetic carrier or composition for topical application characterized by rheological properties which render the carrier or composition semi-solid at rest and a liquid upon application of shear forces thereto. The composition or carrier are prepared by mixing 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, by weight, wherein at least one of them has therapeutic or cosmetic benefits, in the presence or absence of a biologically active substance.

Priority: US2005-294318 Applic. Date: 2005-12-05; US2003-392071 Applic. Date: 2003-03-19; US2000-653267 Applic. Date: 2000-08-31; US20000216162P Applic. Date: 2000-07-03

Inventor: EINI MEIR [IL]; TAMARKIN DOV [IL]

Title: MEDICAMENTS

Applicant/Assignee: RENOVO LIMITED

Application No.: 12/306501   Filing Date: 29/Jun/2007

Abstract:There is provided the use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention, reduction or inhibition of scarring. There is also provided the use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention and/or treatment of a fibrotic disorder. Further aspects relate to methods by which scarring may be prevented, reduced or inhibited, and by which fibrotic disorders may be prevented and/or treated. Therapeutically effective amounts of WNT5A, or its fragments or derivatives, that may be used in the medicaments or methods of the invention are also provided.

Priority: GB20060013031 Applic. Date: 2006-06-30; WO2007GB02445 Applic. Date: 2007-06-29

Inventor: FERGUSON MARK W J [GB]; LAVERTY HUGH G [GB]; OCCLESTON NICHOLAS [GB]; O'KANE SHARON [GB]; NIELD KERRY [GB]; GOLDSPINK NICHOLAS [GB]

Title: COMPOSITION FOR TRANSDERMAL OR TRANSMUCOSAL ADMINISTRATION

Applicant/Assignee: FUJIMOTO CO., LTD

Application No.: 12/452239   Filing Date: 20/Jun/2008

Abstract:The present invention provides a composition for transdermal or transmucosal administration, which is useful as an anti-Alzheimer's drug, an antiparkinson drug, an antidepressant, a psychoactive drug, or a therapeutic agent for drug dependence. The composition for transdermal or transmucosal administration comprising an effective dose of a racemate or an optically acceptable substance of 1-(benzofuran-2-yl)-2-propylaminopentane or a pharmacologically acceptable salt thereof and a vehicle, which can be administered without an invasion of skin and mucous membrane, is an excellent agent serving as an anti-Alzheimer's drug, an antiparkinson drug, an antidepressant, a psychoactive drug or a therapeutic agent for drug dependence, which can allow its active ingredient in a sufficient effective amount to stably arrive, through the skin and mucous membrane, at a body or a brain and is free of disadvantages such as a reduction in an active component caused by a first pass effect in a liver, as well as pains, damages or infections.

Priority: JP20070163692 Applic. Date: 2007-06-21; WO2008JP61300 Applic. Date: 2008-06-20

Inventor: YONEDA FUMIO [JP]; OHDE HIRONORI [JP]; WATANABE MAYUMI [JP]; SUGIMOTO MIKIYO [JP]; KAMADA TAKAHIRO [JP]; HUKUMOTO MIZUE [JP]; TAKASE AZUSA [JP]; HOSHINO NAOYA [JP]

Title: Ibuprofen for Topical Administration

Applicant/Assignee: BIOCHEMICS, INC

Application No.: 12/557470   Filing Date: 10/Sep/2009

Abstract:Set forth herein is a preparation of ibuprofen (2-(4-isobutylphenyl)propionic acid) in the free acid form that is suitable for topical administration. The topical ibuprofen formulation is prepared by dissolving the free acid form of ibuprofen, or preparing a homogeneous suspension of the free acid form of ibuprofen, in the presence of a pharmaceutically acceptable solvent so as to produce a topical drug formulation compatible with the penetration of 2-(4-isobutylphenyl) propionic acid through the skin tissue. Topical formulations of ibuprofen can be based on a pharmaceutically acceptable solvent such as, e.g., a pyrrolidone solvent or dimethylacetamide.

Priority: US20080095672P Applic. Date: 2008-09-10

Inventor: CARTER STEPHEN G [US]; ZHU ZHEN [US]; PATEL KANU [US]; KOZWICH DIANE L [US]

Title: HUMANIZED ANTI-IL-6 ANTIBODIES

Applicant/Assignee: BIOATLA, LLC

Application No.: 12/617915   Filing Date: 13/Nov/2009

Abstract:The present invention relates to novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Priority: US20080114295P Applic. Date: 2008-11-13

Inventor: FREY GERHARD [US]; CHANG HWAI WEN [US]; SHORT JAY [US]

Title: ELECTRONIC SKIN READER

Applicant/Assignee: KENT DISPLAYS, INC

Application No.: 12/631133   Filing Date: 04/Dec/2009

Abstract:A portable electronic device includes a portable electronic device housing having a surface and a primary, light-emissive display. A display skin covers a portion of the surface of the portable electronic device housing. The display skin provides a secondary, light-reflective display. The display skin includes an optically active layer comprising electrooptical material. A first electrode layer is disposed on a first side of the optically active layer proximal the surface of the portable electronic device housing. A second electrode layer disposed on a second side of the optically active layer distal of the surface of the portable electronic device housing. Electronic circuitry selectively activates the optically active layer such that images including portions of a document are selectively displayed by the display skin. The display skin is capable of maintaining a display of a selectively displayed portion of the document while the primary display is in an unpowered state.

Priority: US20080200806P Applic. Date: 2008-12-04; US20090157661P Applic. Date: 2009-03-05

Inventor: JOHNSON ROGER LAVERNE [US]

Title: COSMETIC COMPOSITION COMPRISING AT LEAST ONE APROTIC HYDROCARBON-BASED VOLATILE SOLVENT

Applicant/Assignee:

Application No.: 12/516015   Filing Date: 20/Nov/2007

Abstract:The present application relates to a cosmetic composition comprising, in a physiologically acceptable medium, at least one aprotic hydrocarbon-based volatile solvent comprising no more than one branch, the volatility of said solvent being such that the amount evaporated in 30 minutes is between 4.1 mg/cm2 and 24 mg/cm2. This composition can be used as a product for caring for and/or making up keratin materials, in particular the skin, the lips and/or the integuments.

Priority: FR20060055058 Applic. Date: 2006-11-23; US20060872485P Applic. Date: 2006-12-04; WO2007EP62583 Applic. Date: 2007-11-20

Inventor: AUGUSTE FREDERIC [FR]; FOURON JEAN-YVES [FR]

Title: Ester solvents derived from 4-carboxy-2-pyrrolidinone formulated into UV-screening cosmetic compositions

Applicant/Assignee: L'OREAL

Application No.: 12/654032   Filing Date: 08/Dec/2009

Abstract:Stable UV-screening cosmetic compositions contain at least one ester solvent derived from 4-carboxy-2-pyrrolidinone, of formula (I): in which: R1 is a linear or branched C1-C20 alkyl radical, and R2 is a linear or branched C1-C20 alkyl radical optionally containing a C5-C6 ring member, the phenyl radical, the benzyl radical or the phenethyl radical, and at least one liquid fatty phase and at least one lipophilic UV-screening active agent, the at least one ester derivative constituting a solvent for the at least one active agent in the at least one liquid fatty phase and/or constituting an agent for improving the solubility of the at least one active agent in the at least one fatty phase.

Priority: FR20080058337 Applic. Date: 2008-12-08; US20080193647P Applic. Date: 2008-12-12

Inventor: RICHARD HERVE [FR]; MULLER BENOIT [FR]

Title: Low-residue deodorant or antiperspirant stick based on an oil-in-water emulsion

Applicant/Assignee:

Application No.: 12/622755   Filing Date: 20/Nov/2009

Abstract:Deodorant or antiperspirant sticks based on an oil-in-water dispersion for application to the skin.

Priority: DE200410036689 Applic. Date: 2004-07-28; US2005-192389 Applic. Date: 2005-07-28; US20040600688P Applic. Date: 2004-08-11

Inventor: BANOWSKI BERNHARD [DE]; WADLE ARMIN [DE]; CLAAS MARCUS [DE]

Title: COSMETIC/DERMATOLOGICAL COMPOSITIONS COMPRISING A DERIVATIVE OF GLUCOSE AND OF VITAMIN F AND A SPECIFIC SURFACTANT

Applicant/Assignee: L'OREAL

Application No.: 12/704806   Filing Date: 12/Feb/2010

Abstract:Topically applicable cosmetic/dermatological compositions suited for improving the condition of human keratin fibers, notably human hair, especially for reducing or stopping loss and/or inducing and/or stimulating growth and/or density thereof, contain a thus effective amount of (a) at least one derivative of glucose and of vitamin F, solubilized in a topically applicable, physiologically acceptable medium therefor which includes (b) at least one nonionic surfactant having a hydrophilic/lipophilic balance (HLB) of greater than 10, (c) at least one C1-C4 alcohol and (d) water.

Priority: FR20050050363 Applic. Date: 2005-02-08; US2006-349249 Applic. Date: 2006-02-08; US20050672070P Applic. Date: 2005-04-18

Inventor: MEZURE PATRICIA [FR]; DUBIEF CLAUDE [FR]

Title: Dermatological/pharmaceutical compositions comprising benzoyl peroxide, at least one naphthoic acid compound and at least one polyurethane polymer

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT, BIOT, FRANCE

Application No.: 12/453968   Filing Date: 28/May/2009

Abstract:Topically applicable, dermatological/pharmaceutical compositions contain, formulated into a physiologically acceptable medium, benzoyl peroxide, at least one naphthoic acid compound and at least one compound of the polyurethane polymer type or derivatives thereof, wherein the benzoyl peroxide and the at least one naphthoic acid compound are dispersed therein.

Priority: FR20060055138 Applic. Date: 2006-11-28; WO2007FR52412 Applic. Date: 2007-11-28

Inventor: MALLARD CLAIRE [FR]; AT EMMANUELLE [FR]

Title: TARGETING NCCA-ATP CHANNEL FOR ORGAN PROTECTION FOLLOWING ISCHEMIC EPISODE

Applicant/Assignee: THE UNIVERSITY OF MARYLAND, BALTIMORE

Application No.: 12/522444   Filing Date: 11/Jan/2008

Abstract:The present invention concerns protection of an organ or tissue following an ischemic episode In particular aspects, the invention concerns organ preservation for transplantation, angina pectoris, kidney reperfusion injury, and so forth In specific embodiments, the organ is subjected to an inhibitor of an NCCa-ATP channel that is regulated by SUR1 Exemplary inhibitors include sulfonylurea compounds, such as glibenclamide, for example

Priority: US20070880119P Applic. Date: 2007-01-12; US20070923378P Applic. Date: 2007-04-13; US20070952396P Applic. Date: 2007-07-27; US20070012613P Applic. Date: 2007-12-10; WO2008US50922 Applic. Date: 2008-01-11

Inventor: SIMARD J MARC [US]

Title: Use of Antibody Conjugates

Applicant/Assignee: THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS

Application No.: 12/523438   Filing Date: 22/Jan/2008

Abstract:Provided herein are methods for inducing growth arrest or apoptosis in cancer cells in a subject. Further provided are methods of inhibiting or treating metastasis of a cancer cell in a subject. The methods involve administering to the subject an antibody conjugate containing an antibody, variant thereof, or functional fragment thereof having binding specificity of the antibody as produced by the hybridoma having ATCC accession number PTA 2439 and a biologically active molecule. The antibody (e.g., mAb 3E10) variant or functional fragment thereof provides for the in vivo transduction of the conjugate to the nucleus of mammalian cells, where the conjugated biologically active molecule may exert its effect. In particular embodiments, the antibody conjugate comprises a single chain Fv fragment of an antibody having the binding specificity of mAb 3E10 produced by ATCC PTA 2439, conjugated to p53.

Priority: US20070897012P Applic. Date: 2007-01-22; WO2008US51734 Applic. Date: 2008-01-22

Inventor: WEISBART RICHARD H [US]

Title: Delivery Device

Applicant/Assignee:

Application No.: 12/296978   Filing Date: 10/Apr/2007

Abstract:A process for the production of water-containing silicone rubber device comprising the steps of mixing an external phase comprising an organopolysiloxane polymer having at least two reactive groups per molecule, a water in oil emulsifier and where required one or more active ingredients and/or optional additives

with an internal phase comprising water and optionally one or more active ingredients to form an emulsion

and subsequently introducing a cure package comprising a cure package comprising a suitable catalyst, which will be determined by the cure reaction between the polymer and where required a cross-linker, and which contains more than two reactive groups, designed to react with the reactive groups in the polymer in the presence of said catalyst in order to cure the external phase of the composition, thereby entrapping the water within the body of said water-containing silicone rubber device. The resulting product is preferably used fragrance delivery in applications selected from aromatherapy anti stress ball, aromatherapy pillow, deodorising shoe sole solid deodorising device for houses, external prosthesis, facial mask for delivery of actives.

Priority: GB20060007438 Applic. Date: 2006-04-13; WO2007EP53456 Applic. Date: 2007-04-10

Inventor: VAN REETH ISABELLE [BE]; CAPRASSE VIRGINIE [BE]; THOMAS XAVIER [BE]; LECOMTE JEAN-PAUL [BE]; COUREL BENEDICTE [BE]; SCHIROSI ESTERNIA [BE]

Title: CASEIN NANOPARTICLE

Applicant/Assignee: FUJIFILM CORPORATION

Application No.: 12/630575   Filing Date: 03/Dec/2009

Abstract:It is an object of the present invention to provide: a positively charged nanoparticle which can be produced without using surfactants or synthetic polymers, the size of which can be controlled, which is stable at acidic condition, and which contains an active substance therein

and a method for producing the same. The present invention provides a casein particle, wherein zeta potential is positive.

Priority: JP20080310530 Applic. Date: 2008-12-05

Inventor: KANAZAWA KATSUHIKO [JP]

Title: Composition for Improving Skin Condition and Appearance

Applicant/Assignee:

Application No.: 12/512368   Filing Date: 30/Jul/2009

Abstract:Disclosed is a cosmetic composition comprising prenylated isoflavonoid and a carrier, wherein the prenylated isoflavonoid is from about 0.0000001% to about 10%, preferably from 0.00001% to 1%, most preferably from 0.01% to 1%, by weight, based on the total weight of the composition. The active agent prenylated isoflavonoid induces a statistically significant upregulation of collagen 1A1 and elastin genes in normal human dermal fibroblasts. The composition is effective to stimulate the production of collagen and elastin and improve the appearance and condition of the skin.

Priority: US20080085114P Applic. Date: 2008-07-31

Inventor: GRUBER JAMES V [US]

Title: Polymeric Biosufactants

Applicant/Assignee:

Application No.: 12/227825   Filing Date: 31/May/2007

Abstract:The present invention is directed to biosurfactants that can self-assemble or auto-aggregate into polymeric micellar structures and their use in topically-applied dermatologic products. The invention relates in particular to polymeric acylated biosurfactants (PABs) conforming to the formula Acyl-AA-Term where Acyl is an 8- to 22-membered carbon chain, branched or unbranched, saturated or unsaturated, AA is a consecutive sequence of four to nine amino acid residues, where at least one, preferably at least two of the amino acid residues is charged, and Term is an acid C-terminus or an amide C-terminus. PABs of the present invention have low critical micelle concentrations (predominantly less than about 100 ppm) in an aqueous environment of Minimal Essential Media (MEM) and can lower the surface tension in the aqueous MEM environment to less about 50 dynes/cm2. They also have the ability to increase metabolic soluble proteins.

Priority: US20060809825P Applic. Date: 2006-06-01; WO2007US12799 Applic. Date: 2007-05-31

Inventor: OWEN DONALD [US]; FAN LILI [US]

Title: Compositions and Methods for Cancer Treatment

Applicant/Assignee: WOMEN AND INFANTS HOSPITAL OF RI, INC

Application No.: 11/885606   Filing Date: 03/Mar/2006

Abstract:Bromoacetoxycalcidiol (B3CD), which is structurally related to calcidiol, exhibits cytotoxic and apoptotic activity toward cancer cells, including highly aggressive neuroblastoma cells. A series of small molecules designed around the structure of B3CD is expected to have growth inhibitory and apoptogenic activities toward a wide range of malignancies. B3CD shows no apparent toxicity in vivo, indicating potential value as a chemotherapeutic agent which will be particularly useful in treating highly aggressive tumors.

Priority: US20050658627P Applic. Date: 2005-03-04; WO2006US07710 Applic. Date: 2006-03-03

Inventor: SWAMY NARASIMHA [US]; SUNDARESHA HEMA MALINI K [US]

Title: METHODS FOR GENERATING MAMMALIAN MODELS OF ATOPIC DISEASES, AND SCREENING FOR THEIR TREATMENT

Applicant/Assignee: ASSOCIATION POUR LA RECHERCHE A L'IGBMC (ARI)

Application No.: 12/307966   Filing Date: 24/Jul/2007

Abstract:The present invention concerns a method for generating a human atopic disease-like phenotype, preferably an atopic dermatitis (AD)-like phenotype in a mammal comprising administering to said mammal at least one compound selected in the group comprising the physiologically active vitamin D3 (1[alpha],25(OH)2D3) and agonistic analogs thereof. The present invention also concerns a method for treating and/or preventing an atopic disease in a patient in a patent comprising administrating to said patient an effective amount of at least one vitamin D3 antagonist.

Priority: EP20060291201 Applic. Date: 2006-07-24; US20060832864P Applic. Date: 2006-07-24; WO2007IB02102 Applic. Date: 2007-07-24

Inventor: CHAMBON PIERRE [FR]; METZGER DANIEL [FR]; LI MEI [FR]

Title: HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN ATOMS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FOR TREATMENT OF CANCER

Applicant/Assignee: KOREA RESEARCH INSTITITUTE OF BIOSCIENCE AND BIOTECHNOLOGY SEOUL PHARMA, CO., LTD

Application No.: 12/376889   Filing Date: 10/Aug/2007

Abstract:The present invention relates to new heterocyclic compounds containing nitrogen atoms or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and a pharmaceutical composition comprising the same for treatment of cancer. The compounds according to the present invention induce DNA damage due to reactive oxygen species to activate c-abl and p53, induce RhoB to generate apoptosis, and induce cell death by down-regulating Bcl2 involved in cell survival, which is generated by dysregulated signals via the mitochondria pathway, thereby inhibiting tumor cell growth and inducing apoptosis. Accordingly, the composition according to the present invention can be used to treat cancer.

Priority: KR20060075827 Applic. Date: 2006-08-10; WO2007KR03861 Applic. Date: 2007-08-10

Inventor: HAN GYOON HEE [KR]; CHOI EUN HYUN [KR]; YANG JEE SUN [KR]; HONG SUNG HEE [KR]; KIM MYUNG SOOK [KR]; WON MI SUN [JP]; CHUNG KYUNG SOOK [KR]; KIM DONG MYUNG [KR]; YOO HYANG SOOK [KR]; KIM HWAN MOOK [KR]; PARK SONG KYU [KR]; LEE KI HO [KR]; LEE CHANG WOO [KR]; CHOI YOUN WOONG [KR]; JEONG YONG MI [KR]; MIN BYUNG GU [KR]

Title: TOPICALLY APPLICABLE COMPOSITIONS FOR THE TREATMENT OF KERATINIZATION DISORDERS

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT, BIOT, FRANCE

Application No.: 12/652417   Filing Date: 05/Jan/2010

Abstract:Topical compositions containing from 0.01% to 0.09% by weight of adapalene or salts thereof are useful for the treatment or prevention of keratinization disorders, particularly acne, and additionally contain at least one gelling agent selected from among carbomers, polysaccharides, cellulose and its derivatives, copolymers of acrylate and of alkyl acrylate, copolymers of acrylamide and of sodium acrylamido-2-methylpropanesulfonate, and xanthan gum.

Priority: WO2008EP58775 Applic. Date: 2008-07-07; US20070929652P Applic. Date: 2007-07-06

Inventor: DOUTREMEPUICH JEAN-DANIEL [FR]

Title: METHOD, APPARATUS, AND KIT FOR ONYCHOMYCOSIS TREATMENT

Applicant/Assignee: POWER PAPER, LTD

Application No.: 12/632277   Filing Date: 07/Dec/2009

Abstract:Methods, apparatus, and kits for onychomycosis treatment are presented. In one embodiment, a kit for treatment includes an anti-fungal agent, in a composition, and an electrically powered patch. Exemplary embodiments of the patch include a first electrode, a power source having a first and second terminal, a second electrode coupled to the second terminal of the power source, and a base member supporting the first electrode, the second electrode, and the power source. Embodiments include those where the first and second electrode and power source are printed on the base member. Anti-fungal agents may be unionized while the composition includes an ionizing agent. Home use may be practiced, as embodiments include those in which the voltage or current of the power source cannot be adjusted by a user. Exemplary methods include the selection of a nail or diseased area to which treatment is desired and administering the kit as described.

Priority: US2004-890297 Applic. Date: 2004-07-14; US20030486973P Applic. Date: 2003-07-14

Inventor: NITZAN ZVI [IL]; TAMARKIN DOV [IL]; MAVOR DANIELA [IL]; HAREL NURIT [IL]; EMANUEL NOAM [IL]

Title: Antibodies to IL-6 and use thereof

Applicant/Assignee:

Application No.: 12/624778   Filing Date: 24/Nov/2009

Abstract:The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.

Priority: US2009-502581 Applic. Date: 2009-07-14; US2009-399156 Applic. Date: 2009-03-06; US2009-391717 Applic. Date: 2009-02-24; US2009-366567 Applic. Date: 2009-02-05; US20080117839P Applic. Date: 2008-11-25; US20080117861P Applic. Date: 2008-11-25; US20080117811P Applic. Date: 2008-11-25

Inventor: GARCIA-MARTINEZ LEON [US]; JENSEN ANNE ELISABETH CARVALHO [US]; OLSON KATIE [US]; DUTZAR BEN [US]; LATHAM JOHN [US]; KOVACEVICH BRIAN [US]; SMITH JEFFREY T L [US]; LITTON MARK [US]; SCHATZMAN RANDALL [US]

Title: Artificially coloring the skin with a carotene compound, a xanthophyll compound and a lipophilic green dye composition

Applicant/Assignee: L'OREAL

Application No.: 12/591778   Filing Date: 01/Dec/2009

Abstract:A method for artificially coloring the skin entails topical application thereon of a composition containing, formulated into a physiologically acceptable medium: a) at least one compound of the carotene type, b) at least one compound of the xanthophyll type, c) at least one lipophilic green dye

the composition advantageously includes a mixture of dyes including: a) at least one compound of the carotene type, b) at least astaxanthin, c) at least one lipophilic green dye.

Priority: FR20080058152 Applic. Date: 2008-12-01; US20080193580P Applic. Date: 2008-12-08

Inventor: CASSIN GUILLAUME [FR]; POURHAMIDI SAYEH [FR]; ELGUIDJ IRENE [FR]

Title: USE OF TELLURIUM COMPOUNDS FOR TREATMENT OF BASAL CELL CARCINOMA AND/OR ACTINIC KERATOSIS

Applicant/Assignee: BIOMAS LTD

Application No.: 12/517222   Filing Date: 02/Jun/2009

Abstract:Methods for treating skin conditions such as basal cell carcinoma and/or actinic keratosis are provided, which are effected by administering a pharmaceutically effective amount of a tellurium-containing compound. A pharmaceutical composition for treatment of skin conditions such as basal cell carcinoma an/or actinic keratosis is also provided.

Priority: US20050716923P Applic. Date: 2005-09-15; WO2006IL01080 Applic. Date: 2006-09-14

Inventor: SREDNI BENJAMIN [IL]; ALBECK MICHAEL [IL]

Title: Affinity matured CRIg variants

Applicant/Assignee:

Application No.: 12/387794   Filing Date: 06/May/2009

Abstract:The present invention concerns affinity matured CRIg variants. In particular, the invention concerns CRIg variants having increased binding affinity to C3b and retaining selective binding to C3b over C3.

Priority: US20080189653P Applic. Date: 2008-08-20; US20080050888P Applic. Date: 2008-05-06

Inventor: SIDHU SACHDEV S [CA]; LI BING [US]; CAMPAGNE MENNO VAN LOOKEREN [US]; WIESMANN CHRISTIAN [US]

Title: ANTI-IGF ANTIBODIES

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 12/636195   Filing Date: 11/Dec/2009

Abstract:Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.

Priority: EP20080171554 Applic. Date: 2008-12-12

Inventor: ADAM PAUL [AT]; BORGES ERIC [AT]

Title: Structured Composition Comprising an Encapsulated Active

Applicant/Assignee:

Application No.: 12/581941   Filing Date: 20/Oct/2009

Abstract:A structured liquid composition having a liquid matrix having water and a fibrous network structurant, the fibrous network structurant having a non-polymeric crystalline hydroxyl-functional materials

a bacterial cellulose network

and mixtures thereof

and an encapsulated active. The encapsulated active is suspended within the liquid matrix of the structured liquid composition such that the encapsulated actives do not undesirably sink, float, or collect in any discrete portion of the composition. Further, the structured liquid composition can be in the form of a raw material such as an encapsulated active slurry, in the form of an additive such as a laundry additive, and as a consumer end product. In one embodiment, the encapsulated active is a perfume microcapsule.

Priority: US20080106723P Applic. Date: 2008-10-20

Inventor: DIHORA JITEN ODHAVJI [US]; JAFFER SHAFFIQ AMIN [US]; RADOMYSELSKI ANNA VADIMOVNA [US]; VINSON PHILLIP KYLE [US]

Title: SUBSTRATES PROVIDING MULTIPLE RELEASES OF ACTIVE AGENTS

Applicant/Assignee:

Application No.: 12/336243   Filing Date: 16/Dec/2008

Abstract:The present disclosure comprises a polymeric substrate that provides multiple releases of active agents. A substrate for multiple phase delivery of active agents is provided having a first polymer matrix layer having a first active agent disposed therein, a second polymer matrix layer having a second active agent disposed therein, and a coacervate layer disposed between the first polymer matrix layer and the second polymer matrix layer. Selected first and second active agents are included in the first and second polymer matrices such that as the first and second polymer matrices dissolve, the active agents are released. Multiple phase active agent release is achieved by constructing multiple layers of a polymer matrix containing an active agents formed with polymers having different solubility characteristics or with active agents at different concentration levels.

Priority:

Inventor: HOFFMAN DOUGLAS ROBERT [US]; SMILTNEEK ANDREA JO [US]; CARNEY SARA ANN [US]; WENZEL SCOTT W [US]; KOENIG DAVID WILLIAM [US]; SEIDLING JEFFERY RICHARD [US]

Title: AMPHIPHILIC ENTITY NANOPARTICLES

Applicant/Assignee: ANTERIOS, INC

Application No.: 12/517154   Filing Date: 30/Nov/2007

Abstract:The present invention provides nanoparticle compositions comprising AE nanoparticles. The present invention provides AE nanoparticles comprising one or more amphiphilic entities and pharmaceutical compositions comprising AE nanoparticles. The present invention provides methods of manufacturing AE nanoparticles. The present invention provides methods of delivering a biologically active agent to a subject by administering AE nanoparticles containing a biologically active agent to a subject.

Priority: US20060872198P Applic. Date: 2006-12-01; WO2007US86018 Applic. Date: 2007-11-30

Inventor: KOTYLA TIMOTHY [US]

Title: Guggulphospholipid Methods and Compositions

Applicant/Assignee: JINA PHARMACEUTICALS, INC

Application No.: 12/513654   Filing Date: 06/Nov/2007

Abstract:The present invention relates to the methods for preparing synthetic guggulphospholipids, their fatty acid analogues and other bioactive molecules. The present invention relates to E-guggulsterone and Z-guggulsterone or mixture of E- and Z-guggulsterones. The present invention also provides a novel method for the preparation of E-guggulsterol and Z-guggulsterol or mixture of E- and Z-guggulsterols from a mixture of E- and Z-guggulsterones. The present invention further relates to guggulphospholipids and other bioactive molecules incorporated into complexes such as liposomes, complexes, emulsions, vesicles, micelles, and mixed micelles, which can include other active agents, such as hydrophobic or hydrophilic drugs for use, e.g., in treatment of human and animal diseases.

Priority: US20060856952P Applic. Date: 2006-11-06; WO2007US83832 Applic. Date: 2007-11-06

Inventor: AHMAD MOGHIS U [US]; ALI SHOUKATH M [US]; AHMAD ATEEQ [US]; SHEIKH SAIFUDDIN [US]; AHMAD IMRAN [US]

Title: PHARMACEUTICAL AND/OR COSMETIC COMPOSITION CONTAINING PEPTIDES

Applicant/Assignee: SOCIETE D'EXTRACTION DES PRINCIPES ACTIFIS SA (VINCIENCE)

Application No.: 12/446951   Filing Date: 26/Oct/2007

Abstract:The present invention concerns the use of peptide fragments of the protein SLC24A5 as active agents designed to induce, increase, or restore the synthesis of melanin in the melanocytes of the epidermis or of the pilar bulb, alone or in association with at least one other active agent, in a cosmetic composition or for the preparation of a pharmaceutical or particularly dermatological composition. The invention is also related to any composition containing the active agents.

Priority: FR20060009415 Applic. Date: 2006-10-26; WO2007FR01774 Applic. Date: 2007-10-26

Inventor: DAL FARRA CLAUDE [FR]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]

Title: PYRIMIDINE DERIVATIVES

Applicant/Assignee: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG BOEHRINGER INGELHEIM PHARMACEUTICALS, INC

Application No.: 12/711364   Filing Date: 24/Feb/2010

Abstract:The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.

Priority: US2005-313380 Applic. Date: 2005-12-21; US2002-271763 Applic. Date: 2002-10-16; US20010330145P Applic. Date: 2001-10-17

Inventor: DAHMANN GEORG [DE]; HIMMELSBACH FRANK [DE]; KRIST BERND [DE]; LENTER MARTIN [DE]; PAUTSCH ALEXANDER [DE]; SCHNAPP GISELA [DE]; STEEGMAIER MARTIN [DE]; WITTNEBEN HELMUT [DE]; PROKOPOWICZ ANTHONY S [US]; SPEVAK WALTER [AT]; SCHOOP ANDREAS [DE]; STEURER STEFFEN [AT]

Title: Feminine undergarment

Applicant/Assignee:

Application No.: 12/654241   Filing Date: 15/Dec/2009

Abstract:An undergarment comprises a strapless, coreless web sized and configured between an anterior end and a posterior end to cover, in use, at least the vulva of an adult female wearer. The undergarment is pre-adherent to the wearer, e.g., having pre-applied adhesive or pre-applied suction material on the body side of the web, suitable for contact with human skin and sufficiently adherent to removably hold the undergarment in place during use. In another aspect, a feminine undergarment comprises such pre-adherent strapless, coreless web with a removable protective cover over at least the adhesive. In another aspect, a package of feminine undergarments comprises outer packaging containing at least multiple of such feminine undergarments and optionally inner packaging for each of the undergarments individually.

Priority: US20080138343P Applic. Date: 2008-12-17

Inventor: CARLOZZI ANTONELLA F [US]

Title: LIQUID SURFACTANT COMPOSITIONS THAT ADHERE TO SURFACES AND SOLIDIFY AND SWELL IN THE PRESENCE OF WATER AND ARTICLES USING THE SAME

Applicant/Assignee:

Application No.: 12/336262   Filing Date: 16/Dec/2008

Abstract:A liquid surfactant composition includes at least one anionic surfactant and at least one cationic surfactant. The combination of surfactants is formulated to provide a liquid composition that swells in the presence of water or body fluids, becomes a moldable solid in the presence of an excess of water, and adheres to surfaces. In addition, the liquid surfactant composition may be incorporated into or onto a substrate, such as an absorbent substrate, a fabric or cloth substrate, a tissue substrate, or a protective garment substrate.

Priority:

Inventor: SEIDLING JEFFERY RICHARD [US]; WENZEL SCOTT W [US]; KOENIG DAVID WILLIAM [US]

Title: COSMETIC COMPOSITION COMPRISING AT LEAST ONE ORTHO-DIPHENOL, METAL SALT, HYDROGEN PEROXIDE, (BI)CARBONATE AND SURFACE-ACTIVE AGENT, AND DYEING METHOD THEREWITH

Applicant/Assignee:

Application No.: 12/637251   Filing Date: 14/Dec/2009

Abstract:The disclosure relates to a method for dyeing keratinous fibers by applying to said fibers i) at least one entity chosen from ortho-diphenol and derivatives thereof, ii) at least one metal salt, iii) hydrogen peroxide or at least one system which generates hydrogen peroxide, iv) at least one (bi)carbonate and v) at least one surface-active agent chosen from anionic and nonionic surface-active agents. The disclosure also relates to a composition comprising i) at least one entity chosen from ortho-diphenol and derivatives thereof, ii) at least one metal salt, iii) hydrogen peroxide or at least one system which generates hydrogen peroxide, iv) at least one (bi)carbonate and v) at least one surface-active agent chosen from anionic and nonionic surface-active agents. The disclosure also relates to a multicompartment device comprising from 2 to 5 compartments comprising from 2 to 5 compositions in which the ingredients i) at least one entity chosen from ortho-diphenol and derivatives thereof, ii) at least one metal salt, iii) hydrogen peroxide or at least one system which generates hydrogen peroxide, iv) at least one (bi)carbonate, and v) at least one surface-active agent chosen from anionic and nonionic surface-active agents are distributed, said compositions being aqueous or pulverulent, with one at least of these compositions being aqueous.

Priority: FR20080058555 Applic. Date: 2008-12-12; US20080141400P Applic. Date: 2008-12-30

Inventor: GUERIN FREDERIC [FR]; GOURLAOUEN LUC [FR]